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1. Supplementary Methods 
 
1.1 Patient samples 
This study used patient samples approved by the institutional review board at Washington 
University in St. Louis under protocol 201011766 and was conducted in accordance with the 
provisions of the Declaration of Helsinki. All samples were obtained from patients either known 
or suspected to have a diagnosis of AML or MDS who consented to genomic studies and were 
seen at Washington University in St. Louis. Samples were selected for sequencing for three 
specific purposes: 1) WGS performance assessment, 2) Establishing diagnostic yield and 
clinical feasibility, and 3) Evaluation of risk prediction in patients with unsuccessful or incomplete 
cytogenetic studies. To achieve these objectives, a combination of retrospective and 
prospective patient cohorts was used, descriptions of which are provided below. 
 
Retrospective cohort (N=146) 
Retrospective samples from AML and MDS patients consented under the abovementioned 
protocol were obtained from the Siteman Cancer Center Tissue Procurement Core and included 
DNA extracted from either cryopreserved bone marrow (N=133) or peripheral blood (N=13) 
specimens. For WGS performance evaluation, 111 samples were selected based on DNA 
availability and results from conventional cytogenetic studies in order to include a wide range of 
chromosomal abnormalities, including risk-defining translocations, copy number alterations 
(CNAs), and either a complex or normal karyotype. Separately, to determine whether WGS 
could be used to predict outcomes for patients with unknown cytogenetics, 35 retrospective 
samples were selected from patients treated with induction chemotherapy and for whom 
cytogenetics was unknown, unsuccessful, or inconclusive at diagnosis (see Section 1.3 for 
definitions). Of note, samples with successful cytogenetic studies from the prospective cohort 
below were also used for WGS performance evaluation, and likewise, prospective samples with 
unsuccessful or inconclusive cytogenetics were used for the analysis of WGS-based risk 
prediction in patients with unknown cytogenetics.  
 
Prospective cohort (N=117) 
Evaluation of the feasibility and diagnostic yield of WGS compared to standard testing used 
samples from a cohort of 117 prospective patients. These samples included bone marrow 
aspirate (N=116) or peripheral blood (N=1) specimens from 117 consecutive, unselected 
patients for whom clinical cytogenetic analysis via karyotyping in the Cytogenomics and 
Molecular Pathology Laboratory was requested between May 2019 and February 2020. The 
only selection criteria for these patients were that they were consented under the 
abovementioned protocol and there was sufficient remaining specimen left after standard 
cytogenetic analysis to be used for sequencing (some samples required the addition of RPMI-
based media to wash residual material out of the sodium heparin tubes prior to DNA extraction). 
Samples were transported from the Cytogenomics laboratory to the CLIA-licensed Environment 
(CLE) clinical sequencing laboratory at the McDonnell Genome Institute (MGI) for DNA 
extraction and sequencing. As stated above, this cohort included patients with both successful 
and unsuccessful cytogenetic studies, and therefore contributed to WGS performance 
evaluation and WGS-based risk prediction analysis for patients with unknown cytogenetics. 
 
1.2 WGS procedures 
Tumor-only WGS was performed in the CLIA-licensed environment clinical sequencing 
laboratory in the McDonnell Genome Institute at Washington University School of Medicine 
(MGI-CLE; CLIA ID #26D2092546, CAP #9047655, David H. Spencer MD, PhD, Medical 
Director). No normal tissue comparator was used for this assay in order to reduce time, 
complexity, and cost, and because the purpose is to identify clearly pathogenic somatic events 
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that generally do not require a germline control. All samples were accessioned into the MGI 
laboratory information management system (LIMS) upon receipt prior to DNA extraction (for 
prospective samples) or library preparation (for retrospective samples received as DNA). DNA 
from prospective peripheral blood or bone marrow aspirate specimens was extracted using 200 
uL of material with the QIAamp DNA mini kit (Qiagen, Hilden, Germany) as detailed in the 
package insert, followed by quantification with the Qubit 1.0 fluorometer High Sensitivity dsDNA 
assay (ThermoFisher, Waltham, MA). Subsequent WGS procedures are described below. 
 
Library preparation 
WGS library preparation used the Nextera Flex library preparation kit (cat# 20015804, Illumina, 
Inc, San Diego, CA) along with dual unique index library adapters (cat# 20015881). This on-
bead tagmentation-based library construction method was selected because it is fast, simple, 
and automatable, and thus fits well in a clinical testing environment where training of laboratory 
staff and turnaround time are important considerations. For this study, library construction was 
performed in a single day in batches of 2 to 16 samples by individual laboratory staff who 
followed the protocol detailed in the package insert without modification. In general, 500 ng of 
input DNA was used for library construction, although as little as 35 ng was used when DNA 
amounts were limiting. Completed libraries were accessioned into the LIMS, then assessed for 
size using an Agilent 2100 Bioanalyzer with a DNA High Sensitivity chip (Agilent, Santa Clara, 
CA), and quantified via Qubit (ThermoFisher, Waltham, MA). Final libraries were optionally 
quantified further via qPCR (generally on a subsequent day) using Kapa SYBR Fast qPCR 
library quantification (Roche, Basel Switzerland), and then diluted to 1 nM for equimolar pooling 
prior to sequencing. 
 
Sequencing 
Sequencing was performed on NovaSeq 6000 sequencing instruments (Illumina) using either 
S1 or S4 flowcells and 2x150 sequencing chemistry. Retrospective samples were sequenced on 
S4 flowcells in pools of 16 (or pools of 4 samples on one S4 lane using the XP lane loader) and 
prospective ‘real-time’ sequencing used S1 flow cells in pools of 3 samples, which is designed 
to yield >133 Gbp of raw sequence and 60x genome coverage per sample. Flowcell loading and 
sequencing were performed as recommended by the manufacturer. Times for sequencing are 
25 and 44 hours for S1 and S4 flowcells, respectively, and were documented in the MGI LIMS 
system. 
Data processing 
Completed sequencing runs were processed into aligned CRAM files using the GRCh38 human 
reference genome via two approaches: 
 
- Local processing: For retrospective samples, instrument data were processed and 
demultiplexed into FASTQ files using bcl2fastq (Illumina) via the in-house LIMS. Data were 
then aligned via a local installation of the DRAGEN (version 3.5.7) hardware-accelerated 
sequence processing software suite using default alignment parameters. Processing time 
with this approach for S4 flowcells were generally 47 hours for sequencing data transfer and 
12 hours for demultiplexing. Alignment times using DRAGEN ranged from 20-40 minutes 
depending on coverage.  
- BaseSpace processing: To speed the processing of prospective samples, data generated 
on S1 flowcells were streamed from the NovaSeq instrument to the cloud-based BaseSpace 
sequence analysis platform. This saved time at both the sequencing and data processing 
steps, owing to the shorter run time for S1 flowcells and ‘on-demand’ rapid data processing. 
After the sequencing run completed, demultiplexing and FASTQ generation was 
automatically launched in BaseSpace. Data were then aligned via manual launching of the 
DRAGEN Germline (alignment only) BaseSpace App (version 3.2.8, see 
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https://basespace.illumina.com/apps/6840834/DRAGEN-Germline-Pipeline), which 
completed in about the same amount of time as the local DRAGEN installation. We note that 
the manual step of launching DRAGEN can be automated via the BaseSpace API to further 
reduce turnaround time. 
 
Alignments in CRAM format generated using both the in-house and cloud-based procedures 
were used as input for the variant analysis workflow described below. 
 
Variant analysis and reporting 
Tumor-only variant analysis used a custom analysis workflow (‘ChromoSeq’) specified in the 
WDL workflow language and executed using the Cromwell workflow engine1 in dockerized 
compute containers, which is available for public use as a custom application on BaseSpace 
(https://basespace.illumina.com/apps/6984978/Chromoseq -- pending BaseSpace approval for 
public release). Analysis involves three components: CNA identification, SV identification, and 
gene-level variant identification. All three of these components are subject to targeted analysis 
and filtering to yield variants that may be clinically relevant. 
 
CNA identification  
 
Cytogenetically evident CNAs greater than 5 Mbp, which are of a size potentially detectable by 
karyotype analysis, are identified via a read-depth approach using a previously published purity 
and subclone-aware Hidden Markov Model, ichorCNA2; 
https://github.com/GavinHaLab/ichorCNA). The input for this script is a file with read counts in 
500,000 bp nonoverlapping windows across the genome, either generated using bedtools3 or 
outputted directly from the DRAGEN mapping software during alignment using the command: 
 
dragen -r $obj->{_dragenref} --fastq-list $fastqfile --fastq-list-sample-id $samplename --enable-cnv true --cnv-target-
bed /staging/garza_testing/reference/all_sequences.fa.bed --cnv-interval-width 500000 --output-directory $cramout --
output-file-prefix $sample --output-format CRAM --enable-bam-indexing true --enable-duplicate-marking true 
 
Binned read counts are supplied to ichorCNA for normalization for GC content, mappability, and 
using a ‘panel of normals’ normalization file generated from 20 normal karyotype cases per the 
instructions on the ichorCNA github repo. Outputs from ichorCNA were text-processed via a 
custom PERL script (available upon request) to retain CNAs >5 Mbp and converted to VCF 
format, and then combined with SV calls (below) for input into the ChromoSeq reporting script. 
CNA abundance as a percentage was calculated using the equation: 
 
Abundance = (2^L2R - 1.0) / ((CN/2.0 - 1.0)))*100 
 
Where L2R is the log2 normalized coverage ratio vs. a panel of normals and CN is the 




SV identification is performed with the break-end caller Manta4 and broken into two ‘tiers’, with 
recurrrent and risk defining events are detected with a high sensitivity approach, and novel SVs 
are subject to more rigorous filtering. Manta is run directly from the aligned CRAM file in ‘tumor’ 
mode and with custom parameters to increase the sensitivity and limit calls to those that are at 
least 100 kbp in length to reduce the number of calls with unknown clinical significance. SVs are 
then filtered to identify translocations, deletions, duplications, and inversions that overlap a 
curated list of 612 recurrent and/or risk-defining SVs obtained from published sources, including 
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the WHO and the Atlas of Genetics and Cytogenetics in Oncology (see Table S2). Genomic 
events where both ends overlap one of these recurrent SVs are reported as ‘top-level’ findings 
in ChromoSeq without additional filtering. Although the remaining SVs will rarely be clinically 
relevant, they could include patient-specific events or identify cytogenetically cryptic 
rearrangements involving genes relevant for AML or MDS. We therefore perform rigorous 
annotation and filtering using a custom PERL script (available upon request) and report the 
remaining high-quality novel events as secondary findings. The following criteria must be met to 
yield a passing call: 1) at least 2 ‘paired and 2 ‘split’ reads supporting the break-ends, 2) 
absence of an overlapping call from a large set of SVs identified from >17,795 human 
genomes5, 3) coverage depth of deletion or duplication call must be <0.8 or >1.3 compared to 
the background6, respectively, and 4) a defined breakpoint must be identified and the spanning 
contig generated by Manta must map back to the reported breakpoints. This procedure 
dramatically reduces the number of reported calls. For example, the mean number of raw Manta 
calls per case is >5,000; after filtering we reported a mean of 11 calls across all 263 cases in 
this study (including recurrent SVs). SVs are then converted to VCF format, combined with CNA 
calls (from above), and annotated with VEP7 using Ensembl version 90, prior to reporting with 
the ChromoSeq reporting script. 
 
Gene-level variant identification 
 
Gene mutations are identified in ~85 kbp targeting 40 genes and gene hotspots that are 
recurrently mutated in AML or MDS8. This target space was selected to be identical to that of 
the targeted gene panel used for clinical testing of these patients at our institution, and is 
relatively small so that rare inherited variants (i.e., variants of uncertain significance (VUS)), are 
minimized. The primary variant caller is Varscan29, which is run in SNV and indel mode using 
custom parameters to enhance sensitivity. The indel caller Pindel10 and Manta are also run on 
exons 13-15 of FLT3 to identify FLT3 ITD alleles11. In addition, a read count based ‘hotspot’ 
analysis is performed on 66 recurrently mutated positions to recover low abundance variants 
that are not detected by Varscan2 (a minimum variant read count of 3 is required to report these 
hotspot positions). Variant calls identified via these approaches are merged and harmonized 
using a custom python script (available upon request), and annotated with VEP using Ensembl 




Annotated CNA, SV, and gene mutation calls are combined with coverage QC information to 
generate a final text report using a custom python script (available upon request). This report 
includes the CNAs, recurrent SVs, and gene mutations identified by the above steps as ‘top-
level’ results. The remaining SVs that remained after filtering are reported in two categories. The 
first includes high-quality novel SVs that affect (overlap) a gene that is included in either the 
recurrent SV or gene mutation target space. The second category is all other high-quality novel 
SVs. Additional coverage QC metrics are also reported. This text file (see Figure S1A) is 
copied to the final case directory along with data files (CRAM, and VCF) and graphical coverage 
plots from ichorCNA. The final text report is also used to generate a graphical ChromoSeq 
report, as shown in Figure S1B.  
 
WGS analysis for study patients 
 
All retrospective samples were sequenced on S4 flowcells and processed using in-house 
demultiplexing, aligned with the local DRAGEN server, and analyzed on a local compute cluster 
 6 
with the ChromoSeq workflow. Prospective samples were sequenced on S1 flowcells and 
initially analyzed using the cloud-based approach on BaseSpace to record failure rates and 
turnaround times. ChromoSeq reports with QC metrics and variants for the prospective patients 
were reviewed in 1 hour sessions by board-certified molecular pathologists (D.H.S., E.J.D.) and 
a board-certified cytogeneticist and molecular geneticist (M.C.S.) without prior knowledge of the 
results from conventional testing. Exact times for processing steps shown in Figure 3A were 
obtained from the MGI LIMS system and from the timestamp in the ChromoSeq text report. A 
final ChromoSeq analysis was performed on all prospective samples at the end of the study to 
harmonize the results and file formats (which changed over the course of the study) with the 
outputs from the retrospective samples. These final results were used for the analysis and 
figures in the main text. See Table S3 for all harmonized WGS results. 
 
1.3 Conventional cytogenetic studies 
Cytogenetics and FISH were performed in the Cytogenomics and Molecular Pathology 
Laboratory at Washington University School of Medicine in St. Louis per standard clinical 
protocols. Culture of cells from bone marrow or leukemic peripheral blood samples was 
performed per standard clinical protocols, followed by harvest, slide dropping, G-banding with 
trypsin/Wright stain, and analysis. Cytogenetic events were considered clonal if they occurred in 
at least two metaphases (at least three metaphases for monosomies). For the purposes of this 
study, cytogenetic analysis was called ‘unsuccessful’ if no metaphases were obtained for 
analysis, and ‘inconclusive’ if fewer than 20 metaphases were analyzed without detection of 
clonal abnormalities, which is similar to approaches taken by other studies12–14. 15FISH results 
used for risk stratification and calculation of the yield of WGS in the prospective cohort were 
obtained from clinical reports performed at diagnosis. For AML patients, most FISH studies (60 
of 68 patients) included the ELN-recommended panel of PML-RARA (LSI PML/RARA Dual 
Color, Dual Fusion, Abbot/Vysis) CBFB-MYH11 (LSI CBFB Dual Color, Break Apart 
Rearrangement Probe, Abbot/Vysis), RUNX1-RUNX1T1 (LSI RUNX1T1/RUNX1 Dual Color, 
Dual Fusion, Vysis), del(5q) (D5S630/D5S2064 Dual Color Probe, Cytocell/Aquarius), and 
del(7q) (LSI D7S486/D7Z1 Dual Color Probe, Abbot/Vysis). Additional FISH assays were also 
performed to confirm WGS findings but were not used to for risk group assignments. 
 
1.4 Targeted sequencing 
Gene mutations were obtained as part of standard diagnostic testing using a commercially 
available PCR-based assay for the FLT3 internal tandem duplication mutation (ITD) 
(Invivoscribe, San Diego, CA), in-house testing for the NPM1c mutation, and/or a laboratory-
developed clinical sequencing assay, including either clinical tumor/normal exome sequencing16 
or a clinical gene panel that targets 40 recurrently mutated genes or gene hotspots in AML and 
MDS (Myeloseq; Department of Pathology and Immunology, Washington University School of 
Medicine, see Table S1) performed in the CLIA-Licensed Environment Clinical Sequencing 
Laboratory at the McDonnell Genome Institute at Washington University in St. Louis. 
 
1.5 Comparison and confirmation procedures 
WGS results were compared to conventional cytogenetics and FISH to determine the sensitivity 
and positive predictive value for detecting recurrent SVs and CNAs. These comparisons used 
the following approaches: 
 
- SVs: Cases with successful cytogenetics (at least 3 metaphases analyzed, N=235) were 
used to evaluate SV performance. SVs identified by WGS were manually compared to ISCN 
karyotypes obtained from clinical testing to identify true positives. Breakpoints were required 
to occur within 1 chromosome band. New SVs that were not reported by conventional 
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cytogenetics were subject to confirmation using either FISH, PCR for SV breakpoints, or 
analysis of existing RNA-seq data for fusion transcripts (see below). 
- CNAs: CNAs from WGS were compared to ISCN karyotypes using 143 cases with 
conclusive cytogenetic results (i.e., 20 metaphases) and no ambiguous findings, such as 
composite karyotypes, marker chromosomes, or additional unidentifiable material, as these 
preclude definitive comparisons. ISCN cytogenetic karyotypes were transformed into a 
matrix of gains and losses for each chromosome band using published software17, which 
were then converted with a custom PERL script to BEDPE format using band coordinates 
based on the GRCh38 human reference. The bedtools program was then used to compare 
CNAs between WGS and cytogenetics using at least 1 bp of overlap to identify concordant 
events. New CNAs were subject to confirmation using either FISH or chromosomal 
microarrays (CMA).  
Every effort was made to confirm all novel findings, although priority was given to findings in the 




WGS findings not present in the karyotype or confirmed by diagnostic FISH results were 
confirmed using FISH studies where possible (see Table S4). FISH was the primary means of 
confirmation for new SVs and CNAs when appropriate probes were available and clinical 
specimens were available for testing. All FISH studies were performed in the Cytogenomics and 
Molecular Pathology Laboratory using validated probes and standard clinical procedures using 
200 cells and were reviewed by board certified cytogeneticists. The presence of an abnormal 
result in the specified study was considered as support for the genomic event identified by 
WGS. For example, we considered an abnormal result for the KMT2A dual color/dual fusion 
FISH assay as confirmation of an SV involving KTM2A in the WGS data. 
 
PCR 
Selected SVs that could not be confirmed via FISH because of insufficient or inadequate 
samples were confirmed via PCR from DNA using primers spanning the SV breakends 
identified by Manta when FISH studies could not be performed due to limited material and/or 
lack of appropriate FISH probes (see Table S4). PCR primers were designed from breakpoint-
spanning sequence contigs generated from Manta and were used in standard PCR reactions 
with human genomic DNA. Amplified fragments were excised, purified, sequenced with Sanger 
sequencing, and analyzed with Blat to verify localization to the breakpoint region. 
 
CMA 
CNAs were confirmed via chromosomal microarray (CMA) for cases with available DNA but 
insufficient material or probe for FISH assays (see Table S5). CMAs were performed in the 
Washington University School of Medicine Cytogenetics Core per standard methods using the 
CytoScan HD platform (ThermoFisher) with subsequent analysis in Chromosome Analysis Suite 
(ThermoFisher). Data were reviewed and interpreted by a board-certified cytogeneticist and 
molecular geneticist (M.C.S.) 
 
RNA-seq 
SVs in two cases with KMT2A rearrangements (380949 and 410324, see Table S4) were 
confirmed using existing RNA-seq data that was published as part of the TCGA AML study (see 
Supplemental Table 1 in ref. 18, which can be accessed here: 
https://api.gdc.cancer.gov/data/b9196563-a05d-40b8-80dc-640ec712eb06; samples 380949 
and 410324). We note that clinical FISH using a KMT2A breakapart probe for these cases was 
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also abnormal, and the identification of a fusion transcript via RNA-seq provided the definitive 
confirmation of the translocation partner. 
 
1.6 Risk stratification  
Conventional 
 
Cytogenetics, FISH (for the panel described above, when performed, see section 1.3), and 
molecular results were used to assign patients to established genomic risk categories, which 
used the 2017 ELN guidelines for AML patients12 and the cytogenetic component of the IPSS-R 
scoring system for MDS patients19, both without modification (see Table S9). Cytogenetic 
abnormalities were required to meet the abovementioned criteria to be considered clonal. For 
AML patients, risk group assignment was performed using cytogenetic results, FLT3 ITD 
mutation allele ratio from PCR (or presence/absence if the allelic ratio was not available), and 
the mutation status for CEBPA, NPM1, TP53, RUNX1, and ASXL1 from either clinical 
tumor/normal exome sequencing (N=12) or gene panel sequencing (using Myeloseq, N=71, see 
above, or a commercial assay, N=1). Sequencing assays were not performed for 6 retrospective 
patients who were either assigned to a risk group using only NPM1 and FLT3 ITD mutation 
status (N=3), or they were assigned to intermediate risk (N=3). Patients with a normal karyotype 
and <20 metaphases were not assigned to a risk group with unless there was an unequivocal 
result from either FISH or targeted sequencing (e.g., a positive PML-RARA or del(5q) by FISH, 
or a TP53 mutation by targeted sequencing). IPSS-R risk groups do not involve gene mutations 




WGS results were used to assign patients to risk groups using the identical guidelines as above 
for both AML and MDS patients (see Tables S9, S10). For AML patients, risk assignment used 
CNAs, recurrent SVs, and gene mutations. FLT3 ITD mutation results from PCR were used 
instead of the WGS result (even though ITD alleles can be detected) because the PCR assay is 
an FDA-cleared companion diagnostic for the FLT3 targeted therapy midostaurin. For both AML 
and MDS patients, the clinically important classifications of normal karyotype and complex 
karyotype used only CNAs and recurrent SVs and not SVs reported as secondary findings. A 
normal karyotype was designated if no variants in either category were identified, and a 
complex karyotype was designated if at least 3 chromosomal abnormalities were identified, 
including recurrent SVs (not WHO category-defining events) or CNAs greater than 5 Mbp that 
were identified by copy number analysis and that involved separate chromosome arms. All but 3 
of the patients with a complex karyotype could be assigned to this category based on CNAs 




Survival analyses of 139 AML patients (and subgroups thereof) were performed using death as 
the endpoint. Censoring of patients in these analyses was random and occurred because of 
limited follow-up time. Survival analyses of patients with defined cytogenetic risk (N=71 non-
transplanted patients; N=101 total patients) was pre-planned using patients within our cohort 
(i.e., they were not selected specifically for outcome analysis) and was performed by Kaplan-
Meier analyses using the log-rank test for equal survival across the groups. Cox proportional-
hazards regression was used to calculate hazard ratios and test for equal survival between the 
adverse risk group and either intermediate, favorable, or a combined intermediate/favorable ‘not 
adverse’ risk group. All log-rank tests performed in the paper were adjusted for multiple 
comparisons using the method of Benjamini and Hochberg (1995). Cox regression was adjusted 
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for age (binned by decade), which was significantly associated with overall survival in the 71 
non-transplanted patients with defined risk stratified by conventional risk groups (HR: 1.46, 95% 
CI 1.05-2.05) but not WGS-based risk groups (HR: 1.29, 95% CI 0.92-1.81). The log of the 
white blood cell count was also used as a covariate with ELN risk, but was not significant in any 
analysis (P>0.05 in all analyses) and therefore was not included in the model. The proportional 
hazards assumption was found to be tenable for all Cox models.  
 
The same approaches were used for AML patients with undefined cytogenetic risk (N=27 non-
transplanted patients; N=38 total patients). Prior to this pre-planned analysis, we performed a 
power calculation to estimate the sample size necessary to observe a difference in survival 
among ELN risk groups in this cohort. This used the Power and Sample Size task in SAS/Studio 
software along with the observed survival in the defined cytogenetic risk cohort above (N=71), 
which was largely consistent with published data on a mixture of older (60 and over) and 
younger (less than 60) patients14. The power calculation used a median survival of 3600 days of 
survival for the favorable group and 346 for the adverse group, with a minimum follow-up 
interval of 279 days and a total number of days (accrual + follow-up) of 750 days. This 
demonstrated 80% power to detect a survival difference between favorable and adverse risk at 
a sample size of 12 (per group) using an alpha of 0.05. Additional exploratory analyses were 
performed but not presented, including log-rank tests for differences in survival among all three 
risk groups (rather than not adverse vs. adverse) and unadjusted Cox regression tests, which 
yielded similar results to those shown here. Survival statistics were obtained using SAS for 
Windows, Version 9.4. The survminer package in R was used for visualization. 
 
1.8 Cost analysis 
Conventional testing: cytogenetics, FISH, and targeted gene sequencing 
The cost estimate for conventional testing was based on the Centers for Medicare and Medicaid 
Services 2019 and 2020 laboratory and professional reimbursement fee schedule 
(https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched). We 
assumed that genomic testing for new AML and MDS patients would include targeted gene 
sequencing, karyotyping for 20 metaphases, 6 FISH assays using 10 probes (4 breakapart 
assays with 2 probes each and 2 single probe assays for del(5q) and del(7), interpretation and 
reporting. Based on this testing, the following CPT codes would be billed at the CMS rates 
shown below. 
 
CPT code Description Rate Quantity Cost 
81450 Targeted genomic seq analysis $         759.53 1 $    759.53  
88264 Chromosome analysis 20-25 $         144.61 1 $    144.61  
88237 Tissue culture bone marrow $         143.75 1 $    143.75  
88271 Cytogenetics dna probe $           21.42 10 $    214.20  
88275 Cytogenetics 100-300 $           51.19 6 $    307.14  
88291 Cyto/molecular report $           33.88 1 $      33.88  
   
Total $ 1,603.11  
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Of course, this is the reimbursement by CMS and not the laboratory cost. However, this amount 
is likely close to the laboratory cost given that laboratories are unlikely to generate sizeable 
profits from CMS for a single case, nor are they likely to run at a tremendous loss because 
many AML and MDS patients are over 65 and covered by Medicare. If one were to assume that 
the laboratory generates up to 10% profit or runs at a loss of up to 20% relative to the CMS 
reimbursement amount for these tests, then the aggregate cost for these assays would be: 
Lower bound: $1,603.11 / 120% = $1,335.92 
Upper bound: $1,603.11 * 120% = $2,003.89 
These calculations are consistent with internal data on laboratory costs at Washington 
University as well as previous studies of the cost of diagnostic testing for new AML patients20. 
We note that this estimate includes a relatively small set of FISH studies. Expanding these 
would obviously increase the cost of conventional testing.  
 
Cost of WGS 
The total cost of WGS analysis was estimated using current reagent costs and labor. As stated 
in the main text of the article, the cost of WGS is driven mostly by sequencing, which is highly 
dependent on volume. This relationship relates both to the volume at the time of sequencing 
(i.e., the ‘flow cell’ used to sequence a particular batch of samples), and the overall volume in a 
laboratory, which determines the reagent cost per billion base pairs (Gbp) of sequence data 
generated. We therefore considered these variables in our cost calculations. We used costs 
from 2 sources. The first is the list price for Illumina flow cells that we combined with the 
minimum throughput for each flow cell to arrive at a cost per Gbp of sequence data generated. 
The second is the cost of commodity sequencing tracked by the National Human Genome 
Research Institute (NHGRI)21. The cost for WGS at 60x coverage (using a very conservative 
estimate of 150 Gbp of raw sequence data) using these sources is shown in the table below: 
Cost model / flow cell Flow cell throughput (Gbp) Cost Cost / Gbp Cost for 150 Gbp 
SP 200  $             3,000   $       15.00   $             2,250.00  
S1 400  $             5,250   $       13.13   $             1,968.75  
S2 1000  $             9,600   $         9.60   $             1,440.00  
S4 2400  $          14,400   $         6.00   $                900.00  
Mean across flow cells N/A 
 
 $       10.93   $             1,639.69  
NHRGI commodity cost* N/A $         6.74  $          1,011.00  
* NHGRI tracked cost of commodity sequencing, see https://www.genome.gov/about-
genomics/fact-sheets/DNA-Sequencing-Costs-Data. 
 
Additional costs for WGS include reagents for library preparation and QC, data processing and 
analysis, and technologist labor. These amounts are summarized below, assuming a mean of 2 
samples are prepared per batch: 
Item Quantity Cost Cost per sample 
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Nextera DNA Flex LPK (24) 24 libraries  $     1,038.00   $     43.25  
Nextera DNA CD Idx (24)  24 libraries $      124.00   $        5.17  
Library QC* 1 $        12.50 $       12.50 
Library quantification* 1 $        17.00 $       17.00 
Technologist labor† 12 hours/batch $        30.00/hour $       180.00 
Data processing/analysis on 
BaseSpace‡ 
1 $        25.00 $        15.60 
  Total $     273.52 
* Values are established based on current costs for Agilent TapeStation, Qubit, and qPCR reagents. 
† Labor includes library preparation, QC/quantification, and loading of sequencer 
‡ Assumes DRAGEN alignment (2 hours) and ChromoSeq analysis (2 hours) using BaseSpace Apps 
 
Combined with the raw sequencing cost, the current marginal cost range for WGS would be: 
 
Lower (NHGRI commodity cost): $1,284.52 
Mean (mean list flowcell cost): $1,913.21 
Upper (highest list flowcell cost): $2,523.52 
 
These estimates do not include additional overhead, such as amortized instrument cost, service 
contracts, proficiency testing and alternative assessments required by CAP, etc. However, in 
many laboratories some of these costs can be distributed over additional aspects of laboratory 
operations that laboratory-specific and difficult to model (e.g., other sequencing assays, 
research sequencing, etc). In addition, the assumptions here are that batch sizes will be small 
and a handled by a single technician who is dedicated to WGS, which results in higher labor 
cost. While imperfect, these estimates nonetheless provide a rough idea of the marginal cost of 
WGS compared to standard testing. 
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2. Supplementary Figures 
 
 
Figure S1A. Sample WGS text report.  
Text output of the ChromoSeq workflow showing CNAs, recurrent SVs, gene mutations, then 
novel SVs. QC data on overall coverage and coverage of specific genes appears at the bottom 




Figure S1B. Graphical WGS report.  
Page 1 of a graphical ChromoSeq report highlighting the clinically significant findings in the 




Figure S1C. Distribution of genome coverage.  
Histogram of the genome-wide coverage depth in unique reads for 235 WGS cases. 
 
 
Figure S1D. Variants detected per patient.  




















Figure S2A. Confirmation of SVs.  
FISH results from metaphase and interphase FISH analysis utilizing a dual color, breakapart 
probe targeting KMT2A (manufactured by Vysis). A normal signal hybridizaiton pattern is 2Y. 
Rearrangement of a KMT2A locus generates a separation of the green signal, which 
encompasses the 5’ segment of KMT2A and surrounding region, and the red signal, which 
encompasses the 3’ segment of KMT2A and surrounding region.  
994357) ish t(11;19)(5’KMT2A+,3’KMT2A-;3'KMT2A+) shown by WGS to have a 
t(11;19)(q23.3;p13.11) 
332282) nuc ish(KMT2Ax2)(5’KMT2A sep 3’KMT2A)x1 in sample shown by WGS to have a 
t(9;11)(p21.3;q23.3) 
677982) nuc ish(5’KMT2Ax2,3’KMT2Ax1)(5’KMT2A con 3’KMT2Ax1) in a sample shown by 
WGS to have a t(6;11)(q27;q23.3) 
616274) nuc ish(KMT2Ax2)(5’KMT2A sep 3’KMT2A)x1 in sample shown by WGS to have a 
t(9;11)(p21.3;q23.3) 






Figure S2A, continued. PCR confirmation of t(10,11) in 451513 and t(7;21) in 586748. PCR 
using primers flanking the SV breakpoint were used to amplify across the breakpoint region, 





Figure S2B. Confirmation of CNAs 
Confirmation of selected CNAs by FISH. See also Table S5.  
538465) nuc ish(D8Z2x3)[44/20],(CEP10x3)[29/200] 







Figure S2B, continued. Confirmation of CNAs. 





















Figure S2B, continued. Confirmation of CNAs. 




Figure S2C. WGS-only CNAs 
Normalized coverage plots of WGS results for CNAs that were detected by WGS but could not 







* Note for 922185, a del(20q) was also present, but was not discordant between WGS and cytogenetics.  
 





7.5% abundance 10% abundance 
13% abundance 15% abundance 
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Figure S2D. Sensitivity of WGS for mutations in AML risk-defining genes. Gold standard 
mutations NPM1 (NPM1c only), CEBPA, FLT3 (non-ITD mutations), RUNX1, and TP53 were 
obtained from targeted sequencing (>500x coverage) using a clinical assay (N=103 patients). 
FLT3-ITD mutations were obtained from clinical testing via PCR and capillary electrophoresis 
(N=104 patients). Numbers above each bar indicate the sensitivity (TP/(TP+FN) x 100) and the 







Figure S2E. FLT3-ITD detection by WGS vs. PCR. Results for 35 patients with FLT3-ITD 
mutations detected by either PCR and capillary electrophoresis or WGS. Rows show results for 
each patient with a positive ITD assay, including WGS, a clinical targeted sequencing assay, 
and PCR. The ITD allele sizes and allele ratios are indicated for each assay. Allele sizes and 
ratios were available for all positive results. Data from PCR include an in-house laboratory 
developed test (LDT) and the commercial FDA companion diagnostic assay, and therefore the 
allele size and ratios were not always reported. Note that ITD alleles were detected by WGS in 
two patients for whom the in-house LDT assay was negative (in 2002). ITD alleles were also 






Figure S2F. Abundance and coverage depth of gene mutations in WGS data. Shown are 
the VAFs from deep targeted sequencing and WGS coverage for 348 variants detected in 102 
patients using a clinical targeted sequencing assay. Left panels show the VAF from targeted 
sequencing (top) and WGS coverage for variants detected (N=300, in blue) and missed (N=48, 
in orange) by WGS. Right panels show the distribution of VAFs and WGS coverage for detected 
and missed variants. This analysis demonstrates the mutations not detected by WGS were 
significantly lower in abundance (top left; mean VAF by targeted sequencing of 14.7% vs. 
41.6%, P < 0.0001, T-test), and occurred at positions with significantly less coverage (top right) 
in the WGS data compared to those that were detected (mean WGS coverage of 43x vs. 55x, 





Figure S2G. Coverage metrics and for false negative gene mutations. Left panel shows 
WGS coverage (indicated by the height of the bar) and variant supporting reads (height of the 
blue bar) for 48 variants that were detected by clinical targeted sequencing but missed by WGS. 
Most of the variants (41/48) were present in the WGS data, but at very low frequency. Detection 
of gene variants required >3 variant-supporting reads and >6x total coverage. Variants 
highlighted by the asterisk were subsequently detected upon top-up sequencing of 4 cases. 
Right panel demonstrates the theoretical binomial sampling probability for detecting variants at 
VAFs ranging from 2% to 20% and coverage levels from 0 to 100x. Note that at 50x coverage 
(the mean obtained for this study), there is a 45% probability of sampling a variant >3 times if 
the true abundance is 5%. This is consistent with previous work showing that ‘standard 
coverage’ WGS is inadequate for robust detection of low frequency variants, but this can be 






Figure S2H. Additional variants detected after top-up sequencing. WGS missed 11 gene 
variants from patients 312088, 681540, 416413, and 262878 that were either present at low 
abundance in targeted sequencing data (<20% VAF, N=7) or occurred at position with low 
coverage in the WGS data (<25x, N=4). Additional sequencing of these samples increased the 
coverage for these samples from a mean of 35x (range: 17x-58x) to 83x (range: 59x-121x), and 
resulted in the detection of 9 of the 11 missed variants. The remaining 2 variants were present 
at low frequency in the WGS data but were not detected by the variant analysis pipeline.  
  

















































312088 chr1 114716123 NRAS p.Gly13Asp 7.7% 39 3 7.7% 72 7 9.7%
312088 chr5 171410539 NPM1 p.Trp288CysfsTer12 38.4% 24 7 24.2% 84 29 34.5%
312088 chr8 116854320 RAD21 p.Met362SerfsTer8 42.6% 27 10 32.3% 62 26 41.9%
312088 chr11 32435332 WT1 p.Ala5Val 47.6% 21 7 33.3% 39 17 43.6%
312088 chr11 32435333 WT1 p.Ala5Thr 47.7% 23 9 39.1% 41 19 46.3%
312088 chr2 25234374 DNMT3A p.Arg882Cys 44.7% 32 17 53.1% 62 36 58.1%
312088 chr12 25227342 KRAS p.Gln61Leu 8.8% 32 2 NOT DETECTED 66 7 10.6%
312088 chr12 112450359 PTPN11 p.Gly60Val 18.8% 34 4 NOT DETECTED 61 10 16.4%
681540 chr20 32434599 ASXL1 p.Glu635ArgfsTer15 10.6% 62 3 9.9% 171 16 9.4%   
681540 chr21 34886941 RUNX1 p.His85ThrfsTer38 44.3% 50 24 50.5% 150 76 50.70%
681540 chr4 105275394 TET2 p.Tyr1628Ter 5.8% 45 6 NOT DETECTED 101 9 8.90%
681540 chr4 105276142 TET2 p.Arg1878Cys 6.5% 53 2 NOT DETECTED 125 7 5.60%
681540 chrX 15818643 ZRSR2 splice 24.7% 13 5 NOT DETECTED 31 6 NOT DETECTED
416413 chr1 114716126 NRAS p.Gly12Asp 27.3% 11 3 27.3% 76 21 27.6%
416413 chr20 32434638 ASXL1 p.Gly646TrpfsTer12 41.5% 32 11 35.9% 114 44 38.6%
416413 chr11 119278568 CBL p.Ile429Asn 43.9% 22 9 40.9% 70 35 50.0%
416413 chr17 7673773 TP53 p.Arg283Cys 46.6% 11 6 54.5% 61 37 60.7%
416413 chr19 33301429 CEBPA p.Glu329GlyfsTer74 14.2% 16 0 NOT DETECTED 72 7 9.7%
416413 chr4 105235633 TET2 p.Trp564Ter 50.3% 18 4 NOT DETECTED 60 25 41.7%
416413 chr4 105236832 TET2 p.Gln964Ter 45.2% 15 3 NOT DETECTED 71 28 39.4%
416413 chrX 124081379 STAG2 splice 93.8% 6 6 NOT DETECTED 27 27 100.0%
262878 chr12 25245350 KRAS p.Gly12Asp 5.7% 60 7 11.7% 121 13 10.7%
262878 chr8 116849009 RAD21 p.Gly547AlafsTer65 36.2% 55 20 33.9% 126 38 30.2%
262878 chr5 171410539 NPM1 p.Trp288CysfsTer12 37.9% 60 23 35.2% 139 52 37.4%
262878 chr17 31221870 NF1 p.Gln554His 42.0% 47 24 51.1% 95 43 45.3%
262878 chr12 25245347 KRAS p.Gly13Asp 5.2% 59 1 NOT DETECTED 122 5 NOT DETECTED
262878 chr13 28018505 FLT3 p.Asp835His 13.1% 60 6 NOT DETECTED 121 18 14.9%
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Figure S3. Diagnostic yield from prospective sequencing of MDS patients. Diagnostic yield 
of WGS in 42 consecutive MDS patients. Figure is organized as in Figure 3B. Consecutive MDS 
patients were sequenced from April 2019 to February 2020 to estimate the diagnostic yield of 
WGS compared to standard testing. Top panel shows the cumulative number of patients with 
new findings (in blue) and the cumulative number of patients with findings that changed the 
IPSS-R cytogenetic risk score. IPSS-R from cytogenetics and sequencing are shown in the 
middle panel. Middle panels show chromosomal abnormalities obtained from WGS and 
indicates new findings (in blue) and findings that changed the IPSS-R category. Bottom panel 
shows mutations in MDS-associated genes referenced in NCCN guidelines, with concordance 
between WGS and targeted sequencing indicated by the color (concordant in black, WGS only 
in orange, and targeted sequencing only in green). Note that the yield in risk-defining events in 
this cohort is due entirely to cases where cytogenetics was unsuccessful or inconclusive, 
resulting in an undetermined IPSS-R risk category. 
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Figure S4A. AML patients with reclassified risk groups by WGS. AML patients included in 
the outcome analysis with defined cytogenetic risk that were reclassified by WGS. Top panel 
shows the ELN risk groups by cytogenetics combined with FISH for PML-RARA, RUNX1-
RUNX1T1, CBFB-MYH11, del(5q), and del(7q) (bottom), and gene mutation testing either via 
targeted sequencing or PCR, and WGS and FLT3-ITD PCR only (top). Lower panels show 
WGS results (with the risk-defining event highlighted in red), and results from cytogenetics, 
FISH, and gene mutation analysis. FLT3-ITD mutation status by PCR was used for both WGS 
and conventional risk group assignments. Cells outlined in red indicate that testing was either 
not performed or failed. Also shown is the clinical status of each patient, including whether they 
expired or relapsed, and the follow-up time in months from diagnosis. WGS identified new 
adverse risk findings in 5 patients, while 3 patients had differences in gene mutations in ASXL1 
and NPM1 and either due to lack of testing at diagnosis (N=2) or a missed low abundance 




Figure S4B,C. Survival analysis of 101 AML patients with defined risk.  
Panel B) Kaplan Meier survival curves using death as the endpoint for 101 AML patients 
treated with either post-remission chemotherapy alone (N=71) or allogeneic stem cell transplant 
(N=30) stratified by ELN risk groups from cytogenetics, targeted sequencing, and FLT3 ITD 
mutation testing. Log-rank test for equal survival across the groups, adjusted P=0.43. Age-
adjusted Cox regression for death in not adverse vs. adverse cytogenetic risk groups: 1.06, 95% 
CI 0.45 to 2.50.  
Panel C) Kaplan Meier survival curves using death as the endpoint for 101 AML patients treated 
with either post-remission chemotherapy alone (N=71) or allogeneic stem cell transplant (N=30) 
stratified by ELN risk groups from WGS and FLT3 ITD mutation testing. Log-rank test for equal 
survival across the groups, adjusted P=0.09. Age-adjusted Cox regression for death in not 







Figure S4D. WGS results for AML patients with inconclusive cytogenetics. Patients with 
unsuccessful (N=6), inconclusive (N=13), or unknown (N=8) cytogenetic and FISH studies that 
precluded definitive genomic risk assignment. WGS-based ELN risk group is shown in the top 
panel. Results from WGS, cytogenetics, FISH, and gene mutation testing are shown below. 
FLT3-ITD mutation status was determined by PCR and was used for risk stratification according 
to ELN criteria using an allele ratio cutoff of 0.5, or presence/absence if an allele ratio was not 
available. Bottom panel shows clinical status and follow-up time in months. WGS identified risk-
defining chromosomal abnormalities in four patients, including KMT2A and RUNX1-RUNX1T1 
rearrangements (N=1 each) and a complex karyotype (N=2). The remaining 23 patients were 





Figure S4E,F. Survival analysis of AML patients with inconclusive cytogenetics. 
Panel E) Kaplan Meier survival curve for 27 AML patients with unsuccessful for inconclusive 
cytogenetics stratified by gene mutations only. Patients were considered intermediate risk 
unless favorable risk or adverse risk gene mutations were identified. Log-rank test for equal 
survival across the groups, adjusted P=0.09. Age-adjusted Cox regression hazard ratio for 
death in not adverse vs. adverse risk, 0.4; 95% CI, 0.14 to 1.1. 
Panel F) Kaplan Meier survival curves using death as the endpoint for the above cohort of 38 
patients stratified by ELN risk groups from WGS and FLT3 ITD mutation testing. Median survival 
for this expanded cohort was 22.3 months, 95% CI, 6.8 to 46.1. Log-rank test for equal survival 
across the groups, adjusted P=0.02. Age-adjusted Cox regression hazard ratio for death in not 
adverse vs. adverse risk, 0.28; 95% CI, 0.11 to 0.71.  
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3. Supplementary Tables 
 
Table S1. Target list for gene mutation identification. 
Chrom Start End Exon Strand GeneName GeneID TranscriptID 
chr1 114713797 114713981 NRAS_exon_3 - NRAS ENSG00000213281 ENST00000369535 
chr1 114716047 114716163 NRAS_exon_2 - NRAS ENSG00000213281 ENST00000369535 
chr1 36466356 36466911 CSF3R_exon_17 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36467226 36467314 CSF3R_exon_16 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36467554 36467654 CSF3R_exon_15 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36467818 36467965 CSF3R_exon_14 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36468071 36468224 CSF3R_exon_13 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36469152 36469260 CSF3R_exon_12 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36469648 36469843 CSF3R_exon_11 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36471429 36471649 CSF3R_exon_10 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36472062 36472142 CSF3R_exon_9 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36472234 36472394 CSF3R_exon_8 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36472513 36472689 CSF3R_exon_7 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36473431 36473625 CSF3R_exon_6 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36473760 36473890 CSF3R_exon_5 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36475373 36475676 CSF3R_exon_4 - CSF3R ENSG00000119535 ENST00000373103 
chr1 36479429 36479499 CSF3R_exon_3 - CSF3R ENSG00000119535 ENST00000373103 
chr1 43349260 43349362 MPL_exon_10 + MPL ENSG00000117400 ENST00000372470 
chr10 110567813 110567834 SMC3_exon_1 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110568934 110569016 SMC3_exon_2 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110573703 110573748 SMC3_exon_3 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110575332 110575406 SMC3_exon_4 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110577417 110577495 SMC3_exon_5 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110577831 110577917 SMC3_exon_6 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110578624 110578709 SMC3_exon_7 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110580900 110581024 SMC3_exon_8 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110581919 110582101 SMC3_exon_9 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110582558 110582645 SMC3_exon_10 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110583380 110583551 SMC3_exon_11 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110583837 110583965 SMC3_exon_12 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110584179 110584399 SMC3_exon_13 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110589601 110589711 SMC3_exon_14 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110589888 110589994 SMC3_exon_15 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110590408 110590575 SMC3_exon_16 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110590987 110591135 SMC3_exon_17 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110593069 110593226 SMC3_exon_18 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110596394 110596553 SMC3_exon_19 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110598135 110598293 SMC3_exon_20 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110599650 110599815 SMC3_exon_21 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110600435 110600549 SMC3_exon_22 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110601018 110601133 SMC3_exon_23 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110601633 110601887 SMC3_exon_24 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110601962 110602181 SMC3_exon_25 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110602470 110602668 SMC3_exon_26 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110602821 110603005 SMC3_exon_27 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110603180 110603293 SMC3_exon_28 + SMC3 ENSG00000108055 ENST00000361804 
chr10 110604227 110604302 SMC3_exon_29 + SMC3 ENSG00000108055 ENST00000361804 
chr11 119278163 119278300 CBL_exon_8 + CBL ENSG00000110395 ENST00000264033 
chr11 119278507 119278716 CBL_exon_9 + CBL ENSG00000110395 ENST00000264033 
chr11 32389057 32389182 WT1_exon_10 - WT1 ENSG00000184937 ENST00000332351 
chr11 32391968 32392067 WT1_exon_9 - WT1 ENSG00000184937 ENST00000332351 
chr11 32392662 32392758 WT1_exon_8 - WT1 ENSG00000184937 ENST00000332351 
chr11 32396253 32396410 WT1_exon_7 - WT1 ENSG00000184937 ENST00000332351 
chr11 32399944 32400047 WT1_exon_6 - WT1 ENSG00000184937 ENST00000332351 
chr11 32416486 32416543 WT1_exon_5 - WT1 ENSG00000184937 ENST00000332351 
chr11 32417573 32417657 WT1_exon_4 - WT1 ENSG00000184937 ENST00000332351 
chr11 32427952 32428061 WT1_exon_3 - WT1 ENSG00000184937 ENST00000332351 
chr11 32428493 32428622 WT1_exon_2 - WT1 ENSG00000184937 ENST00000332351 
chr11 32434696 32435348 WT1_exon_1 - WT1 ENSG00000184937 ENST00000332351 
chr12 112450315 112450515 PTPN11_exon_3 + PTPN11 ENSG00000179295 ENST00000351677 
chr12 112489021 112489178 PTPN11_exon_13 + PTPN11 ENSG00000179295 ENST00000351677 
chr12 112502141 112502259 PTPN11_exon_14 + PTPN11 ENSG00000179295 ENST00000351677 
chr12 11650124 11650163 ETV6_exon_1 + ETV6 ENSG00000139083 ENST00000396373 
chr12 11752446 11752582 ETV6_exon_2 + ETV6 ENSG00000139083 ENST00000396373 
chr12 11839136 11839307 ETV6_exon_3 + ETV6 ENSG00000139083 ENST00000396373 
chr12 11853423 11853564 ETV6_exon_4 + ETV6 ENSG00000139083 ENST00000396373 
chr12 11869420 11869972 ETV6_exon_5 + ETV6 ENSG00000139083 ENST00000396373 
chr12 11884441 11884590 ETV6_exon_6 + ETV6 ENSG00000139083 ENST00000396373 
chr12 11885922 11886029 ETV6_exon_7 + ETV6 ENSG00000139083 ENST00000396373 
chr12 11890937 11891046 ETV6_exon_8 + ETV6 ENSG00000139083 ENST00000396373 
chr12 25227231 25227415 KRAS_exon_3 - KRAS ENSG00000133703 ENST00000256078 
chr12 25245271 25245387 KRAS_exon_2 - KRAS ENSG00000133703 ENST00000256078 
chr13 28018463 28018592 FLT3_exon_20 - FLT3 ENSG00000122025 ENST00000241453 
chr13 28033884 28033994 FLT3_exon_15 - FLT3 ENSG00000122025 ENST00000241453 
chr13 28034079 28034217 FLT3_exon_14 - FLT3 ENSG00000122025 ENST00000241453 
chr13 28034298 28034410 FLT3_exon_13 - FLT3 ENSG00000122025 ENST00000241453 
chr15 90088584 90088750 IDH2_exon_4 - IDH2 ENSG00000182054 ENST00000330062 
chr17 31095306 31095372 NF1_exon_1 + NF1 ENSG00000196712 ENST00000358273 
chr17 31155979 31156129 NF1_exon_2 + NF1 ENSG00000196712 ENST00000358273 
chr17 31159006 31159096 NF1_exon_3 + NF1 ENSG00000196712 ENST00000358273 
chr17 31163182 31163379 NF1_exon_4 + NF1 ENSG00000196712 ENST00000358273 
chr17 31169887 31170000 NF1_exon_5 + NF1 ENSG00000196712 ENST00000358273 
chr17 31181418 31181492 NF1_exon_6 + NF1 ENSG00000196712 ENST00000358273 
chr17 31181706 31181788 NF1_exon_7 + NF1 ENSG00000196712 ENST00000358273 
chr17 31182504 31182668 NF1_exon_8 + NF1 ENSG00000196712 ENST00000358273 
chr17 31200418 31200598 NF1_exon_9 + NF1 ENSG00000196712 ENST00000358273 
chr17 31201033 31201162 NF1_exon_10 + NF1 ENSG00000196712 ENST00000358273 
chr17 31201407 31201488 NF1_exon_11 + NF1 ENSG00000196712 ENST00000358273 
chr17 31206236 31206374 NF1_exon_12 + NF1 ENSG00000196712 ENST00000358273 
chr17 31214447 31214588 NF1_exon_13 + NF1 ENSG00000196712 ENST00000358273 
chr17 31219001 31219121 NF1_exon_14 + NF1 ENSG00000196712 ENST00000358273 
chr17 31221846 31221932 NF1_exon_15 + NF1 ENSG00000196712 ENST00000358273 
chr17 31223440 31223570 NF1_exon_16 + NF1 ENSG00000196712 ENST00000358273 
chr17 31225091 31225253 NF1_exon_17 + NF1 ENSG00000196712 ENST00000358273 
chr17 31226431 31226687 NF1_exon_18 + NF1 ENSG00000196712 ENST00000358273 
chr17 31227214 31227294 NF1_exon_19 + NF1 ENSG00000196712 ENST00000358273 
chr17 31227519 31227609 NF1_exon_20 + NF1 ENSG00000196712 ENST00000358273 
chr17 31229021 31229468 NF1_exon_21 + NF1 ENSG00000196712 ENST00000358273 
chr17 31229831 31229977 NF1_exon_22 + NF1 ENSG00000196712 ENST00000358273 
chr17 31230256 31230385 NF1_exon_23 + NF1 ENSG00000196712 ENST00000358273 
chr17 31230838 31230928 NF1_exon_24 + NF1 ENSG00000196712 ENST00000358273 
chr17 31232069 31232192 NF1_exon_25 + NF1 ENSG00000196712 ENST00000358273 
chr17 31232696 31232884 NF1_exon_26 + NF1 ENSG00000196712 ENST00000358273 
chr17 31232998 31233216 NF1_exon_27 + NF1 ENSG00000196712 ENST00000358273 
chr17 31235607 31235775 NF1_exon_28 + NF1 ENSG00000196712 ENST00000358273 
chr17 31235914 31236024 NF1_exon_29 + NF1 ENSG00000196712 ENST00000358273 
chr17 31248980 31249122 NF1_exon_30 + NF1 ENSG00000196712 ENST00000358273 
chr17 31252934 31253003 NF1_exon_31 + NF1 ENSG00000196712 ENST00000358273 
chr17 31258340 31258505 NF1_exon_32 + NF1 ENSG00000196712 ENST00000358273 
chr17 31259028 31259132 NF1_exon_33 + NF1 ENSG00000196712 ENST00000358273 
chr17 31260365 31260518 NF1_exon_34 + NF1 ENSG00000196712 ENST00000358273 
chr17 31261707 31261860 NF1_exon_35 + NF1 ENSG00000196712 ENST00000358273 
chr17 31265225 31265342 NF1_exon_36 + NF1 ENSG00000196712 ENST00000358273 
chr17 31325816 31326255 NF1_exon_37 + NF1 ENSG00000196712 ENST00000358273 
chr17 31327495 31327842 NF1_exon_38 + NF1 ENSG00000196712 ENST00000358273 
chr17 31330292 31330501 NF1_exon_39 + NF1 ENSG00000196712 ENST00000358273 
chr17 31334834 31335034 NF1_exon_40 + NF1 ENSG00000196712 ENST00000358273 
chr17 31336329 31336476 NF1_exon_41 + NF1 ENSG00000196712 ENST00000358273 
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chr17 31336631 31336917 NF1_exon_42 + NF1 ENSG00000196712 ENST00000358273 
chr17 31337364 31337585 NF1_exon_43 + NF1 ENSG00000196712 ENST00000358273 
chr17 31337815 31337883 NF1_exon_44 + NF1 ENSG00000196712 ENST00000358273 
chr17 31338021 31338142 NF1_exon_45 + NF1 ENSG00000196712 ENST00000358273 
chr17 31338700 31338808 NF1_exon_46 + NF1 ENSG00000196712 ENST00000358273 
chr17 31340501 31340648 NF1_exon_47 + NF1 ENSG00000196712 ENST00000358273 
chr17 31343005 31343138 NF1_exon_48 + NF1 ENSG00000196712 ENST00000358273 
chr17 31349116 31349254 NF1_exon_49 + NF1 ENSG00000196712 ENST00000358273 
chr17 31350179 31350321 NF1_exon_50 + NF1 ENSG00000196712 ENST00000358273 
chr17 31352253 31352417 NF1_exon_51 + NF1 ENSG00000196712 ENST00000358273 
chr17 31356456 31356585 NF1_exon_52 + NF1 ENSG00000196712 ENST00000358273 
chr17 31356956 31357093 NF1_exon_53 + NF1 ENSG00000196712 ENST00000358273 
chr17 31357265 31357372 NF1_exon_54 + NF1 ENSG00000196712 ENST00000358273 
chr17 31358476 31358625 NF1_exon_55 + NF1 ENSG00000196712 ENST00000358273 
chr17 31358965 31359018 NF1_exon_56 + NF1 ENSG00000196712 ENST00000358273 
chr17 31360483 31360706 NF1_exon_57 + NF1 ENSG00000196712 ENST00000358273 
chr17 31374009 31374155 NF1_exon_58 + NF1 ENSG00000196712 ENST00000358273 
chr17 31937243 31937523 SUZ12_exon_1 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31940282 31940335 SUZ12_exon_2 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31940418 31940489 SUZ12_exon_3 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31947613 31947688 SUZ12_exon_4 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31966143 31966199 SUZ12_exon_5 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31973142 31973234 SUZ12_exon_6 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31975478 31975716 SUZ12_exon_7 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31976517 31976617 SUZ12_exon_8 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31982995 31983107 SUZ12_exon_9 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31988316 31988500 SUZ12_exon_10 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31993238 31993336 SUZ12_exon_11 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31993861 31994011 SUZ12_exon_12 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31994560 31994724 SUZ12_exon_13 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31995560 31995765 SUZ12_exon_14 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31996794 31996880 SUZ12_exon_15 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 31998654 31999003 SUZ12_exon_16 + SUZ12 ENSG00000178691 ENST00000322652 
chr17 60662991 60663552 PPM1D_exon_6 + PPM1D ENSG00000170836 ENST00000305921 
chr17 7669608 7669693 TP53_exon_11 - TP53 ENSG00000141510 ENST00000269305 
chr17 7670605 7670718 TP53_exon_10 - TP53 ENSG00000141510 ENST00000269305 
chr17 7673531 7673611 TP53_exon_9 - TP53 ENSG00000141510 ENST00000269305 
chr17 76736796 76737163 SRSF2_exon_1 - SRSF2 ENSG00000161547 ENST00000392485 
chr17 7673697 7673840 TP53_exon_8 - TP53 ENSG00000141510 ENST00000269305 
chr17 7674177 7674293 TP53_exon_7 - TP53 ENSG00000141510 ENST00000269305 
chr17 7674855 7674974 TP53_exon_6 - TP53 ENSG00000141510 ENST00000269305 
chr17 7675049 7675239 TP53_exon_5 - TP53 ENSG00000141510 ENST00000269305 
chr17 7675990 7676275 TP53_exon_4 - TP53 ENSG00000141510 ENST00000269305 
chr17 7676378 7676406 TP53_exon_3 - TP53 ENSG00000141510 ENST00000269305 
chr17 7676517 7676597 TP53_exon_2 - TP53 ENSG00000141510 ENST00000269305 
chr19 12943710 12943913 CALR_exon_9 + CALR ENSG00000179218 ENST00000316448 
chr19 33301337 33302417 CEBPA_exon_1 - CEBPA ENSG00000245848 ENST00000498907 
chr2 197392302 197392464 SF3B1_exon_25 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197392968 197393191 SF3B1_exon_24 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197396052 197396331 SF3B1_exon_23 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197397981 197398119 SF3B1_exon_22 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197398457 197398584 SF3B1_exon_21 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197400051 197400169 SF3B1_exon_20 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197400248 197400437 SF3B1_exon_19 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197400711 197400939 SF3B1_exon_18 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197401396 197401528 SF3B1_exon_17 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197401738 197401891 SF3B1_exon_16 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197401981 197402133 SF3B1_exon_15 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197402552 197402829 SF3B1_exon_14 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197402945 197403038 SF3B1_exon_13 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197403581 197403767 SF3B1_exon_12 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197405072 197405180 SF3B1_exon_11 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197405271 197405475 SF3B1_exon_10 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197407994 197408122 SF3B1_exon_9 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197408365 197408584 SF3B1_exon_8 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197409766 197410010 SF3B1_exon_7 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197416737 197416914 SF3B1_exon_6 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197418505 197418591 SF3B1_exon_5 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197420424 197420545 SF3B1_exon_4 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197421025 197421136 SF3B1_exon_3 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197423804 197423977 SF3B1_exon_2 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 197434968 197435002 SF3B1_exon_1 - SF3B1 ENSG00000115524 ENST00000335508 
chr2 208248366 208248663 IDH1_exon_4 - IDH1 ENSG00000138413 ENST00000415913 
chr2 25234278 25234423 DNMT3A_exon_23 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25235703 25235828 DNMT3A_exon_22 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25236932 25237008 DNMT3A_exon_21 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25239126 25239218 DNMT3A_exon_20 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25240298 25240453 DNMT3A_exon_19 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25240636 25240733 DNMT3A_exon_18 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25241558 25241710 DNMT3A_exon_17 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25243894 25243985 DNMT3A_exon_16 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25244151 25244341 DNMT3A_exon_15 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25244536 25244655 DNMT3A_exon_14 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25245249 25245335 DNMT3A_exon_13 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25246016 25246067 DNMT3A_exon_12 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25246156 25246312 DNMT3A_exon_11 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25246616 25246779 DNMT3A_exon_10 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25247047 25247161 DNMT3A_exon_9 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25247587 25247752 DNMT3A_exon_8 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25248033 25248255 DNMT3A_exon_7 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25274937 25275090 DNMT3A_exon_6 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25275496 25275546 DNMT3A_exon_5 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25282437 25282714 DNMT3A_exon_4 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25300135 25300246 DNMT3A_exon_3 - DNMT3A ENSG00000119772 ENST00000264709 
chr2 25313909 25313987 DNMT3A_exon_2 - DNMT3A ENSG00000119772 ENST00000264709 
chr20 32358772 32358835 ASXL1_exon_1 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32366380 32366469 ASXL1_exon_2 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32367723 32367732 ASXL1_exon_3 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32369011 32369126 ASXL1_exon_4 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32428124 32428251 ASXL1_exon_5 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32428321 32428425 ASXL1_exon_6 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32429334 32429434 ASXL1_exon_7 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32429897 32430056 ASXL1_exon_8 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32431317 32431487 ASXL1_exon_9 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32431579 32431682 ASXL1_exon_10 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32432876 32432988 ASXL1_exon_11 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32433280 32433920 ASXL1_exon_12 + ASXL1 ENSG00000171456 ENST00000375687 
chr20 32434428 32437338 ASXL1_exon_13 + ASXL1 ENSG00000171456 ENST00000375687 
chr21 34792134 34792613 RUNX1_exon_8 - RUNX1 ENSG00000159216 ENST00000300305 
chr21 34799297 34799465 RUNX1_exon_7 - RUNX1 ENSG00000159216 ENST00000300305 
chr21 34834406 34834604 RUNX1_exon_6 - RUNX1 ENSG00000159216 ENST00000300305 
chr21 34859470 34859581 RUNX1_exon_5 - RUNX1 ENSG00000159216 ENST00000300305 
chr21 34880553 34880716 RUNX1_exon_4 - RUNX1 ENSG00000159216 ENST00000300305 
chr21 34886839 34887099 RUNX1_exon_3 - RUNX1 ENSG00000159216 ENST00000300305 
chr21 34892921 34892966 RUNX1_exon_2 - RUNX1 ENSG00000159216 ENST00000300305 
chr21 35048838 35048902 RUNX1_exon_1 - RUNX1 ENSG00000159216 ENST00000300305 
chr21 43094652 43094791 U2AF1_exon_6 - U2AF1 ENSG00000160201 ENST00000291552 
chr21 43104312 43104405 U2AF1_exon_2 - U2AF1 ENSG00000160201 ENST00000291552 
chr3 128481018 128481321 GATA2_exon_6 - GATA2 ENSG00000179348 ENST00000341105 
chr3 128481815 128481947 GATA2_exon_5 - GATA2 ENSG00000179348 ENST00000341105 
chr3 128483856 128484008 GATA2_exon_4 - GATA2 ENSG00000179348 ENST00000341105 
chr3 128485723 128486371 GATA2_exon_3 - GATA2 ENSG00000179348 ENST00000341105 
chr3 128486799 128487034 GATA2_exon_2 - GATA2 ENSG00000179348 ENST00000341105 
chr4 105233939 105237354 TET2_exon_3 + TET2 ENSG00000168769 ENST00000540549 
chr4 105241335 105241432 TET2_exon_4 + TET2 ENSG00000168769 ENST00000540549 
chr4 105242830 105242930 TET2_exon_5 + TET2 ENSG00000168769 ENST00000540549 
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chr4 105243566 105243781 TET2_exon_6 + TET2 ENSG00000168769 ENST00000540549 
chr4 105259615 105259772 TET2_exon_7 + TET2 ENSG00000168769 ENST00000540549 
chr4 105261755 105261851 TET2_exon_8 + TET2 ENSG00000168769 ENST00000540549 
chr4 105269606 105269750 TET2_exon_9 + TET2 ENSG00000168769 ENST00000540549 
chr4 105272560 105272921 TET2_exon_10 + TET2 ENSG00000168769 ENST00000540549 
chr4 105275044 105276519 TET2_exon_11 + TET2 ENSG00000168769 ENST00000540549 
chr4 54695509 54695784 KIT_exon_2 + KIT ENSG00000157404 ENST00000288135 
chr4 54723581 54723701 KIT_exon_8 + KIT ENSG00000157404 ENST00000288135 
chr4 54725854 54726053 KIT_exon_9 + KIT ENSG00000157404 ENST00000288135 
chr4 54727215 54727327 KIT_exon_10 + KIT ENSG00000157404 ENST00000288135 
chr4 54727413 54727545 KIT_exon_11 + KIT ENSG00000157404 ENST00000288135 
chr4 54728008 54728124 KIT_exon_13 + KIT ENSG00000157404 ENST00000288135 
chr4 54733067 54733195 KIT_exon_17 + KIT ENSG00000157404 ENST00000288135 
chr5 171410524 171410565 NPM1_exon_11 + NPM1 ENSG00000181163 ENST00000296930 
chr7 101816027 101816096 CUX1_exon_1 + CUX1 ENSG00000257923 ENST00000360264 
chr7 101916111 101916228 CUX1_exon_2 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102028094 102028148 CUX1_exon_3 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102070335 102070420 CUX1_exon_4 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102097360 102097504 CUX1_exon_5 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102104332 102104462 CUX1_exon_6 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102111694 102111777 CUX1_exon_7 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102115203 102115276 CUX1_exon_8 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102158556 102158611 CUX1_exon_9 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102170442 102170553 CUX1_exon_10 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102178465 102178660 CUX1_exon_11 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102189809 102189874 CUX1_exon_12 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102193838 102193893 CUX1_exon_13 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102195503 102195606 CUX1_exon_14 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102196630 102197308 CUX1_exon_15 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102198798 102198870 CUX1_exon_16 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102200067 102200175 CUX1_exon_17 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102201356 102202207 CUX1_exon_18 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102204387 102204559 CUX1_exon_19 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102205110 102205173 CUX1_exon_20 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102227363 102227672 CUX1_exon_21 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102234048 102234243 CUX1_exon_22 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102239316 102239587 CUX1_exon_23 + CUX1 ENSG00000257923 ENST00000360264 
chr7 102248408 102249042 CUX1_exon_24 + CUX1 ENSG00000257923 ENST00000360264 
chr7 140753272 140753396 BRAF_exon_15 - BRAF ENSG00000157764 ENST00000288602 
chr7 148807645 148807709 EZH2_exon_20 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148809067 148809158 EZH2_exon_19 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148809306 148809393 EZH2_exon_18 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148810329 148810417 EZH2_exon_17 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148811621 148811723 EZH2_exon_16 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148813955 148814140 EZH2_exon_15 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148814910 148815042 EZH2_exon_14 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148815502 148815549 EZH2_exon_13 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148816680 148816781 EZH2_exon_12 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148817218 148817394 EZH2_exon_11 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148817873 148818120 EZH2_exon_10 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148819592 148819690 EZH2_exon_9 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148826450 148826635 EZH2_exon_8 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148827160 148827269 EZH2_exon_7 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148828736 148828883 EZH2_exon_6 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148829724 148829851 EZH2_exon_5 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148832630 148832753 EZH2_exon_4 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148846466 148846601 EZH2_exon_3 - EZH2 ENSG00000106462 ENST00000320356 
chr7 148847178 148847301 EZH2_exon_2 - EZH2 ENSG00000106462 ENST00000320356 
chr8 116847499 116847694 RAD21_exon_14 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116848942 116849032 RAD21_exon_13 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116850614 116850770 RAD21_exon_12 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116851944 116852099 RAD21_exon_11 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116852545 116852711 RAD21_exon_10 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116854241 116854471 RAD21_exon_9 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116856162 116856291 RAD21_exon_8 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116856642 116856774 RAD21_exon_7 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116857263 116857476 RAD21_exon_6 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116858348 116858461 RAD21_exon_5 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116861837 116861943 RAD21_exon_4 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116863126 116863262 RAD21_exon_3 - RAD21 ENSG00000164754 ENST00000297338 
chr8 116866582 116866732 RAD21_exon_2 - RAD21 ENSG00000164754 ENST00000297338 
chr9 5069922 5070055 JAK2_exon_12 + JAK2 ENSG00000096968 ENST00000381652 
chr9 5073695 5073788 JAK2_exon_14 + JAK2 ENSG00000096968 ENST00000381652 
chrX 124022624 124022674 STAG2_exon_3 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124025836 124025921 STAG2_exon_4 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124030957 124031128 STAG2_exon_5 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124037523 124037626 STAG2_exon_6 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124042565 124042648 STAG2_exon_7 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124045160 124045371 STAG2_exon_8 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124047350 124047508 STAG2_exon_9 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124049001 124049081 STAG2_exon_10 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124050182 124050312 STAG2_exon_11 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124051117 124051222 STAG2_exon_12 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124051311 124051397 STAG2_exon_13 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124056124 124056238 STAG2_exon_14 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124057862 124057980 STAG2_exon_15 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124061220 124061344 STAG2_exon_16 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124061767 124061877 STAG2_exon_17 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124062898 124062997 STAG2_exon_18 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124063112 124063208 STAG2_exon_19 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124063844 124064054 STAG2_exon_20 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124065872 124065949 STAG2_exon_21 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124066171 124066265 STAG2_exon_22 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124066352 124066439 STAG2_exon_23 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124068560 124068659 STAG2_exon_24 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124071145 124071326 STAG2_exon_25 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124076328 124076474 STAG2_exon_26 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124077953 124078061 STAG2_exon_27 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124081376 124081531 STAG2_exon_28 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124083417 124083552 STAG2_exon_29 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124086543 124086773 STAG2_exon_30 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124090571 124090767 STAG2_exon_31 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124090850 124090967 STAG2_exon_32 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124094014 124094147 STAG2_exon_33 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124095368 124095452 STAG2_exon_34 + STAG2 ENSG00000101972 ENST00000218089 
chrX 124100570 124100597 STAG2_exon_35 + STAG2 ENSG00000101972 ENST00000218089 
chrX 130005228 130005320 BCORL1_exon_1 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 130012574 130012671 BCORL1_exon_2 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 130012946 130016216 BCORL1_exon_3 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 130020981 130021153 BCORL1_exon_4 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 130022893 130022980 BCORL1_exon_5 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 130024986 130025382 BCORL1_exon_6 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 130028631 130028864 BCORL1_exon_7 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 130037363 130037536 BCORL1_exon_8 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 130039133 130039285 BCORL1_exon_9 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 130050713 130050797 BCORL1_exon_10 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 130051856 130052019 BCORL1_exon_11 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 130055850 130056136 BCORL1_exon_12 + BCORL1 ENSG00000085185 ENST00000540052 
chrX 134377614 134377758 PHF6_exon_2 + PHF6 ENSG00000156531 ENST00000332070 
chrX 134378001 134378109 PHF6_exon_3 + PHF6 ENSG00000156531 ENST00000332070 
chrX 134393497 134393637 PHF6_exon_4 + PHF6 ENSG00000156531 ENST00000332070 
chrX 134393905 134393955 PHF6_exon_5 + PHF6 ENSG00000156531 ENST00000332070 
chrX 134413487 134413660 PHF6_exon_6 + PHF6 ENSG00000156531 ENST00000332070 
chrX 134413819 134413969 PHF6_exon_7 + PHF6 ENSG00000156531 ENST00000332070 
chrX 134415012 134415123 PHF6_exon_8 + PHF6 ENSG00000156531 ENST00000332070 
chrX 134417165 134417305 PHF6_exon_9 + PHF6 ENSG00000156531 ENST00000332070 
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chrX 134425197 134425330 PHF6_exon_10 + PHF6 ENSG00000156531 ENST00000332070 
chrX 15321505 15321775 PIGA_exon_6 - PIGA ENSG00000165195 ENST00000333590 
chrX 15324661 15324874 PIGA_exon_5 - PIGA ENSG00000165195 ENST00000333590 
chrX 15325016 15325155 PIGA_exon_4 - PIGA ENSG00000165195 ENST00000333590 
chrX 15325910 15326049 PIGA_exon_3 - PIGA ENSG00000165195 ENST00000333590 
chrX 15331212 15331933 PIGA_exon_2 - PIGA ENSG00000165195 ENST00000333590 
chrX 15790492 15790539 ZRSR2_exon_1 + ZRSR2 ENSG00000169249 ENST00000307771 
chrX 15790930 15791016 ZRSR2_exon_2 + ZRSR2 ENSG00000169249 ENST00000307771 
chrX 15799868 15799956 ZRSR2_exon_3 + ZRSR2 ENSG00000169249 ENST00000307771 
chrX 15803684 15803799 ZRSR2_exon_4 + ZRSR2 ENSG00000169249 ENST00000307771 
chrX 15804107 15804200 ZRSR2_exon_5 + ZRSR2 ENSG00000169249 ENST00000307771 
chrX 15808229 15808274 ZRSR2_exon_6 + ZRSR2 ENSG00000169249 ENST00000307771 
chrX 15809196 15809321 ZRSR2_exon_7 + ZRSR2 ENSG00000169249 ENST00000307771 
chrX 15815673 15815893 ZRSR2_exon_8 + ZRSR2 ENSG00000169249 ENST00000307771 
chrX 15818583 15818645 ZRSR2_exon_9 + ZRSR2 ENSG00000169249 ENST00000307771 
chrX 15820203 15820319 ZRSR2_exon_10 + ZRSR2 ENSG00000169249 ENST00000307771 
chrX 15822727 15823242 ZRSR2_exon_11 + ZRSR2 ENSG00000169249 ENST00000307771 
chrX 40052108 40052403 BCOR_exon_15 - BCOR ENSG00000183337 ENST00000378444 
chrX 40053882 40054045 BCOR_exon_14 - BCOR ENSG00000183337 ENST00000378444 
chrX 40054252 40054336 BCOR_exon_13 - BCOR ENSG00000183337 ENST00000378444 
chrX 40055364 40055516 BCOR_exon_12 - BCOR ENSG00000183337 ENST00000378444 
chrX 40057151 40057324 BCOR_exon_11 - BCOR ENSG00000183337 ENST00000378444 
chrX 40062135 40062396 BCOR_exon_10 - BCOR ENSG00000183337 ENST00000378444 
chrX 40062742 40063074 BCOR_exon_9 - BCOR ENSG00000183337 ENST00000378444 
chrX 40063604 40063955 BCOR_exon_8 - BCOR ENSG00000183337 ENST00000378444 
chrX 40064332 40064602 BCOR_exon_7 - BCOR ENSG00000183337 ENST00000378444 
chrX 40070969 40071162 BCOR_exon_6 - BCOR ENSG00000183337 ENST00000378444 
chrX 40071633 40071693 BCOR_exon_5 - BCOR ENSG00000183337 ENST00000378444 
chrX 40072345 40075183 BCOR_exon_4 - BCOR ENSG00000183337 ENST00000378444 
chrX 40076450 40076535 BCOR_exon_3 - BCOR ENSG00000183337 ENST00000378444 
chrX 40077840 40077932 BCOR_exon_2 - BCOR ENSG00000183337 ENST00000378444 
chrX 53380102 53380189 SMC1A_exon_25 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53380616 53380733 SMC1A_exon_24 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53381014 53381090 SMC1A_exon_23 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53382228 53382386 SMC1A_exon_22 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53382502 53382663 SMC1A_exon_21 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53383093 53383256 SMC1A_exon_20 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53394774 53394891 SMC1A_exon_19 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53396223 53396383 SMC1A_exon_18 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53396468 53396620 SMC1A_exon_17 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53399585 53399733 SMC1A_exon_16 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53403562 53403675 SMC1A_exon_15 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53403773 53403896 SMC1A_exon_14 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53405008 53405152 SMC1A_exon_13 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53405241 53405394 SMC1A_exon_12 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53405489 53405675 SMC1A_exon_11 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53405767 53405959 SMC1A_exon_10 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53409058 53409272 SMC1A_exon_9 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53409417 53409506 SMC1A_exon_8 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53411757 53411904 SMC1A_exon_7 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53411991 53412256 SMC1A_exon_6 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53412896 53413141 SMC1A_exon_5 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53413228 53413438 SMC1A_exon_4 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53414754 53414873 SMC1A_exon_3 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53414977 53415172 SMC1A_exon_2 - SMC1A ENSG00000072501 ENST00000322213 
chrX 53422488 53422603 SMC1A_exon_1 - SMC1A ENSG00000072501 ENST00000322213 
Coordinates are based on the GRCh38 human reference 




Table S2. Recurrent SVs in AML and MDS. 
Chrom1 Start1 End1 Chrom2 Start2 End2 Gene_Pair Gene1_Strand Gene2_Strand 
chr1 3069210 3438621 chr1 2228694 2310119 PRDM16_SKI + + 
chr1 110338505 110346677 chr22 40410280 40636685 RBM15_MRTFA + - 
chr1 148808465 149032955 chr5 150113836 150155860 PDE4DIP_PDGFRB + - 
chr1 154157317 154192058 chr5 150113836 150155860 TPM3_PDGFRB - - 
chr1 186311651 186375325 chr8 38411138 38468834 TPR_FGFR1 - - 
chr1 221701423 221742176 chr1 3069210 3438621 DUSP10_PRDM16 - + 
chr1 234604268 234609525 chr17 40309193 40356796 IRF2BP2_RARA - + 
chr10 134464 254626 chr17 51177424 51260066 ZMYND11_MBTD1 + - 
chr10 21524674 21743630 chr9 41890313 42129250 MLLT10_CNTNAP3B + - 
chr10 21524674 21743630 chrX 41333347 41364472 MLLT10_DDX3X + + 
chr10 32009009 32056431 chr4 54229096 54298247 KIF5B_PDGFRA - + 
chr10 59788762 59906656 chr5 150113836 150155860 CCDC6_PDGFRB - - 
chr10 74824935 75032284 chr16 3725053 3880726 KAT6B_CREBBP + - 
chr10 94501433 94602098 chr8 2938098 4994972 HELLS_CSMD1 + - 
chr10 101130504 101137789 chr7 142299010 142813287 TLX1_TRB + + 
chr10 102394109 102402529 chr6 117288299 117425855 NFKB2_ROS1 + - 
chr11 925808 1012245 chr14 52004802 52069228 AP2A2_NID2 + - 
chr11 3675009 3797792 chr11 3675009 3797792 NUP98_NUP98 - - 
chr11 3675009 3797792 chr11 108665024 108940930 NUP98_DDX10 - + 
chr11 3675009 3797792 chr11 118436463 118526832 NUP98_KMT2A - + 
chr11 3675009 3797792 chr12 280128 389454 NUP98_KDM5A - - 
chr11 3675009 3797792 chr17 7235027 7239506 NUP98_PHF23 - - 
chr11 3675009 3797792 chr2 176092890 176095938 NUP98_HOXD13 - + 
chr11 3675009 3797792 chr2 176107285 176109588 NUP98_HOXD11 - + 
chr11 3675009 3797792 chr20 41028817 41124487 NUP98_TOP1 - + 
chr11 3675009 3797792 chr3 87259403 87276587 NUP98_POU1F1 - - 
chr11 3675009 3797792 chr3 100401192 100456319 NUP98_LNP1 - + 
chr11 3675009 3797792 chr5 177133078 177300210 NUP98_NSD1 - + 
chr11 3675009 3797792 chr6 138773508 138793317 NUP98_CCDC28A - + 
chr11 3675009 3797792 chr7 27162434 27165530 NUP98_HOXA9 - - 
chr11 3675009 3797792 chr7 27181514 27185216 NUP98_HOXA11 - - 
chr11 3675009 3797792 chr7 27194363 27200106 NUP98_HOXA13 - - 
chr11 3675009 3797792 chr8 38269696 38382272 NUP98_NSD3 - - 
chr11 3675009 3797792 chr9 15464065 15511019 NUP98_PSIP1 - - 
chr11 3675009 3797792 chr9 129665640 129722674 NUP98_PRRX2 - + 
chr11 3675009 3797792 chrX 150983285 150990775 NUP98_HMGB3 - + 
chr11 3855701 4093209 chr5 177133078 177300210 STIM1_NSD1 + + 
chr11 8106092 8169043 chr7 142299010 142813287 RIC3_TRB - + 
chr11 8106092 8169043 chr7 142801040 142802748 RIC3_TRBC2 - + 
chr11 20156154 20160613 chr9 36833274 37034185 DBX1_PAX5 - - 
chr11 34051682 34101156 chr5 150113836 150155860 CAPRIN1_PDGFRB + - 
chr11 59142747 59155039 chr6 135181314 135219171 FAM111A_MYB + + 
chr11 62559600 62573973 chr6 73368554 73395093 EEF1G_OOEP - - 
chr11 72002864 72080693 chr17 40309193 40356796 NUMA1_RARA - + 
chr11 72814405 72843674 chr11 118436463 118526832 ATG16L2_KMT2A + + 
chr11 85957687 86069097 chr10 21524674 21743630 PICALM_MLLT10 - + 
chr11 101451563 101583928 chr8 109240918 109334385 TRPC6_NUDCD1 - - 
chr11 114059592 114250676 chr17 40309193 40356796 ZBTB16_RARA + + 
chr11 117427772 117797261 chr11 118436463 118526832 DSCAML1_KMT2A - + 
chr11 117836980 117877486 chr11 118436463 118526832 FXYD6_KMT2A - + 
chr11 118436463 118526832 chr1 51354262 51519328 KMT2A_EPS15 + - 
chr11 118436463 118526832 chr1 151057757 151068497 KMT2A_MLLT11 + + 
chr11 118436463 118526832 chr10 20783905 21174187 KMT2A_NEBL + - 
chr11 118436463 118526832 chr10 21524674 21743630 KMT2A_MLLT10 + + 
chr11 118436463 118526832 chr10 26746595 26861087 KMT2A_ABI1 + - 
chr11 118436463 118526832 chr10 68560655 68694482 KMT2A_TET1 + + 
chr11 118436463 118526832 chr11 73308288 73369091 KMT2A_ARHGEF17 + + 
chr11 118436463 118526832 chr11 85957687 86069097 KMT2A_PICALM + - 
chr11 118436463 118526832 chr11 95976597 96343180 KMT2A_MAML2 + - 
chr11 118436463 118526832 chr11 118436463 118526832 KMT2A_KMT2A + + 
chr11 118436463 118526832 chr11 119206275 119308149 KMT2A_CBL + + 
chr11 118436463 118526832 chr11 120337077 120489936 KMT2A_ARHGEF12 + + 
chr11 118436463 118526832 chr12 55757273 55817756 KMT2A_SARNP + - 
chr11 118436463 118526832 chr14 66507406 67181803 KMT2A_GPHN + + 
chr11 118436463 118526832 chr14 104865279 104896742 KMT2A_CEP170B + + 
chr11 118436463 118526832 chr15 40594019 40664342 KMT2A_KNL1 + + 
chr11 118436463 118526832 chr15 40807088 40815084 KMT2A_ZFYVE19 + + 
chr11 118436463 118526832 chr16 3725053 3880726 KMT2A_CREBBP + - 
chr11 118436463 118526832 chr17 9913849 10198551 KMT2A_GAS7 + - 
chr11 118436463 118526832 chr17 38705541 38729803 KMT2A_MLLT6 + + 
chr11 118436463 118526832 chr17 38869858 38921770 KMT2A_LASP1 + + 
chr11 118436463 118526832 chr17 40309193 40356796 KMT2A_RARA + + 
chr11 118436463 118526832 chr19 4360369 4400547 KMT2A_SH3GL1 + - 
chr11 118436463 118526832 chr19 6210378 6279948 KMT2A_MLLT1 + - 
chr11 118436463 118526832 chr19 18442662 18522127 KMT2A_ELL + - 
chr11 118436463 118526832 chr2 203328218 203447723 KMT2A_ABI2 + + 
chr11 118436463 118526832 chr22 41091785 41180079 KMT2A_EP300 + + 
chr11 118436463 118526832 chr3 48673843 48685927 KMT2A_NCKIPSD + - 
chr11 118436463 118526832 chr3 108549868 108589452 KMT2A_CIP2A + - 
chr11 118436463 118526832 chr3 155870535 155944026 KMT2A_GMPS + + 
chr11 118436463 118526832 chr3 188212932 188890671 KMT2A_LPP + + 
chr11 118436463 118526832 chr4 39822862 39977956 KMT2A_PDS5A + - 
chr11 118436463 118526832 chr4 48497362 48780299 KMT2A_FRYL + - 
chr11 118436463 118526832 chr4 52590971 52659335 KMT2A_USP46 + - 
chr11 118436463 118526832 chr4 76949808 77040384 KMT2A_SEPT11 + + 
chr11 118436463 118526832 chr4 86935001 87141054 KMT2A_AFF1 + + 
chr11 118436463 118526832 chr4 185585443 185956368 KMT2A_SORBS2 + - 
chr11 118436463 118526832 chr5 127517608 127555089 KMT2A_PRRC1 + + 
chr11 118436463 118526832 chr5 139274103 139331671 KMT2A_MATR3 + + 
chr11 118436463 118526832 chr5 142770376 143229011 KMT2A_ARHGAP26 + + 
chr11 118436463 118526832 chr5 160251656 160312928 KMT2A_CCNJL + - 
chr11 118436463 118526832 chr6 70667775 70862015 KMT2A_SMAP1 + + 
chr11 118436463 118526832 chr6 89829899 89871412 KMT2A_CASP8AP2 + + 
chr11 118436463 118526832 chr6 108559834 108684774 KMT2A_FOXO3 + + 
chr11 118436463 118526832 chr6 136557046 136792518 KMT2A_MAP3K5 + - 
chr11 118436463 118526832 chr6 167826990 167972020 KMT2A_AFDN + + 
chr11 118436463 118526832 chr7 5306789 5423546 KMT2A_TNRC18 + - 
chr11 118436463 118526832 chr7 87628412 87832296 KMT2A_RUNDC3B + + 
chr11 118436463 118526832 chr9 20341664 20622543 KMT2A_MLLT3 + - 
chr11 118436463 118526832 chr9 96450200 96491336 KMT2A_HABP4 + + 
chr11 118436463 118526832 chr9 121567101 121785528 KMT2A_DAB2IP + + 
chr11 118436463 118526832 chr9 129887186 130043194 KMT2A_FNBP1 + - 
chr11 118436463 118526832 chr9 131009081 131093059 KMT2A_LAMC3 + + 
chr11 118436463 118526832 chrX 71096196 71103535 KMT2A_FOXO4 + + 
chr11 118436463 118526832 chrX 119615723 119693370 KMT2A_SEPT6 + - 
chr11 118436463 118526832 chrX 135760156 135768191 KMT2A_CT45A3 + - 
chr11 118436463 118526832 chrX 135811980 135820012 KMT2A_CT45A2 + - 
chr11 118436463 118526832 chrX 154348525 154374638 KMT2A_FLNA + - 
chr11 119206275 119308149 chr9 470290 746105 CBL_KANK1 + + 
chr11 122655674 122814473 chr7 23504779 23532041 UBASH3B_TRA2A + - 
chr12 991207 1495933 chr5 150113836 150155860 ERC1_PDGFRB + - 
chr12 6666476 6689510 chr5 64165881 64372869 ZNF384_RNF180 - + 
chr12 10158300 10172138 chrX 123859811 123913976 OLR1_XIAP - + 
chr12 10170541 10191785 chrX 123859811 123913976 TMEM52B_XIAP + + 
chr12 11649853 11895402 chr1 3069210 3438621 ETV6_PRDM16 + + 
chr12 11649853 11895402 chr1 179099326 179229601 ETV6_ABL2 + - 
chr12 11649853 11895402 chr10 99396869 99431569 ETV6_GOT1 + - 
chr12 11649853 11895402 chr12 11649853 11895402 ETV6_ETV6 + + 
chr12 11649853 11895402 chr12 56595595 56636366 ETV6_BAZ2A + - 
chr12 11649853 11895402 chr12 70638081 70920843 ETV6_PTPRR + - 
chr12 11649853 11895402 chr15 87859750 88256747 ETV6_NTRK3 + - 
chr12 11649853 11895402 chr17 8144054 8156360 ETV6_PER1 + - 
chr12 11649853 11895402 chr18 44680886 45068510 ETV6_SETBP1 + + 
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chr12 11649853 11895402 chr3 41194740 41239949 ETV6_CTNNB1 + + 
chr12 11649853 11895402 chr3 169084760 169663470 ETV6_MECOM + - 
chr12 11649853 11895402 chr4 54009788 54064690 ETV6_CHIC2 + - 
chr12 11649853 11895402 chr4 54229096 54298247 ETV6_PDGFRA + + 
chr12 11649853 11895402 chr5 131949975 132011914 ETV6_ACSL6 + - 
chr12 11649853 11895402 chr5 150113836 150155860 ETV6_PDGFRB + - 
chr12 11649853 11895402 chr5 158695919 159099761 ETV6_EBF1 + - 
chr12 11649853 11895402 chr6 115931148 116060758 ETV6_FRK + - 
chr12 11649853 11895402 chr6 124962544 125092633 ETV6_RNF217 + + 
chr12 11649853 11895402 chr7 36389805 36453791 ETV6_ANLN + + 
chr12 11649853 11895402 chr7 36854360 37449249 ETV6_ELMO1 + - 
chr12 11649853 11895402 chr8 55879834 56014168 ETV6_LYN + + 
chr12 11649853 11895402 chr8 98454694 98942571 ETV6_STK3 + - 
chr12 11649853 11895402 chr9 4985244 5128183 ETV6_JAK2 + + 
chr12 11649853 11895402 chr9 90801786 90898549 ETV6_SYK + + 
chr12 11649853 11895402 chr9 130713945 130885683 ETV6_ABL1 + + 
chr12 14365631 14502935 chr9 4985244 5128183 ATF7IP_JAK2 + + 
chr12 26938382 26966553 chr8 38411138 38468834 FGFR1OP2_FGFR1 + - 
chr12 48935722 48957551 chr6 149317533 149411395 ARF3_TAB2 - + 
chr12 49018974 49055324 chr4 82819010 82900538 KMT2D_SEC31A - - 
chr12 51281281 51324668 chr5 150113836 150155860 BIN2_PDGFRB - - 
chr12 53452101 53481161 chr9 131394092 131500197 PCBP2_PRRC2B + + 
chr12 65824130 65966295 chr12 65824130 65966295 HMGA2_HMGA2 + + 
chr12 69239536 69274358 chr8 38411138 38468834 CPSF6_FGFR1 + - 
chr12 71754873 71800285 chr12 71839717 71927248 RAB21_TBC1D15 + + 
chr12 104456970 104762014 chrX 120362084 120383249 CHST11_ATP1B4 + + 
chr12 108522579 108561389 chr5 150113836 150155860 SART3_PDGFRB - - 
chr12 109929801 109996389 chr5 150113836 150155860 GIT2_PDGFRB - - 
chr12 117453053 117968983 chr3 4303303 4317567 KSR2_SETMAR - + 
chr12 121429098 121581015 chr5 132875378 132963634 KDM2B_AFF4 - - 
chr12 121429098 121581015 chrY 13248378 13480673 KDM2B_UTY - - 
chr12 124324414 124535603 chr6 117288299 117425855 NCOR2_ROS1 - - 
chr12 132489550 132585188 chr9 36833274 37034185 FBRSL1_PAX5 + - 
chr13 19958669 20091829 chr8 38411138 38468834 ZMYM2_FGFR1 + - 
chr13 48303725 48481890 chr7 15200317 15562015 RB1_AGMO + - 
chr14 21621903 22552132 chr14 95709966 95714196 TRA_TCL1A + - 
chr14 21621903 22552132 chr6 118460780 118710075 TRA_CEP85L + - 
chr14 21621903 22552132 chr7 142299010 142813287 TRA_TRB + + 
chr14 21621903 22552132 chr9 21968104 21995301 TRA_CDKN2A + - 
chr14 21621903 22552132 chr9 136494432 136545786 TRA_NOTCH1 + - 
chr14 21621903 22552132 chrX 155065320 155147775 TRA_MTCP1 + - 
chr14 22422545 22466577 chr14 95709966 95714196 TRD_TCL1A + - 
chr14 22422545 22466577 chr5 170861869 171300015 TRD_RANBP17 + + 
chr14 22422545 22466577 chr5 171309283 171312134 TRD_TLX3 + + 
chr14 22422545 22466577 chr5 173232108 173235357 TRD_NKX2-5 + - 
chr14 22422545 22466577 chr8 127736068 127741434 TRD_MYC + + 
chr14 22422545 22466577 chr8 127890627 128101253 TRD_PVT1 + + 
chr14 22422545 22466577 chr9 77716086 78031458 TRD_GNAQ + - 
chr14 30893798 31026401 chr9 4985244 5128183 STRN3_JAK2 - + 
chr14 50719762 50831121 chr5 150113836 150155860 NIN_PDGFRB - - 
chr14 73958009 74015928 chr6 135283531 135497745 ENTPD5_AHI1 - - 
chr14 91271324 91417777 chr5 150113836 150155860 CCDC88C_PDGFRB - - 
chr14 91965990 92040059 chr5 150113836 150155860 TRIP11_PDGFRB - - 
chr14 99169286 99271485 chr14 99169286 99271485 BCL11B_BCL11B - - 
chr14 99169286 99271485 chr5 173232108 173235357 BCL11B_NKX2-5 - - 
chr14 105586436 106879844 chr3 187721376 187745727 IGH_BCL6 - - 
chr14 105586436 106879844 chr4 190173773 190175845 IGH_DUX4 - + 
chr14 105586436 106879844 chr5 1253166 1295047 IGH_TERT - - 
chr14 105586436 106879844 chr5 112976735 113020970 IGH_DCP2 - + 
chr14 105586436 106879844 chr5 158695919 159099761 IGH_EBF1 - - 
chr14 105586436 106879844 chr6 391738 411447 IGH_IRF4 - + 
chr14 105586436 106879844 chr7 55019100 55211628 IGH_EGFR - + 
chr14 105586436 106879844 chr7 92468379 92477915 IGH_ERVW-1 - - 
chr14 105586436 106879844 chr7 110663053 111562517 IGH_IMMP2L - - 
chr14 105586436 106879844 chr8 47736908 47739086 IGH_CEBPD - - 
chr14 105586436 106879844 chr9 36833274 37034185 IGH_PAX5 - - 
chr14 105586436 106879844 chr9 124011609 124033301 IGH_LHX2 - + 
chr15 43407208 43510614 chr5 150113836 150155860 TP53BP1_PDGFRB - - 
chr15 43510957 43531620 chr9 128947698 129007096 MAP1A_NUP188 + + 
chr15 73994728 74047812 chr17 40309193 40356796 PML_RARA + + 
chr15 75370932 75455783 chr9 33524393 33573001 SIN3A_ANKRD18B - + 
chr15 80947328 80989828 chrX 41514933 41923169 MESD_CASK - - 
chr15 91853855 92172435 chr7 36854360 37449249 SLCO3A1_ELMO1 + - 
chr16 176679 177522 chr5 150401669 150412929 HBA1_CD74 + - 
chr16 3725053 3880726 chr7 142645960 142646467 CREBBP_TRBV23-1 - + 
chr16 3725053 3880726 chr8 41929478 42052026 CREBBP_KAT6A - - 
chr16 10877197 10936388 chr9 5450502 5470566 CIITA_CD274 + + 
chr16 10877197 10936388 chr9 5510569 5571254 CIITA_PDCD1LG2 + + 
chr16 10877197 10936388 chr9 133097719 133149334 CIITA_RALGDS + - 
chr16 11976737 12574289 chr9 4985244 5128183 SNX29_JAK2 + + 
chr16 15643266 15726353 chr5 150113836 150155860 NDE1_PDGFRB + - 
chr16 31180109 31194871 chr21 38380029 38661780 FUS_ERG + - 
chr16 31180109 31194871 chr9 128683654 128696400 FUS_SET + + 
chr16 67029146 67101058 chr16 15703171 15857011 CBFB_MYH11 + - 
chr16 88874857 88977204 chr16 4314760 4339597 CBFA2T3_GLIS2 - + 
chr17 5282299 5385812 chr5 150113836 150155860 RABEP1_PDGFRB + - 
chr17 16029156 16215549 chr8 55879834 56014168 NCOR1_LYN - + 
chr17 17042759 17192648 chr5 150113836 150155860 MPRIP_PDGFRB + - 
chr17 20009362 20314138 chr5 150113836 150155860 SPECC1_PDGFRB + - 
chr17 27456469 27626435 chrX 124375902 124963817 KSR1_TENM1 + - 
chr17 29071123 29180412 chr5 150113836 150155860 MYO18A_PDGFRB - - 
chr17 29071123 29180412 chr8 38411138 38468834 MYO18A_FGFR1 - - 
chr17 42199167 42276406 chr17 40309193 40356796 STAT5B_RARA - + 
chr17 50183288 50201632 chr5 150113836 150155860 COL1A1_PDGFRB - - 
chr17 50962173 51120865 chr9 4985244 5128183 SPAG9_JAK2 - + 
chr17 57256533 57684685 chr17 57256533 57684685 MSI2_MSI2 + + 
chr17 57256533 57684685 chr7 27162434 27165530 MSI2_HOXA9 + - 
chr17 68515399 68551319 chr17 40309193 40356796 PRKAR1A_RARA + + 
chr17 80260867 80398786 chr8 127736068 127741434 RNF213_MYC + + 
chr17 82519714 82604607 chr7 74289474 74405943 FOXK2_CLIP2 + + 
chr18 2847029 2915993 chr9 36833274 37034185 EMILIN2_PAX5 + - 
chr18 12785477 12884338 chr5 159263080 159286040 PTPN2_UBLCP1 - + 
chr18 58671385 58754477 chr3 47850695 48088839 MALT1_MAP4 + - 
chr19 2360237 2426239 chr9 36833274 37034185 TMPRSS9_PAX5 + - 
chr19 10718092 10831884 chr7 93188585 93226524 DNM2_HEPACAM2 + - 
chr19 13099032 13102867 chr7 142299010 142813287 LYL1_TRB - + 
chr19 19385832 19508931 chr8 55879834 56014168 GATAD2A_LYN + + 
chr19 21020619 21060050 chr9 4985244 5128183 ZNF430_JAK2 + + 
chr19 34172565 34229515 chr9 130713945 130885683 LSM14A_ABL1 + + 
chr19 44748546 44760044 chr8 127736068 127741434 BCL3_MYC + + 
chr19 58183028 58213562 chr9 4985244 5128183 ZNF274_JAK2 + + 
chr19 58305318 58315663 chr8 38411138 38468834 ERVK3-1_FGFR1 + - 
chr2 32946971 33399359 chr2 32357027 32618899 LTBP1_BIRC6 + + 
chr2 43230835 43596046 chr3 169084760 169663470 THADA_MECOM - - 
chr2 54456316 54671445 chr5 150113836 150155860 SPTBN1_PDGFRB + - 
chr2 60450519 60554467 chr3 169084760 169663470 BCL11A_MECOM - - 
chr2 108719480 108785811 chr2 29192773 29921566 RANBP2_ALK + - 
chr2 108719480 108785811 chr8 38411138 38468834 RANBP2_FGFR1 + - 
chr2 108719480 108785811 chr9 130713945 130885683 RANBP2_ABL1 + + 
chr2 191678135 191696659 chr17 40309193 40356796 NABP1_RARA + + 
chr2 237627575 237780315 chr8 38411138 38468834 LRRFIP1_FGFR1 + - 
chr20 18587892 18763917 chr5 150113836 150155860 DTD1_PDGFRB + - 
chr20 32277663 32335011 chr7 142299010 142813287 KIF3B_TRB + + 
chr20 34714773 34825649 chr8 70051650 70071327 NCOA6_PRDM14 - - 
chr20 44496223 44522085 chr9 37120538 37358149 SERINC3_ZCCHC7 - + 
chr20 47209213 47356889 chr5 150113836 150155860 ZMYND8_PDGFRB - - 
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chr20 52051662 52191779 chr21 34787800 35049344 ZFP64_RUNX1 - - 
chr21 14961234 15065000 chr3 169084760 169663470 NRIP1_MECOM - - 
chr21 15730024 15880069 chr9 4985244 5128183 USP25_JAK2 + + 
chr21 29024628 29054488 chr21 34787800 35049344 USP16_RUNX1 + - 
chr21 34516483 34615142 chr4 123396794 123403760 RCAN1_SPRY1 - + 
chr21 34787800 35049344 chr1 3069210 3438621 RUNX1_PRDM16 - + 
chr21 34787800 35049344 chr1 28736620 28769774 RUNX1_YTHDF2 - + 
chr21 34787800 35049344 chr1 86424085 86456558 RUNX1_CLCA2 - + 
chr21 34787800 35049344 chr1 151282311 151291903 RUNX1_ZNF687 - + 
chr21 34787800 35049344 chr11 33542274 33674102 RUNX1_KIAA1549L - + 
chr21 34787800 35049344 chr11 58526870 58578166 RUNX1_LPXN - - 
chr21 34787800 35049344 chr11 63998557 64166061 RUNX1_MACROD1 - - 
chr21 34787800 35049344 chr16 88874857 88977204 RUNX1_CBFA2T3 - - 
chr21 34787800 35049344 chr21 34787800 35049344 RUNX1_RUNX1 - - 
chr21 34787800 35049344 chr3 169084760 169663470 RUNX1_MECOM - - 
chr21 34787800 35049344 chr3 169483670 169484080 RUNX1_RPL22P1 - - 
chr21 34787800 35049344 chr4 151120286 151325632 RUNX1_SH3D19 - - 
chr21 34787800 35049344 chr5 127517608 127555089 RUNX1_PRRC1 - + 
chr21 34787800 35049344 chr5 129460264 129738683 RUNX1_ADAMTS19 - + 
chr21 34787800 35049344 chr6 17582033 17582305 RUNX1_SUMO2P13 - + 
chr21 34787800 35049344 chr7 6104883 6161564 RUNX1_USP42 - + 
chr21 34787800 35049344 chr7 27242699 27247825 RUNX1_EVX1 - + 
chr21 34787800 35049344 chr8 91954966 92103226 RUNX1_RUNX1T1 - - 
chr21 34787800 35049344 chr8 105318691 105804532 RUNX1_ZFPM2 - + 
chr21 34787800 35049344 chr8 115408495 115669001 RUNX1_TRPS1 - - 
chr21 34787800 35049344 chrX 23667445 23686399 RUNX1_PRDX4 - + 
chr21 38380029 38661780 chr4 190173773 190175845 ERG_DUX4 - + 
chr21 42653749 42775509 chr8 85656441 85663039 PDE9A_REXO1L1P + - 
chr22 22026075 22922913 chr4 1793292 1808872 IGL_FGFR3 + + 
chr22 22026075 22922913 chr6 391738 411447 IGL_IRF4 + + 
chr22 22026075 22922913 chr6 41934933 42050357 IGL_CCND3 + - 
chr22 22026075 22922913 chr8 127890627 128101253 IGL_PVT1 + + 
chr22 23180209 23318037 chr4 54229096 54298247 BCR_PDGFRA + + 
chr22 23180209 23318037 chr8 38411138 38468834 BCR_FGFR1 + - 
chr22 23180209 23318037 chr9 4985244 5128183 BCR_JAK2 + + 
chr22 23180209 23318037 chr9 126914773 127223164 BCR_RALGPS1 + + 
chr22 23180209 23318037 chr9 130713945 130885683 BCR_ABL1 + + 
chr22 41091785 41180079 chr7 27153715 27156677 EP300_HOXA7 + - 
chr3 9397718 9478154 chr7 50304668 50405101 SETD5_IKZF1 + + 
chr3 10115591 10127190 chr3 10141007 10152220 BRK1_VHL + + 
chr3 12583600 12664226 chr3 12734706 12769457 RAF1_TMEM40 - - 
chr3 15560703 15601852 chr3 15450132 15521751 HACL1_COLQ - - 
chr3 15667235 15859771 chr11 3675009 3797792 ANKRD28_NUP98 - - 
chr3 16315855 16513706 chr8 127890627 128101253 RFTN1_PVT1 - + 
chr3 28241594 28325142 chr3 27372720 27484420 CMC1_SLC4A7 + - 
chr3 30606501 30694134 chr19 4044363 4066945 TGFBR2_ZBTB7A + - 
chr3 37243176 37366751 chr5 150113836 150155860 GOLGA4_PDGFRB + - 
chr3 37988058 38007188 chr9 137007233 137028922 VILL_ABCA2 + - 
chr3 39051997 39096388 chr5 150113836 150155860 WDR48_PDGFRB + - 
chr3 47016688 47163967 chr3 46921730 46982010 SETD2_CCDC12 - - 
chr3 47585271 47781917 chr17 47970533 47981772 SMARCC1_CDK5RAP3 - + 
chr3 47850695 48088839 chr18 58671385 58754477 MAP4_MALT1 - + 
chr3 48599002 48610037 chr3 43365847 43622068 UQCRC1_ANO10 - - 
chr3 48673843 48685927 chr3 48636468 48662915 NCKIPSD_CELSR3 - - 
chr3 49940006 50077249 chr5 150053290 150113372 RBM6_CSF1R + - 
chr3 100609588 100695479 chr3 100709360 100748942 ADGRG7_TFG + + 
chr3 100709360 100748942 chr3 100609588 100695479 TFG_ADGRG7 + + 
chr3 101324204 101513184 chr12 11649853 11895402 SENP7_ETV6 - + 
chr3 121663202 121749767 chr13 28003273 28100592 GOLGB1_FLT3 - - 
chr3 121663202 121749767 chr5 150113836 150155860 GOLGB1_PDGFRB - - 
chr3 128479426 128493185 chr3 169084760 169663470 GATA2_MECOM - - 
chr3 128479426 128493185 chr7 27162434 27165530 GATA2_HOXA9 - - 
chr3 128479426 128493185 chr7 27171219 27180261 GATA2_HOXA10 - - 
chr3 128571999 128576086 chr3 169084760 169663470 LINC01565_MECOM - - 
chr3 128620158 128681075 chr1 3069210 3438621 RPN1_PRDM16 - + 
chr3 128620158 128681075 chr3 169084760 169663470 RPN1_MECOM - - 
chr3 134157132 134250744 chr21 33903452 33915980 RYK_ATP5PO - - 
chr3 136148921 136195846 chr3 177019354 177196478 MSL2_TBL1XR1 - - 
chr3 152268039 152465779 chr9 36833274 37034185 MBNL1_PAX5 + - 
chr3 152268039 152465779 chr9 130713945 130885683 MBNL1_ABL1 + + 
chr3 160494994 160565588 chr9 109640787 109946703 KPNA4_PALM2 - + 
chr3 169084760 169663470 chr21 34787800 35049344 MECOM_RUNX1 - - 
chr3 169084760 169663470 chr3 169084760 169663470 MECOM_MECOM - - 
chr3 169084760 169663470 chr7 92604920 92833917 MECOM_CDK6 - - 
chr3 169084760 169663470 chr7 142299010 142813287 MECOM_TRB - + 
chr3 172040553 172401665 chr3 169084760 169663470 FNDC3B_MECOM + - 
chr3 177019354 177196478 chr17 40309193 40356796 TBL1XR1_RARA - + 
chr3 177019354 177196478 chr3 139357405 139389732 TBL1XR1_COPB2 - - 
chr3 177019354 177196478 chr3 189631426 189897279 TBL1XR1_TP63 - + 
chr3 177019354 177196478 chr5 150053290 150113372 TBL1XR1_CSF1R - - 
chr3 180912301 180982753 chr3 177019354 177196478 FXR1_TBL1XR1 + - 
chr3 186147200 186362237 chr4 15703095 15732787 DGKG_BST1 - + 
chr3 187721376 187745727 chr13 46125919 46211348 BCL6_LCP1 - - 
chr3 187721376 187745727 chr16 10877197 10936388 BCL6_CIITA - + 
chr3 187721376 187745727 chr19 6677703 6720682 BCL6_C3 - - 
chr3 187721376 187745727 chr3 152268039 152465779 BCL6_MBNL1 - + 
chr3 187721376 187745727 chr6 37170202 37175426 BCL6_PIM1 - + 
chr3 187721376 187745727 chr8 66562174 66613249 BCL6_MYBL1 - - 
chr3 188212932 188890671 chr3 187721376 187745727 LPP_BCL6 + - 
chr3 189631426 189897279 chr3 177019354 177196478 TP63_TBL1XR1 + - 
chr4 1009978 1026891 chr4 1211447 1249137 FGFRL1_CTBP1 + - 
chr4 1289850 1340137 chr4 1211447 1249137 MAEA_CTBP1 + - 
chr4 1347315 1395989 chr4 1289850 1340137 UVSSA_MAEA + + 
chr4 26860690 27025381 chr7 50304668 50405101 STIM2_IKZF1 + + 
chr4 53377644 53459668 chr17 40309193 40356796 FIP1L1_RARA + + 
chr4 53377644 53459668 chr4 54229096 54298247 FIP1L1_PDGFRA + + 
chr4 54009788 54064690 chr12 11649853 11895402 CHIC2_ETV6 - + 
chr4 54229096 54298247 chr10 91798311 91865276 PDGFRA_TNKS2 + + 
chr4 54229096 54298247 chr12 11649853 11895402 PDGFRA_ETV6 + + 
chr4 67468747 67545606 chr9 130713945 130885683 CENPC_ABL1 - + 
chr4 78776377 78912185 chr12 6666476 6689510 BMP2K_ZNF384 + - 
chr4 81087369 81215117 chr5 150113836 150155860 PRKG2_PDGFRB - - 
chr4 86935001 87141054 chr11 117427772 117797261 AFF1_DSCAML1 + - 
chr4 86935001 87141054 chr11 117836980 117877486 AFF1_FXYD6 + - 
chr4 86935001 87141054 chr11 118998141 119015745 AFF1_CCDC84 + + 
chr4 86935001 87141054 chr14 67819828 68730218 AFF1_RAD51B + + 
chr4 88592422 88708542 chr4 88709788 88730103 HERC3_FAM13A-AS1 + + 
chr4 108047544 108168956 chr6 42050521 42087461 LEF1_TAF8 - + 
chr4 139716752 140154184 chr4 77157150 77170059 MAML3_CCNG2 - + 
chr4 150264658 151015727 chr4 151120286 151325632 LRBA_SH3D19 - - 
chr4 158124473 158173050 chr4 158210248 158255411 FAM198B_TMEM144 - + 
chr4 190173773 190175845 chr10 133623894 133626792 DUX4_FRG2B + - 
chr4 190173773 190175845 chr14 105586436 106879844 DUX4_IGH + - 
chr4 190173773 190175845 chr21 38380029 38661780 DUX4_ERG + - 
chr4 190173773 190175845 chr4 118467589 118554100 DUX4_CEP170P1 + + 
chr5 864272 892824 chr15 34343314 34357737 BRD9_NUTM1 - + 
chr5 35856848 35879603 chr7 142801040 142802748 IL7R_TRBC2 + + 
chr5 36876758 37066413 chr12 11649853 11895402 NIPBL_ETV6 + + 
chr5 36876758 37066413 chr17 48621158 48626356 NIPBL_HOXB9 + - 
chr5 36876758 37066413 chr7 27162434 27165530 NIPBL_HOXA9 + - 
chr5 40759378 40798198 chr5 40512332 40755908 PRKAA1_TTC33 - - 
chr5 55307759 55425581 chr11 116843401 117098421 MTREX_SIK3 + - 
chr5 56815573 56896152 chr16 58157906 58197920 MAP3K1_CSNK2A2 + - 
chr5 64165881 64372869 chr15 85380714 85749355 RNF180_AKAP13 + + 
chr5 65517765 65563171 chr11 118436463 118526832 CENPK_KMT2A - + 
chr5 81413020 81751253 chr5 108747821 109196841 SSBP2_FER - + 
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chr5 81413020 81751253 chr5 150053290 150113372 SSBP2_CSF1R - - 
chr5 83940553 84384793 chr7 131110095 131487844 EDIL3_MKLN1 - + 
chr5 88718240 88904257 chr11 118436463 118526832 MEF2C_KMT2A - + 
chr5 98853984 98928957 chr21 34787800 35049344 CHD1_RUNX1 - - 
chr5 112976735 113020970 chr14 61695539 61748258 DCP2_HIF1A + + 
chr5 122774995 122830108 chr9 130713945 130885683 SNX2_ABL1 + + 
chr5 132060528 132063204 chr14 105586436 106879844 IL3_IGH + - 
chr5 134148934 134177038 chr5 132875378 132963634 SKP1_AFF4 - - 
chr5 140691425 140699318 chr5 140700333 140706676 HARS2_ZMAT2 + + 
chr5 141639301 141651419 chr7 140719326 140924810 FCHSD1_BRAF - - 
chr5 144158158 144170659 chr5 143277930 143435512 YIPF5_NR3C1 - - 
chr5 150113836 150155860 chr14 91271324 91417777 PDGFRB_CCDC88C - - 
chr5 150113836 150155860 chr14 91965990 92040059 PDGFRB_TRIP11 - - 
chr5 150113836 150155860 chr17 29071123 29180412 PDGFRB_MYO18A - - 
chr5 150113836 150155860 chr20 18587892 18763917 PDGFRB_DTD1 - + 
chr5 150401669 150412929 chr5 150113836 150155860 CD74_PDGFRB - - 
chr5 151029948 151087158 chr5 150113836 150155860 TNIP1_PDGFRB - - 
chr5 157785742 157859145 chr5 88718240 88904257 CLINT1_MEF2C - - 
chr5 158695919 159099761 chr9 4985244 5128183 EBF1_JAK2 - + 
chr5 170861869 171300015 chr14 22422545 22466577 RANBP17_TRD + + 
chr5 171309283 171312134 chr14 99169286 99271485 TLX3_BCL11B + - 
chr5 171387115 171410883 chr17 40309193 40356796 NPM1_RARA + + 
chr5 171387115 171410883 chr19 10350532 10380676 NPM1_TYK2 + - 
chr5 171387115 171410883 chr3 158571162 158606460 NPM1_MLF1 + + 
chr5 172983756 173035445 chr12 62260337 62416389 ATP6V0E1_USP15 + + 
chr5 173056351 173139284 chr14 96392110 96489427 CREBRF_AK7 + + 
chr5 177133078 177300210 chr11 3675009 3797792 NSD1_NUP98 + - 
chr5 177133078 177300210 chr11 61792636 61797244 NSD1_FEN1 + + 
chr5 177331561 177351852 chr14 96502372 96567111 LMAN2_PAPOLA - + 
chr5 177331561 177351852 chr5 177133078 177300210 LMAN2_NSD1 - + 
chr5 179614178 179624669 chr10 21524674 21743630 HNRNPH1_MLLT10 - + 
chr5 179614178 179624669 chr21 38380029 38661780 HNRNPH1_ERG - - 
chr5 179820758 179838078 chr8 38411138 38468834 SQSTM1_FGFR1 + - 
chr5 179820758 179838078 chr9 131125560 131234670 SQSTM1_NUP214 + + 
chr6 5998001 6007605 chr19 2511218 2702709 NRN1_GNG7 - - 
chr6 17615034 17706834 chr9 130713945 130885683 NUP153_ABL1 - + 
chr6 18223867 18264823 chr9 131125560 131234670 DEK_NUP214 - + 
chr6 31676739 31680377 chr6 31686948 31703444 LY6G5C_ABHD16A - - 
chr6 33620364 33696574 chr6 36243202 36308595 ITPR3_PNPLA1 + + 
chr6 39299000 39314553 chr6 39329989 39725405 KCNK17_KIF6 - - 
chr6 41934933 42050357 chr12 11649853 11895402 CCND3_ETV6 - + 
chr6 44219504 44234151 chr6 44246165 44253888 SLC29A1_HSP90AB1 + + 
chr6 45898450 46080348 chr6 44828731 45377933 CLIC5_SUPT3H - - 
chr6 69675950 69867236 chr20 41402100 41618494 LMBRD1_CHD6 - - 
chr6 75602046 75718278 chr6 123804140 124825657 SENP6_NKAIN2 + + 
chr6 85660949 85678748 chr6 85505495 85593913 SNHG5_SNX14 - - 
chr6 89926528 90296908 chr11 19117128 19176415 BACH2_ZDHHC13 - + 
chr6 106969830 106975465 chrX 48574523 48579066 CD24_RBM3 - + 
chr6 115931148 116060758 chr12 11649853 11895402 FRK_ETV6 - + 
chr6 124962544 125092633 chr12 11649853 11895402 RNF217_ETV6 + + 
chr6 130013698 130141449 chr6 127968778 128520674 L3MBTL3_PTPRK + - 
chr6 135181314 135219171 chr16 89644430 89657845 MYB_CHMP1A + - 
chr6 135181314 135219171 chr5 71455614 71567820 MYB_BDP1 + + 
chr6 135181314 135219171 chr6 135283531 135497745 MYB_AHI1 + - 
chr6 135181314 135219171 chr6 143940301 144064599 MYB_PLAGL1 + - 
chr6 135181314 135219171 chr7 156994050 157009075 MYB_MNX1 + - 
chr6 135181314 135219171 chrX 48786553 48794308 MYB_GATA1 + + 
chr6 138773508 138793317 chr11 3675009 3797792 CCDC28A_NUP98 + - 
chr6 143060853 143340290 chr17 30477361 30527592 AIG1_GOSR1 + + 
chr6 144291828 144853034 chr14 73958009 74015928 UTRN_ENTPD5 + - 
chr6 156776019 157210779 chr12 6666476 6689510 ARID1B_ZNF384 + - 
chr6 166999181 167052713 chr10 43077026 43130351 FGFR1OP_RET + + 
chr6 166999181 167052713 chr8 38411138 38468834 FGFR1OP_FGFR1 + - 
chr6 167826990 167972020 chr11 118436463 118526832 AFDN_KMT2A + + 
chr7 876551 896434 chr7 5306789 5423546 GET4_TNRC18 + - 
chr7 2631950 2664802 chr7 1815793 2233243 TTYH3_MAD1L1 + - 
chr7 5190187 5233826 chr12 112013315 112023451 WIPI2_ERP29 + + 
chr7 6374522 6403977 chr6 75084325 75206051 RAC1_COL12A1 + - 
chr7 10931950 10940256 chr7 12570685 12660179 NDUFA4_SCIN - + 
chr7 16646130 16706523 chr7 65960683 65982314 BZW2_GUSB + - 
chr7 27162434 27165530 chr8 107251511 107336522 HOXA9_ANGPT1 - - 
chr7 27168898 27171915 chr6 109366513 109382812 HOXA10-AS_CD164 + - 
chr7 27171219 27180261 chr19 1086578 1095357 HOXA10_POLR2E - - 
chr7 27171219 27180261 chr7 142299010 142813287 HOXA10_TRB - + 
chr7 27181514 27185216 chr7 16646130 16706523 HOXA11_BZW2 - + 
chr7 27184670 27189169 chr7 92604920 92833917 HOXA11-AS_CDK6 + - 
chr7 27201843 27207259 chr3 18347939 18438773 HOTTIP_SATB1 + - 
chr7 30289793 30289890 chr7 30284306 30367692 MIR550A1_ZNRF2 + + 
chr7 34928875 35038041 chr7 27181514 27185216 DPY19L1_HOXA11 - - 
chr7 37683871 37741374 chr15 52756988 52790012 GPR141_ONECUT1 + - 
chr7 38240023 38368055 chr14 95709966 95714196 TRG_TCL1A - - 
chr7 40126022 40134652 chr6 27866848 27867529 MPLKIP_HIST1H1B - - 
chr7 43112598 43566001 chr5 150113836 150155860 HECW1_PDGFRB + - 
chr7 45736786 45765812 chr7 56011066 56051604 SEPT7P2_PSPH - - 
chr7 50304668 50405101 chr1 3069210 3438621 IKZF1_PRDM16 + + 
chr7 50304668 50405101 chr12 11649853 11895402 IKZF1_ETV6 + + 
chr7 50304668 50405101 chr12 55966768 55972784 IKZF1_CDK2 + + 
chr7 50304668 50405101 chr15 34343314 34357737 IKZF1_NUTM1 + + 
chr7 50304668 50405101 chr17 16415541 16437003 IKZF1_TRPV2 + + 
chr7 50304668 50405101 chr3 9397718 9478154 IKZF1_SETD5 + + 
chr7 50304668 50405101 chr7 48171459 48647495 IKZF1_ABCA13 + + 
chr7 50590062 50793462 chr7 3301447 4269000 GRB10_SDK1 - + 
chr7 66114604 66154561 chr10 96593311 96720514 CRCP_PIK3AP1 + - 
chr7 74657684 74760692 chr17 40309193 40356796 GTF2I_RARA + + 
chr7 75533299 75738947 chr5 150113836 150155860 HIP1_PDGFRB - - 
chr7 92560792 92590393 chr7 92604920 92833917 FAM133B_CDK6 - - 
chr7 92604920 92833917 chr11 118436463 118526832 CDK6_KMT2A - + 
chr7 92604920 92833917 chr14 36516416 36521149 CDK6_NKX2-1 - - 
chr7 92604920 92833917 chr3 169084760 169663470 CDK6_MECOM - - 
chr7 92604920 92833917 chr5 171309283 171312134 CDK6_TLX3 - + 
chr7 92604920 92833917 chr7 27269356 27269678 CDK6_RPL35P4 - - 
chr7 99472892 99503650 chr7 99493239 99500297 ZNF789_ZNF394 + - 
chr7 100852752 100867008 chr6 135181314 135219171 SLC12A9_MYB + + 
chr7 101815903 102283958 chr4 73436162 73456174 CUX1_AFP + + 
chr7 101815903 102283958 chr7 149126415 149182802 CUX1_ZNF398 + + 
chr7 101815903 102283958 chr8 38411138 38468834 CUX1_FGFR1 + - 
chr7 107923817 108003255 chr7 116862472 116922049 LAMB1_CAPZA2 - + 
chr7 116862472 116922049 chr19 58544468 58550716 CAPZA2_TRIM28 + + 
chr7 138460333 138589993 chr8 38411138 38468834 TRIM24_FGFR1 + - 
chr7 139043519 139109648 chr13 42272152 42323267 ZC3HAV1_AKAP11 - + 
chr7 142299010 142813287 chr10 101130504 101137789 TRB_TLX1 + + 
chr7 142299010 142813287 chr11 8224313 8268716 TRB_LMO1 + - 
chr7 142299010 142813287 chr14 95709966 95714196 TRB_TCL1A + - 
chr7 142299010 142813287 chr22 37125837 37149990 TRB_IL2RB + - 
chr7 142299010 142813287 chr3 169084760 169663470 TRB_MECOM + - 
chr7 142299010 142813287 chr7 27162434 27165530 TRB_HOXA9 + - 
chr7 142299010 142813287 chr7 27181514 27185216 TRB_HOXA11 + - 
chr7 142299010 142813287 chr8 127736068 127741434 TRB_MYC + + 
chr7 142299010 142813287 chrX 108732481 108736409 TRB_IRS4 + - 
chr7 148697913 148800582 chr7 153887096 154894285 CUL1_DPP6 + + 
chr7 152134924 152436005 chr7 152759748 152855378 KMT2C_ACTR3B - + 
chr7 156994050 157009075 chr12 11649853 11895402 MNX1_ETV6 - + 
chr7 158730994 158829628 chr20 3471039 3651122 ESYT2_ATRN - + 
chr8 17922856 18029944 chr9 4985244 5128183 PCM1_JAK2 + + 
chr8 23385782 23457695 chr8 18527300 19013686 ENTPD4_PSD3 - - 
chr8 28890403 29053270 chr9 4985244 5128183 HMBOX1_JAK2 + + 
 40 
chr8 38411138 38468834 chr5 179820758 179838078 FGFR1_SQSTM1 - + 
chr8 38411138 38468834 chr7 101815903 102283958 FGFR1_CUX1 - + 
chr8 38411138 38468834 chr8 38411138 38468834 FGFR1_FGFR1 - - 
chr8 41929478 42052026 chr16 3725053 3880726 KAT6A_CREBBP - - 
chr8 41929478 42052026 chr19 39776594 39786135 KAT6A_LEUTX - + 
chr8 41929478 42052026 chr2 25733752 25878516 KAT6A_ASXL2 - - 
chr8 41929478 42052026 chr20 47501901 47656877 KAT6A_NCOA3 - + 
chr8 41929478 42052026 chr22 41091785 41180079 KAT6A_EP300 - + 
chr8 41929478 42052026 chr8 41929478 42052026 KAT6A_KAT6A - - 
chr8 41929478 42052026 chr8 70109761 70403805 KAT6A_NCOA2 - - 
chr8 42338454 42371808 chr8 132571952 132675617 POLB_LRRC6 + - 
chr8 42896931 43030539 chr8 38411138 38468834 HOOK3_FGFR1 + - 
chr8 51817574 51899186 chr7 549196 727341 PCMTD1_PRKAR1B - - 
chr8 56160903 56211279 chr7 142797455 142797502 PLAG1_TRBJ2-7 - + 
chr8 99013265 99877580 chrX 123961313 124102656 VPS13B_STAG2 + + 
chr8 123219956 123241398 chr7 27184670 27189169 C8orf76_HOXA11-AS - + 
chr8 127736068 127741434 chr6 44828731 45377933 MYC_SUPT3H + - 
chr8 127736068 127741434 chr9 37120538 37358149 MYC_ZCCHC7 + + 
chr8 127736068 127741434 chr9 37438113 37465399 MYC_ZBTB5 + - 
chr8 127890627 128101253 chr13 34942286 35672735 PVT1_NBEA + + 
chr8 127890627 128101253 chr3 169084760 169663470 PVT1_MECOM + - 
chr8 127890627 128101253 chr8 125091852 125367120 PVT1_NSMCE2 + + 
chr8 127890627 128101253 chr8 130052106 130443660 PVT1_ASAP1 + - 
chr8 127890627 128101253 chr9 37120538 37358149 PVT1_ZCCHC7 + + 
chr8 143833720 143840974 chr9 109015151 109119945 NRBP2_TMEM245 - - 
chr9 470290 746105 chr5 150113836 150155860 KANK1_PDGFRB + - 
chr9 2015185 2193620 chr12 6666476 6689510 SMARCA2_ZNF384 + - 
chr9 2015185 2193620 chr9 2621833 2660053 SMARCA2_VLDLR + + 
chr9 3218301 3526001 chr9 4985244 5128183 RFX3_JAK2 - + 
chr9 4985244 5128183 chr16 11976737 12574289 JAK2_SNX29 + + 
chr9 4985244 5128183 chr5 158695919 159099761 JAK2_EBF1 + - 
chr9 15464065 15511019 chr11 3675009 3797792 PSIP1_NUP98 - - 
chr9 21968104 21995301 chr14 21621903 22552132 CDKN2A_TRA - + 
chr9 21968104 21995301 chr9 21455483 21456049 CDKN2A_IFNWP19 - + 
chr9 21968104 21995301 chr9 21802648 21937651 CDKN2A_MTAP - + 
chr9 33041763 33076659 chr9 4985244 5128183 SMU1_JAK2 - + 
chr9 34179012 34252523 chr9 34086386 34126773 UBAP1_DCAF12 + - 
chr9 35812959 35815021 chr9 35792153 35809732 HINT2_NPR2 - + 
chr9 36833274 37034185 chr10 7818503 8016627 PAX5_TAF3 - + 
chr9 36833274 37034185 chr11 33542274 33674102 PAX5_KIAA1549L - + 
chr9 36833274 37034185 chr12 132489550 132585188 PAX5_FBRSL1 - + 
chr9 36833274 37034185 chr14 76310711 76498475 PAX5_ESRRB - + 
chr9 36833274 37034185 chr16 88874857 88977204 PAX5_CBFA2T3 - - 
chr9 36833274 37034185 chr16 89720984 89740903 PAX5_ZNF276 - + 
chr9 36833274 37034185 chr17 47896149 47928957 PAX5_SP2 - + 
chr9 36833274 37034185 chr20 32277663 32335011 PAX5_KIF3B - + 
chr9 36833274 37034185 chr20 32358329 32439319 PAX5_ASXL1 - + 
chr9 36833274 37034185 chr20 32443061 32584890 PAX5_NOL4L - - 
chr9 36833274 37034185 chr20 46060984 46089952 PAX5_NCOA5 - - 
chr9 36833274 37034185 chr3 152268039 152465779 PAX5_MBNL1 - + 
chr9 36833274 37034185 chr6 10747830 10759774 PAX5_TMEM14B - + 
chr9 36833274 37034185 chr7 86643913 86864884 PAX5_GRM3 - + 
chr9 36833274 37034185 chr9 470290 746105 PAX5_KANK1 - + 
chr9 36833274 37034185 chr9 20341664 20622543 PAX5_MLLT3 - - 
chr9 36833274 37034185 chr9 36336403 36401198 PAX5_RNF38 - - 
chr9 36833274 37034185 chr9 37120538 37358149 PAX5_ZCCHC7 - + 
chr9 36833274 37034185 chr9 113165519 113221361 PAX5_FKBP15 - - 
chr9 36833274 37034185 chrX 1462571 1537107 PAX5_P2RY8 - - 
chr9 36833274 37034185 chrX 40051245 40177329 PAX5_BCOR - - 
chr9 36833274 37034185 chrX 120158560 120165630 PAX5_RHOXF2 - + 
chr9 37120538 37358149 chr20 44496223 44522085 ZCCHC7_SERINC3 + - 
chr9 37120538 37358149 chr9 36833274 37034185 ZCCHC7_PAX5 + - 
chr9 37422665 37436990 chr19 6677703 6720682 GRHPR_C3 + - 
chr9 37919133 38069211 chr11 118747765 118791136 SHB_DDX6 - - 
chr9 71683365 71768884 chr8 27311481 27459390 CEMIP2_PTK2B - + 
chr9 92711362 92764812 chr9 4985244 5128183 BICD2_JAK2 - + 
chr9 95875700 95968840 chr19 41330322 41353911 ERCC6L2_TGFB1 + - 
chr9 100302083 100352939 chr9 97674908 97697357 TEX10_XPA - - 
chr9 105662456 105663112 chr7 142299010 142813287 TAL2_TRB + + 
chr9 109640787 109946703 chr9 110048695 110172512 PALM2_AKAP2 + + 
chr9 111525158 111577844 chr9 125261831 125367207 ZNF483_GAPVD1 + + 
chr9 111896765 111935369 chr8 127890627 128101253 UGCG_PVT1 + + 
chr9 120388868 120580170 chr4 54229096 54298247 CDK5RAP2_PDGFRA - + 
chr9 121075011 121177608 chr4 54657917 54740715 CNTRL_KIT + + 
chr9 121075011 121177608 chr8 38411138 38468834 CNTRL_FGFR1 + - 
chr9 123379653 123930107 chr9 37120538 37358149 DENND1A_ZCCHC7 - + 
chr9 124517274 124771277 chr9 133205279 133209250 NR6A1_OBP2B - - 
chr9 128683654 128696400 chr9 131125560 131234670 SET_NUP214 + + 
chr9 129887186 130043194 chr11 118436463 118526832 FNBP1_KMT2A - + 
chr9 130713945 130885683 chr17 74748651 74769353 ABL1_SLC9A3R1 + + 
chr9 130713945 130885683 chr22 23180209 23318037 ABL1_BCR + + 
chr9 130713945 130885683 chr9 131394092 131500197 ABL1_PRRC2B + + 
chr9 131125560 131234670 chr22 16783411 16821699 NUP214_XKR3 + - 
chr9 131125560 131234670 chr7 6374522 6403977 NUP214_RAC1 + + 
chr9 131125560 131234670 chr9 130713945 130885683 NUP214_ABL1 + + 
chr9 131394092 131500197 chr10 129467183 129768007 PRRC2B_MGMT + + 
chr9 131394092 131500197 chr22 23180209 23318037 PRRC2B_BCR + + 
chr9 136440096 136483759 chr9 136494432 136545786 SEC16A_NOTCH1 - - 
chr9 136494432 136545786 chr9 136862118 136866286 NOTCH1_EDF1 - - 
chr9 136658855 136672678 chr17 83079690 83095119 EGFL7_METRNL + + 
chr9 136862118 136866286 chr9 136494432 136545786 EDF1_NOTCH1 - - 
chrX 1462571 1537107 chr9 36833274 37034185 P2RY8_PAX5 - - 
chrX 2691132 2741309 chr9 4985244 5128183 CD99_JAK2 + + 
chrX 13734744 13769353 chr9 4985244 5128183 OFD1_JAK2 + + 
chrX 40051245 40177329 chr17 40309193 40356796 BCOR_RARA - + 
chrX 49028730 49043486 chrX 71283191 71301166 TFE3_NONO - + 
chrX 55075062 55078909 chrX 55009054 55031064 PAGE2B_ALAS2 + - 
chrX 71118555 71142453 chr7 27162434 27165530 MED12_HOXA9 + - 
chrX 71283191 71301166 chr2 43222401 43226609 NONO_ZFP36L2 + - 
chrX 71283191 71301166 chrX 49028730 49043486 NONO_TFE3 + - 
chrX 100969710 100990806 chrX 101009345 101052116 ARL13A_TRMT2B + - 
chrX 123859811 123913976 chr12 10158300 10172138 XIAP_OLR1 + - 
chrX 123961313 124102656 chr7 16646130 16706523 STAG2_BZW2 + + 
chrX 123961313 124102656 chrX 77504877 77786216 STAG2_ATRX + - 
chrX 123961313 124102656 chrX 130384439 130385447 STAG2_GPR119 + - 
chrX 130064873 130110716 chr21 38380029 38661780 ELF4_ERG - - 
chrX 138632677 139205023 chr6 134169245 134318058 FGF13_SGK1 - - 
Coordinates are based on the GRCh38 human reference 
Downloadable version can be found here: https://wustl.box.com/v/rapidclinicalwgs-tables2  
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103395 MDS retrospective BM 46,XY[20] Y N  0 0 ASXL1:p.E635Rfs*15[38.5%] Y N  N 









N N  N 






A382Vfs*4[37.2%] N N 
 N 
142283 MDS retrospective BM 45,X,-Y[8]/46,XY[12] N N  -Y[manual review] 0 DNMT3A:p.G707S[13.7%] N N  N 




0 TET2:p.R1516*[8.8%],FLT3:p.D835E[41.0%] N Y 
CONFIRMED: del(7q) 
called nonclol in 
karyotype 
Complex 






.G13D[7.5%] N N 
 N 






0 TP53:p.R213*[48.9%] N Y CONFIRMED: Cs BY ARRAY N 






















N Y  N 




N N  Not Complex 







Y N  NK 



















N N  del(5)(q14.3q34)[41.8%] 0 SF3B1:p.K700E[10.3%] N N  N 















0 TP53:p.Y220C[61.5%] N Y  N 
















0 TET2:p.E452*[26.3%],TP53:p.I162N[65.9%] N Y 
 N 













0 DNMT3A:p.L637R[30.9%],TP53:p.R337C[32.6%] N Y 
 N 
200915 AML retrospective BM 46,XY[20] Y N None detected 0 0 0 Y N  N 




0 0 IDH2:p.R140Q[27.7%],CEBPA:p.I62Hfs*46[53.7%] Y N 
 N 












N Y  N 





N N  0 t(11;19)(q23.3;p13.11)[29.8%] KRAS:p.G12V[20.4%] N N 





on chr11 or 
chr19 











Y N  N 




N N  gain(11)(q23.3qter)[15.0%] inv(16)(q22.1p13.11)[36.5%] 
CBL:NA[20.0%],PTPN11:p.A7










KIT:p.T417delinsIP[41.7%] N N  N 
266995 MDS retrospective BM 45,XX,-7[2]/46,XX[18] N N  -7[13.6%] 0 GATA2:p.A411V[55.0%] N N  N 
















0 0 N Y  N 







N N  N 








0 0 N Y  N 
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N N  N 







Y N  NK 
285982 AML retrospective BM 46,XY,t(16;22)(q22;q13)[10] N N 
 0 inv(16)(q22.1p13.11)[33.3%] 
NRAS:p.G13D[11.8%],FLT3:p.











0 N N  N 
307995 MDS retrospective BM 46,XY,der(1;7)(q10;p10)[9] N N  gain(1)(q21.2qter)[35.3%],del(7)(q11.21qter)[36.9%] 0 RUNX1:p.D123Gfs*11[18.2%] N N 
CONFIRMED: Cs BY 
ARRAY N 






















0 ASXL1:p.S1064Dfs*24[24.2%] N Y  N 














N N  N 





0 N N  N 





Y N  NK 






D835Y[9.3%] N N 
 N 




N N  del(5)(q11.2qter)[11.8%],del(13)(q12.3q14.3)[10.9%] 0 TP53:p.C238Y[6.9%] N N 
 N 




1:p.E422*[18.6%] N N 
CONFIRMED: Cs BY 
ARRAY N 
377158 MDS retrospective BM 46,XX[19]/46,XX,del(9)(q13)[1] N N 




Y N  N 









0 U2AF1:p.Q157R[8.9%],ETV6:p.L416Ffs*10[47.6%] N Y 
 N 
























0 TP53:p.S37Cfs*9[45.3%] N Y  N 








Y N  N 







N N  N 




N N  0 t(11;19)(q23.3;p13.11)[27.9%] FLT3:p.D835E[21.9%] N N 
 N 




































430998 MDS retrospective BM 47,XY,+14[5]/46,XY,i(14)(q10)[5]/46,XY[10] N N 
 gain(14)(q11.2qter)[51.4%] 0 SF3B1:p.K700E[28.1%],FLT3:p.Y591_F612dup[8.3%] N N 
 N 














N Y  N 





FLT3:p.Y597_K602dup[41.9%] N N  N 



























0 TP53:NA[44.4%],TP53:p.P250L[20.7%] N Y 
 N 
459785 AML retrospective BM 46,XX[11] NA N  0 0 FLT3:p.D835V[36.5%],STAG2:NA[57.7%] Y N 
 NK 

















RAD21:p.E453Vfs*12[50.0%] N N 
 N 
463763 MDS retrospective BM 47,XY,+Y[6]/46,XY[14] N N  +Y[18.4%] 0 BCOR:p.P663Lfs*6[12.5%],U2AF1:p.S34F[13.8%] N N 
 N 
465146 AML retrospective BM 47,XY,+8[19]/46,XY[1] N N NPM1:p.Trp288CysfsTer12[31.2%],KRAS:p.Gly13Asp[3%] +8[67.3%] 0 NPM1:p.W288Cfs*12[22.6%] N N 
 N 





N N  N 
 43 





FLT3:p.F594_D600dup[13.7%] N N  N 















0 JAK2:p.V617F[34.1%],TP53:p.C275Y[32.1%] N Y 
 N 



















0 TP53:p.P177R[85.7%] N Y  N 










0 TP53:NA[60.0%] N Y  N 

















0 TP53:p.R175G[85.9%] N Y  N 









0 DNMT3A:p.M315L[35.0%],NF1:p.K2169_V2175del[42.9%] N Y 
 N 























0 N N  N 






















0 0 N Y  N 







N N  N 







N N  N 











Y N  N 







N N  N 























0 TP53:p.T125%3D[53.3%] N Y  N 











Y N  NK 










N N  N 

















Y N  NK 








N N  N 





0 N N  N 










Y N  N 





Y N  NK 















0 0 CEBPA:p.Q312dup[40.0%],CEBPA:p.P39Sfs*119[20.9%] Y N 
 N 










Y N  N 
 44 
627844 MDS retrospective BM 46,XY,t(17;17)(p13;q11.2)[9]/46,XY[11] N N 
 0 0 RUNX1:p.V79Wfs*44[33.1%] Y N  N 
















0 TP53:p.F113C[18.4%] N Y  N 
























































Y N  N 
668971 AML retrospective BM 45~47,XY,+8[cp10] N N  0 0 0 Y N  NK 










Y N  N 















N Y  N 


























RAD21:NA[47.6%] N Y  N 
706350 AML retrospective BM 46,XX[20] Y N DNMT3A:p.Arg882His[31.5%],IDH1:p.Arg132Cys[28.0%] 0 0 
DNMT3A:p.R882H[34.9%],IDH
1:p.R132C[33.9%] Y N 
 N 










0 TP53:p.E286K[14.3%] N Y  N 
714148 MDS retrospective BM 46,XY[20] Y N  -Y[21.4%] 0 DNMT3A:p.E756K[26.1%],KIT:p.V532I[42.9%] N N 
 new -Y 





Y N  NK 






Y N  NK 





Y N  N 











N N  N 










0 CUX1:p.K54N[66.7%],SRSF2:p.P95R[33.3%] N Y 
 N 





CBL:NA[12.5%] N N  N 
796518 MDS retrospective BM 46,XY,+1,der(1;7)(q10;p10)[20] N N 
 gain(1)(q21.2qter)[58.5%],del
(7)(q11.21qter)[59.4%] 0 0 N N 
CONFIRMED: Cs BY 
ARRAY N 






















N Y  N 






Y N  NK 
 45 
827494 MDS retrospective BM 46,XX,del(5)(q22q35)[8]/46,XX[12] N N 
 del(5)(q15q33.3)[33.6%] 0 SF3B1:p.K700E[16.7%] N N  N 






V397%3D[46.5%] N N 
 N 






















Y N  N 






N N  N 



























Y N  N 


















907471 MDS retrospective BM 46,XX,del(5)(?q12q33)[1]/46,XX[19] N N 
 del(5)(q14.1q34)[10.7%],+19[
5.5%] 0 0 N N 
 N 













Y N  N 





























N N  0 t(8;21)(q21.3;q22.12)[32.6%] ASXL1:p.Y591delins*[36.9%] N N 
 N 











Y N  N 












N N  N 







Y N  NK 


















0 TP53:p.L344P[86.2%] N Y  N 




















N Y  N 









Y N  N 








988638 MDS retrospective BM 46,XY,del(12)(q21q24.1)[13]/46,XY[7] N N 
 del(12)(q21.2q23.3)[44.7%] 0 SRSF2:p.P95H[11.4%],ASXL1:p.G646Wfs*12[12.2%] N N 
 N 












0 TP53:p.C176G[26.9%],TP53:p.L111Q[31.1%] N Y 
 N 








N N  N 










Y N  NK 












Y N  N 
 46 











586748 AML prospective BM 46,XY[20] Y N ETV6:p.Ser131PhefsTer23[35.7%] 0 
t(7;21)(p22.1;q22.12)[23.








N N  N 
























0 TP53:p.R273H[80.0%] N YY  N 
















Y N  N 
281935 PNH prospective BM 46,XY[20] Y N PIGA:p.Tyr43ThrfsTer18[3.9%] 0 0 0 Y N  N 




Y N  N 













0 TP53:p.R273H[84.4%] N YY  N 






















N Y  N 
















0 TP53:NA[46.7%],TP53:p.C238Y[45.7%] N Y 
 N 





del(5)(q21.1q33.3)[36.8%] 0 0 N N  N 











Y N  N 








0 CBL:p.I383L[32.8%],NF1:p.R897Q[59.7%] N Y 
 N 














Y N  N 











N N  N 




















Y N  N 














N N  N 








Y N  N 






























N Y  N 















Y N  N 


























N Y  N 
 47 
150377 MDS prospective BM 46,XX[20] Y N None detected 0 0 0 Y N  N 






Y N  N 










Y N  NK 
606753 MDS prospective BM 46,XY[20] Y N ZRSR2:p.R442dup[100%] 0 0 ZRSR2:p.R442dup[68.0%] Y N  N 















Y N  N 








Y N  N 

















N N  N 
















0 N Y  Complex 













Y N  N 
994807 None prospective BM 46,XY[20] Y N None detected 0 0 0 Y N  N 


















Y N  NK 





















0 TP53:p.Y126C[71.8%],SMC1A:p.I1062M[100.0%] N Y 
 N 


















N N  0 0 SF3B1:p.K700E[34.2%],RUNX1:p.G170Rfs*43[23.2%] Y N 
CONFIRMED: FISH for 
10p: normal result N 










Y N  N 









1:p.Q157P[14.8%] N Y CONFIRMED: Cyto N 
















N N  N 










Y N  N 









Y N  N 











N N  N 

















0 TP53:p.A86Cfs*63[27.5%] N YY  N 










Y N  N 























































N N  Not Complex 


























N Y CONFIRMED: CS BY ARRAY Complex 
677982 AML prospective BM 47,XY,+i(21)(q10)[14]/47,XY,+21[2]/46,XY[4] N N None detected gain(21)(q11.2qter)[173.8%] 
t(6;11)(q27;q23.3)[28.8%
















0 TP53:p.F134V[50.0%] N Y 
CONFIRMED: FISH 
positive for TP53 and 
CEP17 deletion 
Complex 


























N N  N 













Y N  N 











CONFIRMED: FISH and 
array positive for 
deletion of 4q22.1 
Independe
nt clones 






















0 0 TP53:p.R306*[19.5%],ASXL1:p.E635Rfs*15[8.2%] Y N 
 NK 
869692 MDS prospective BM 46,XY[21] Y N  0 0 SF3B1:p.E622D[37.0%] Y N  N 



















0 0 N YY  N 
















N Y CONFIRMED: 4q28.3 deletion by FISH Complex 




















0 TP53:p.Y220C[63.0%],TP53:p.Q167Lfs*15[47.8%] N Y 
 N 













Y N  N 








FLT3:p.S584_D593dup[17.2%] N N  N 

































Y N  N 






] N N 
 N 











N N  N 








SMC3:NA[37.3%] N N  N 










0 N N  N 








Y N  N 





Y N  N 












0 TP53:NA[42.9%],TP53:NA[46.5%],RUNX1:p.R233L[60.7%] N YY 
 N 














0 TP53:p.R248W[27.7%],TP53:p.L145P[27.4%] N Y 
 N 









0 TP53:p.C275Y[75.9%] N Y  Complex 















Y N  N 
985517 MDS prospective BM 47,XY,+11[3] N N SMC3:p.Gly1118Ter[6.2%],TP53:p.Tyr220Cys[8.5%] +11[8.1%] 0 0 N N 
 N 














0 0 N Y CONFIRMED: Cs BY ARRAY N 





0 N N CONFIRMED: +8 and +10 by FISH 
Not 
Complex 






















0 TP53:p.H168R[43.2%] N Y  N 














negative for 3p11.1 and 
3p26.3 C or aneuploidy; 









s due to 
size <5Mbp 
967740 MDS prospective BM 46,XX[18] NA N TP53:p.Tyr126His[2.7%] 0 0 0 Y N  NK 

















Y N  N 















Y N  N 





N N  N 
228950 MDS prospective BM 46,XY[20] Y N None detected 0 0 0 Y N  N 
















Y N  NK 




+19[74.9%] 0 U2AF1:p.Q157P[36.5%],ASXL1:p.G646Wfs*12[41.3%] N N 
 N 





0 0 U2AF1:p.Q157R[24.1%],U2AF1:p.S34Y[30.0%] Y N 
 NK 









Y N  N 








Y N  N 
 50 










N N  N 











Y N  N 














N N  N 
314322 MDS prospective BM 46,XY,del(20)(q11.2)[19]/46,XY[1] N N 
NF1:p.Gly772ArgfsTer16[64.6%




N N  N 












N N  N 



















0 GATA2:p.R362Q[87.9%],TP53:p.S106R[95.3%] N Y 
 N 












Y N  N 

















Y N  N 























0 TP53:p.R175H[92.5%] N YY CONFIRMED: Cs BY ARRAY N 
946179 AML prospective BM 46,XX[20] Y N NRAS:p.Gly12Asp[47.0%],NPM1:p.Trp288CysfsTer12[44.5%] 0 0 
NRAS:p.G12D[51.1%],NPM1:p
.W288Cfs*12[56.9%] Y N 
 N 







































Y N  N 















Y N  N 












ASXL1:p.G646Wfs*12[11.0%] N Y 
CONFIRMED: FISH 
positive for D13, 
CRLF2, BCL6 
Complex 















0 0 CUX1:p.Q623*[8.7%],ASXL1:p.G646Wfs*12[4.8%] Y N 
 NK 























Y N  N 



























N N  N 












0 0 N Y  N 















0 N Y  N 
 
See Supplementary Methods for more information. 
































































285982 AML 46,XY,t(16;22)(q22;q13)[10] inv(16)(q22.1p13.11)[33.3%] inv(16)(q22.1p13.11)[33.3%] CONFIRMED: nuc ish(CBFBx2)(5'CBFB sep 3'CBFBx1) 
332282 AML 47,XX,+8[20] t(9;11)(p21.3;q23.3)[34.5%],t(9;11)(p21.3;q23.3)[26.2%] 
t(9;11)(p21.3;q23.3)[34.5%],t(9;11)(p21.3;q23.3)
[26.2%] 
CONFIRMED: nuc ish(KMT2Ax2)(5'KMT2A sep 
3'KMT2Ax1) 
380949 AML 45,X,-X[21]/46,XX[9] t(10;11)(p12.31;q23.3)[32.1%] t(10;11)(p12.31;q23.3)[32.1%] CONFIRMED: nuc ish(KMT2Ax2)(5'KMT2A sep 3'KMT2Ax1); RNA-seq positive 
410324 AML 52~54,XY,+2,+4,+6,+8,del(11)(q23),+19,+19,+21[17]/46,XY[3] 
t(6;11)(q27;q23.3)[37.9%],t(6;11)(q27;q23.3)[
32.7%] t(6;11)(q27;q23.3)[37.9%] 
CONFIRMED nuc ish(KMT2Ax2)(5'KMT2A sep 
3'KMT2Ax1); RNA-seq positive 
461513 AML 47,XX,+8[1]/46,XX[4] t(10;11)(p12.31;q23.3)[37.0%] t(10;11)(p12.31;q23.3)[37.0%] CONFIRMED: PCR 
544583 AML 46,XX[11] t(11;19)(q23.3;pter)[18.0%] t(11;19)(q23.3;pter)[18.0%] CONFIRMED: PCR 
586748 AML 46,XY[20] t(7;21)(p22.1;q22.12)[23.1%] t(7;21)(p22.1;q22.12)[23.1%] CONFIRMED: PCR 
616274 AML 47,XX,+8[7]/46,XX[13] t(9;11)(p21.3;q23.3)[19.7%],t(9;11)(p21.3;q23.3)[20.8%] 
t(9;11)(p21.3;q23.3)[19.7%],t(9;11)(p21.3;q23.3)
[20.8%] 
CONFIRMED: nuc ish(KMT2Ax2)(5'KMT2A sep 
3'KMT2Ax1) 




869318 AML 46,XX,?t(12;16)(q24.3;q22)[4]/46,XX[4] inv(16)(q22.1p13.11)[32.5%] inv(16)(q22.1p13.11)[31.1%] 
CONFIRMED: nuc ish(CBFBx2)(5'CBFB sep 
3'CBFBx1) 
898627 AML 46,XX[5] t(9;11)(p21.3;q23.3)[19.3%],t(9;11)(p21.3;q23.3)[18.4%] 
t(9;11)(p21.3;q23.3)[19.3%],t(9;11)(p21.3;q23.3)
[18.4%];Complex 
CONFIRMED: nuc ish(KMT2Ax2)(5'KMT2A sep 
3'KMT2Ax1) 
907716 AML 47,XY+8[17]/46,XY[3] t(9;11)(p21.3;q23.3)[32.7%],t(9;11)(p21.3;q23.3)[34.0%] 
t(9;11)(p21.3;q23.3)[32.7%],t(9;11)(p21.3;q23.3)
[34.0%] 
CONFIRMED: nuc ish(KMT2Ax2)(5'KMT2A sep 
3'KMT2Ax1) 
994357 AML 46,XX[20] t(11;19)(q23.3;p13.11)[23.6%],t(11;19)(q23.3;p13.11)[28.5%] 
t(11;19)(q23.3;p13.11)[23.6%],t(11;19)(q23.3;p1
3.11)[28.5%] 
CONFIRMED: nuc ish(KMT2Ax2)(5'KMT2A sep 
3'KMT2Ax1) 
 * ‘Confirmed’ indicates the variant was supported by an orthogonal method, either clinical FISH studies performed at 
diagnosis, confirmation FISH studies, or PCR for sequence-defined breakpoints. See Figure S2A. 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































714148 chrY 7000000 21000000 14000000 DEL MDS retrospective 46,XY[20] -Y[21.4%] 0 new -Y Confirmation not attempted 
 








































395906 chr4 134000000 139500000 5500000 DEL MDS prospective 46,XY,del(3)(q12q25),+8[20] 
del(3)(q21.2q24)[83.4%],del(4)(q28.






















































































































Coordinates are based on the GRCh38 human reference. 
 * ‘Confirmed’ indicates the variant was supported by an orthogonal method, either clinical FISH studies performed at 
diagnosis, confirmation FISH studies, CMA (array), or sequence-defined breakpoints.  

























































104895 chr13 28018505 C A SNV FLT3 0.038 0.0251451 p.Asp835Tyr Y Y 
104895 chr17 76736877 G T SNV SRSF2 0.438 0.46848 p.Pro95His Y Y 
104895 chr15 90088702 C T SNV IDH2 0.423 0.450396 p.Arg140Gln Y Y 
104895 chrX 124051313 A G SNV STAG2 0.451 0.355191  Y Y 
142639 chr4 105275056 C T SNV TET2 0.088 0.040568 p.Arg1516Ter Y Y 
142639 chr13 28018503 A C SNV FLT3 0.41 0.301744 p.Asp835Glu Y Y 
206801 chr15 90088702 C T SNV IDH2 0.277 0.355402 p.Arg140Gln Y Y 
206801 chr19 33302231 T TG INDEL CEBPA 0.537 0.544199 p.Ile62HisfsTer46 Y Y 
250911 chr5 171410539 C CTCTG INDEL NPM1 0.377 0.459245 p.Trp288CysfsTer12 Y Y 
250911 chr13 28034083 A AAACTCTAAATTTTCTCTTGGAAACTCC INDEL FLT3 0.413 0.291209 
p.Glu611_Phe612insLeuGluPhePr
oArgGluAsnLeuGlu Y Y 
250911 chr15 90088702 C T SNV IDH2 0.469 0.491429 p.Arg140Gln Y Y 
465146 chr5 171410543 G GCAGA INDEL NPM1 0.226 0.312388 p.Trp288CysfsTer12 Y Y 
499829 chr17 76736877 G A SNV SRSF2 0.508 0.461538 p.Pro95Leu Y Y 
499829 chr4 105243699 GACAA G INDEL TET2 0.412 0.402341 p.Lys1243SerfsTer9 Y Y 
499829 chr20 32434789 C T SNV ASXL1 0.394 0.347645 p.Arg693Ter Y Y 
499829 chr11 119278535 T C SNV CBL 0.977 0.954214 p.Phe418Ser Y Y 
499829 chr4 105259635 C T SNV TET2 0.528 0.518291 p.Gln1274Ter Y Y 
499829 chr5 171410539 C CTCTG INDEL NPM1  0.0519943 p.Trp288CysfsTer12 N Y 
509179 chr5 171410540 T TCTGC INDEL NPM1 0.232 0.407112 p.Trp288CysfsTer12 Y Y 
509179 chr3 128481291 CCTT C INDEL GATA2 0.029   Y N 
509179 chr4 105272736 G A SNV TET2 0.517 0.495419 p.Arg1452Gln Y Y 
509179 chr12 112450407 A C SNV PTPN11 0.476 0.529412 p.Glu76Ala Y Y 
509179 chr11 32396364 G T SNV WT1 0.413 0.47617 p.Ser381Ter Y Y 
607160 chr15 90088702 C T SNV IDH2 0.527 0.419328 p.Arg140Gln Y Y 
607160 chr13 28034127 C CATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGA INDEL FLT3 0.313 
  Y N 
607160 chr2 25241699 C T SNV DNMT3A 0.366 0.40448 p.Val649Met Y Y 
607160 chr5 171410540 T TCTGC INDEL NPM1 0.377 0.410256 p.Trp288CysfsTer12 Y Y 
623930 chr2 25243930 C T SNV DNMT3A 0.478 0.443627 p.Arg635Gln Y Y 
623930 chr21 34792358 T G SNV RUNX1 0.125   Y N 
623930 chrX 53409109 T C SNV SMC1A 0.517 0.46337 p.Lys500Glu Y Y 
623930 chr1 114716127 C A SNV NRAS  0.0903226 p.Gly12Cys N Y 
623930 chr5 171410541 C CTGTT INDEL NPM1 0.429 0.384615 p.Trp288CysfsTer12 Y Y 
662555 chr2 25234373 C T SNV DNMT3A 0.396 0.49697 p.Arg882His Y Y 
662555 chr13 28034100 T TTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAA INDEL FLT3 0.425 0.29488 p.Phe594_Pro606dup Y Y 
 61 
662555 chr5 171410539 C CTCTG INDEL NPM1 0.288 0.439086 p.Trp288CysfsTer12 Y Y 
879308 chr2 25234373 C T SNV DNMT3A 0.367 0.391036 p.Arg882His Y Y 
879308 chr5 171410539 C CTCTG INDEL NPM1 0.356 0.43364 p.Trp288CysfsTer12 Y Y 
879308 chr11 32434938 A AGGC INDEL WT1 0.373 0.534884 p.Pro136dup Y Y 






INDEL FLT3 0.049 0.0393258 p.Gln577_Phe612dup Y Y 




INDEL FLT3 0.54 0.519565 p.Asp593_Asn609dup Y Y 
907523 chr2 25244564 A G SNV DNMT3A 0.486 0.453353 p.Met548Thr Y Y 
907523 chr2 25241624 T C SNV DNMT3A 0.554 0.445946 p.Met674Val Y Y 
907523 chr5 171410539 C CTCTG INDEL NPM1 0.375 0.434664 p.Trp288CysfsTer12 Y Y 




C INDEL SRSF2 0.055   Y N 
907716 chr7 148809342 T G SNV EZH2  0.0514286 p.Asn693Thr N Y 
938927 chr15 90088702 C T SNV IDH2 0.354 0.426408 p.Arg140Gln Y Y 
938927 chr11 119278645 TATG T INDEL CBL 0.047   Y N 
938927 chr2 25240366 CAGA C INDEL DNMT3A 0.292 0.461054 p.Phe752del Y Y 
938927 chr1 114716126 C T SNV NRAS 0.358 0.436117 p.Gly12Asp Y Y 
938927 chr5 171410539 C CTCTG INDEL NPM1 0.466 0.380805 p.Trp288CysfsTer12 Y Y 
780327 chr7 102104413 C T SNV CUX1 0.46 0.503484 p.Leu173Phe Y Y 
780327 chr15 90088702 C T SNV IDH2 0.412 0.428571 p.Arg140Gln Y Y 
780327 chr7 102201390 G T SNV CUX1 0.48 0.454768 p.Gly709Val Y Y 
780327 chr5 171410542 T TGTAG INDEL NPM1 0.519 0.365108 p.Trp288CysfsTer12 Y Y 
776603 chr20 32434638 A AG INDEL ASXL1 0.385 0.245179 p.Gly646TrpfsTer12 Y Y 
776603 chr21 34834502 A AC INDEL RUNX1  0.0568966 p.Val238GlyfsTer23 N Y 
776603 chr21 34880580 C T SNV RUNX1 0.244 0.171995 p.Arg162Lys Y Y 
776603 chr21 34792554 T TG INDEL RUNX1 0.14 0.149051 p.Ile342HisfsTer258 Y Y 
776603 chr21 43104346 G A SNV U2AF1 0.522 0.326577 p.Ser34Phe Y Y 
994357 chr21 34792313 T G SNV RUNX1  0.333333 p.Glu422Ala N Y 
586748 chr12 11853483 C CT INDEL ETV6 0.463 0.357362 p.Ser131PhefsTer23 Y Y 
553306 chr17 7673802 C T SNV TP53 0.8 0.835125 p.Arg273His Y Y 
677322 chrX 134417211 G T SNV PHF6  0.0566449 p.Glu293Ter N Y 
677322 chr7 148817943 C T SNV EZH2 0.565 0.492437 p.Glu392Lys Y Y 
677322 chrX 53405648 G A SNV SMC1A 0.897 0.894094 p.Arg586Trp Y Y 
677322 chr2 208248388 C T SNV IDH1 0.289 0.424589 p.Arg132His Y Y 
677322 chr2 25244564 A G SNV DNMT3A 0.425 0.436548 p.Met548Thr Y Y 
677322 chrX 134377742 A AC INDEL PHF6  0.0801457 p.His43ProfsTer2 N Y 
677322 chr19 33302311 C CGG INDEL CEBPA 0.49 0.344923 p.Arg35ProfsTer126 Y Y 
677322 chr19 33301813 AGGTGCGCGGGCGGCGG A INDEL CEBPA 0.333 0.765823 p.Pro196TrpfsTer117 Y Y 
504451 chr17 7673802 C T SNV TP53 0.844 0.81203 p.Arg273His Y Y 
 62 
410110 chr21 34880697 T TC INDEL RUNX1 0.553 0.389922 p.Asp123GlyfsTer15 Y Y 




INDEL FLT3 0.065   Y N 
410110 chr21 34880569 G A SNV RUNX1 0.493 0.449102 p.Arg166Ter Y Y 
410110 chr17 76736877 G T SNV SRSF2 0.37 0.484058 p.Pro95His Y Y 
410110 chr2 25234374 G A SNV DNMT3A 0.543 0.456156 p.Arg882Cys Y Y 
296442 chr17 7673533 A G SNV TP53 0.467 0.46994  Y Y 
296442 chr17 7674250 C T SNV TP53 0.457 0.431262 p.Cys238Tyr Y Y 
889663 chr21 34886875 G A SNV RUNX1  0.0826211 p.Arg107Cys N Y 
889663 chr11 32396368 G GT INDEL WT1  0.0943396 p.Arg380ThrfsTer5 N Y 
889663 chrX 130016199 T TGGGAGGGA INDEL BCORL1  0.0590062 p.Ser1143TrpfsTer82 N Y 
889663 chrX 40054335 T C SNV BCOR  0.139896  N Y 
508617 chr4 105234422 T TA INDEL TET2 0.518 0.361345 p.Asp162ArgfsTer9 Y Y 
508617 chr4 105236538 C T SNV TET2 0.286   Y N 
508617 chr17 76736877 G T SNV SRSF2 0.422 0.456767 p.Pro95His Y Y 
508617 chr21 34880572 C T SNV RUNX1 0.273 0.251938 p.Gly165Ser Y Y 
437892 chr11 119278217 A T SNV CBL 0.328 0.220177 p.Ile383Leu Y Y 
437892 chr17 31229305 G A SNV NF1 0.597 0.443627 p.Arg897Gln Y Y 
343604 chr20 32434638 A AG INDEL ASXL1 0.393 0.434307 p.Gly646TrpfsTer12 Y Y 
343604 chr7 148828882 T C SNV EZH2 0.955 0.909953  Y Y 
343604 chr12 25245347 C T SNV KRAS 0.35 0.350453 p.Gly13Asp Y Y 
726806 chr4 105235256 CA C INDEL TET2 0.377 0.522659 p.Asn439ThrfsTer8 Y Y 
726806 chr1 36471622 C T SNV CSF3R 0.633 0.515625 p.Gly366Arg Y Y 
726806 chr20 32429991 G T SNV ASXL1 0.5 0.439655 p.Gly219Val Y Y 
726806 chr5 171410539 C CTCTG INDEL NPM1 0.481 0.464455 p.Trp288CysfsTer12 Y Y 
726806 chr13 28034107 C CTCCCATTTGAGATCATATTCATATTCTCTG INDEL FLT3 0.41 0.233546 
p.Trp603_Glu604insAspArgGluTyr
GluTyrAspLeuLysTrp Y Y 
375074 chr5 171410539 C CTCTG INDEL NPM1 0.203 0.309175 p.Trp288CysfsTer12 Y Y 
375074 chr4 105242872 T A SNV TET2 0.837 0.779874 p.Val1180Asp Y Y 
375074 chr17 76736877 G C SNV SRSF2 0.522 0.448009 p.Pro95Arg Y Y 
375074 chr15 90088702 C T SNV IDH2 0.39 0.486797 p.Arg140Gln Y Y 
557196 chr2 25240427 C CA INDEL DNMT3A 0.444 0.376923 p.Glu733Ter Y Y 
557196 chrX 130015496 C A SNV BCORL1 0.778 0.790909 p.Cys908Ter Y Y 
557196 chr2 25240684 C T SNV DNMT3A 0.325 0.4093 p.Cys710Tyr Y Y 




INDEL FLT3 0.063 0.00833649 p.Tyr589_Glu604dup Y Y 
557196 chr12 25245332 G T SNV KRAS  0.0575472 p.Ala18Asp N Y 
557196 chr4 105269609 G T SNV TET2 0.455 0.372362  Y Y 
557196 chr1 114716127 C T SNV NRAS 0.163 0.235823 p.Gly12Ser Y Y 
557196 chrX 15804193 AAG A INDEL ZRSR2 0.379 0.746269 p.Glu133GlyfsTer11 Y Y 
271002 chrX 134415022 T A SNV PHF6  0.136364 p.Ser246Thr N Y 
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271002 chr12 11869428 CTG C INDEL ETV6 0.122 0.116187 p.Val158ProfsTer10 Y Y 
271002 chr7 148813976 G A SNV EZH2  0.0950704 p.Gln612Ter N Y 
271002 chr2 25234374 G A SNV DNMT3A 0.425 0.411061 p.Arg882Cys Y Y 
271002 chr15 90088702 C T SNV IDH2 0.447 0.389437 p.Arg140Gln Y Y 
271002 chrX 134425256 C T SNV PHF6  0.0571429 p.Arg342Ter N Y 
271002 chrX 134415026 C A SNV PHF6  0.136364 p.Ser247Tyr N Y 
271002 chrX 130037503 A G SNV BCORL1 1 0.994764 p.Asn1481Ser Y Y 
259112 chr2 25234373 C T SNV DNMT3A 0.948 0.897436 p.Arg882His Y Y 
259112 chr17 76736877 G T SNV SRSF2 0.438 0.494824 p.Pro95His Y Y 
259112 chr15 90088702 C T SNV IDH2 0.517 0.442682 p.Arg140Gln Y Y 
819978 chr15 90088702 C T SNV IDH2 0.362 0.410135 p.Arg140Gln Y Y 
819978 chr17 7675217 T C SNV TP53 0.722 0.777619 p.Lys132Arg Y Y 
819978 chr1 114716123 C T SNV NRAS 0.09 0.0897305 p.Gly13Asp Y Y 
819978 chr17 76736877 G A SNV SRSF2 0.547 0.51005 p.Pro95Leu Y Y 
819978 chr12 25245347 C T SNV KRAS  0.105566 p.Gly13Asp N Y 
895870 chr5 171410539 C CTCTG INDEL NPM1 0.3 0.280462 p.Trp288CysfsTer12 Y Y 
895870 chr20 32434638 A AG INDEL ASXL1  0.11126 p.Gly646TrpfsTer12 N Y 
895870 chrX 124081469 TGCTTTAAC T INDEL STAG2  0.0900225 p.Ala956PhefsTer4 N Y 
895870 chr15 90088702 C T SNV IDH2 0.375 0.488538 p.Arg140Gln Y Y 
895870 chr13 28034144 A C SNV FLT3 0.386 0.271178 p.Val592Gly Y Y 
895870 chr17 76736879 G GCGC INDEL SRSF2 0.489 0.458671 p.Arg94dup Y Y 
992091 chr20 32436950 T C SNV ASXL1 0.449 0.347531 p.Leu1413Ser Y Y 
992091 chr17 31226459 A AC INDEL NF1 0.717   Y N 
992091 chr17 7670685 G A SNV TP53 0.719 0.670951 p.Arg342Ter Y Y 
333171 chrX 53414992 C T SNV SMC1A 0.212 0.28595 p.Arg96His Y Y 
333171 chr12 11884493 G A SNV ETV6 0.508 0.497291 p.Arg353Gln Y Y 
333171 chr4 105276400 T C SNV TET2 0.404 0.478554 p.Tyr1964His Y Y 
333171 chr12 25245350 C G SNV KRAS 0.405 0.369942 p.Gly12Ala Y Y 
606753 chrX 15823117 C CGCA INDEL ZRSR2 0.68 1 p.Arg442dup Y Y 
704854 chr7 148807671 A G SNV EZH2  0.0526316 p.Ile744Thr N Y 
704854 chr2 25244214 G A SNV DNMT3A 0.368 0.459297 p.Arg598Ter Y Y 
704854 chr20 32435133 TC T INDEL ASXL1 0.208 0.410985 p.Pro808LeufsTer10 Y Y 
704854 chr3 128481293 TTCTTCATGG T INDEL GATA2 0.298 0.302291 p.Thr387_Lys389del Y Y 
704854 chr12 112489084 G T SNV PTPN11 0.312 0.258204 p.Gly503Val Y Y 
704854 chr2 25234323 G A SNV DNMT3A 0.406 0.420389 p.Arg899Cys Y Y 
952492 chrX 40077898 A G SNV BCOR 1 1 p.Val11Ala Y Y 
952492 chr2 25300185 G A SNV DNMT3A 0.525 0.482845 p.Thr44Met Y Y 
952492 chr20 32433473 C CA INDEL ASXL1 0.329 0.219272 p.Gln428ThrfsTer10 Y Y 
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312088 chr2 25234374 G A SNV DNMT3A 0.531 0.447244 p.Arg882Cys Y Y 
312088 chr12 112450359 G T SNV PTPN11  0.188153 p.Gly60Val N Y 
312088 chr12 25227342 T A SNV KRAS  0.0875445 p.Gln61Leu N Y 
312088 chr11 32435332 G A SNV WT1 0.333 0.476 p.Ala5Val Y Y 
312088 chr1 114716123 C T SNV NRAS 0.077 0.0765306 p.Gly13Asp Y Y 
312088 chr5 171410539 C CTCTG INDEL NPM1 0.242 0.383845 p.Trp288CysfsTer12 Y Y 
312088 chr11 32435333 C T SNV WT1 0.391 0.477046 p.Ala5Thr Y Y 
312088 chr8 116854320 CA C INDEL RAD21 0.323 0.425532 p.Met362SerfsTer8 Y Y 
570496 chr15 90088702 C T SNV IDH2 0.435 0.494118 p.Arg140Gln Y Y 
570496 chrX 124063866 C T SNV STAG2 0.321 0.353556 p.Arg614Ter Y Y 
570496 chr20 32434638 A AG INDEL ASXL1 0.363 0.462963 p.Gly646TrpfsTer12 Y Y 
570496 chr2 197402981 C T SNV SF3B1 0.466 0.411936 p.Glu592Lys Y Y 
570496 chrX 124045347 C T SNV STAG2 0.52 0.404475 p.Arg216Ter Y Y 









229201 chr5 171410539 C CTCTG INDEL NPM1 0.155 0.261972 p.Trp288CysfsTer12 Y Y 
229201 chr15 90088702 C T SNV IDH2 0.377 0.369789 p.Arg140Gln Y Y 
983349 chr17 7675235 T C SNV TP53 0.718 0.535032 p.Tyr126Cys Y Y 
983349 chrX 53382605 G C SNV SMC1A 1 1 p.Ile1062Met Y Y 
534164 chr8 116856286 C A SNV RAD21  0.131579 p.Gly273Cys N Y 
534164 chr12 11884565 C T SNV ETV6 0.379 0.403968 p.Ala377Val Y Y 
534164 chr2 25247629 G A SNV DNMT3A 0.509 0.442248 p.Arg326Cys Y Y 
925086 chrX 40072977 T C SNV BCOR 0.527 0.495556 p.Asn790Ser Y Y 
925086 chr2 25234373 C T SNV DNMT3A 0.429 0.400607 p.Arg882His Y Y 
925086 chr20 32437205 C T SNV ASXL1 0.466 0.505505 p.Thr1498Met Y Y 
925086 chr5 171410539 C CTCTG INDEL NPM1 0.403 0.406479 p.Trp288CysfsTer12 Y Y 
875579 chr21 43094667 T G SNV U2AF1 0.148 0.282226 p.Gln157Pro Y Y 
875579 chr1 36466641 G A SNV CSF3R 0.157 0.286447 p.Gln770Ter Y Y 
679540 chr2 197402649 G C SNV SF3B1 0.397 0.243719 p.His662Asp Y Y 
679540 chr17 31229061 C T SNV NF1 0.433 0.114583 p.Arg816Ter Y Y 
679540 chr17 7675126 GATGGCC G INDEL TP53 0.672 0.387312 p.Met160_Ala161del Y Y 
477377 chr1 114716127 C T SNV NRAS  0.065051 p.Gly12Ser N Y 




C INDEL SRSF2 0.452 0.442539 p.Pro95_Arg102del Y Y 
477377 chrX 53403617 C T SNV SMC1A 0.806 0.814241 p.Arg790Gln Y Y 
477377 chr15 90088702 C T SNV IDH2 0.508 0.445313 p.Arg140Gln Y Y 
493436 chr21 34880640 G GCCGGGC INDEL RUNX1 0.213 0.376623 p.Ser141_Ala142insGlyPro Y Y 
493436 chr1 114716127 C A SNV NRAS 0.458 0.369087 p.Gly12Cys Y Y 
493436 chr21 34799371 TGCTGGGTGCACAGAAG T INDEL RUNX1 0.224 0.368175 p.Pro294GlnfsTer12 Y Y 
429293 chr21 34880620 C G SNV RUNX1  0.227561 p.Ala149Pro N Y 
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429293 chr15 90088702 C T SNV IDH2 0.196 0.245259 p.Arg140Gln Y Y 
429293 chr8 116863211 G A SNV RAD21 0.228 0.209272 p.Arg65Ter Y Y 
429293 chr21 34834409 C T SNV RUNX1 0.259 0.267133  Y Y 
429293 chr12 112450416 A G SNV PTPN11 0.304 0.219114 p.Gln79Arg Y Y 
429293 chrX 40062137 A C SNV BCOR 0.369 0.31338  Y Y 
802619 chr17 7674268 A G SNV TP53  0.248775 p.Ile232Thr N Y 
802619 chr17 7676114 A AG INDEL TP53 0.275 0.247289 p.Ala86CysfsTer63 Y Y 
802619 chr8 116848945 C T SNV RAD21  0.183246  N Y 
294891 chr4 105235529 C CCT INDEL TET2 0.375 0.2 p.Gln530HisfsTer11¬† Y Y 
294891 chr5 171410540 T TCTGC INDEL NPM1 0.073 0.26672 p.Trp288CysfsTer12 Y Y 
294891 chr17 76736877 G T SNV SRSF2 0.422 0.36695 p.Pro95His Y Y 
294891 chr4 105275167 C CA INDEL TET2 0.492 0.188356 p.Thr1554AspfsTer24 Y Y 





INDEL FLT3 0.071 0.165229 p.Glu598_Tyr599insTer Y Y 
731757 chr10 110596398 G A SNV SMC3 0.455 0.447479 p.Gly655Asp Y Y 
731757 chr2 25241590 C A SNV DNMT3A 0.456 0.514398 p.Gly685Val Y Y 
731757 chr5 171410539 C CTCTG INDEL NPM1 0.282 0.40767 p.Trp288CysfsTer12 Y Y 
335141 chr2 25234373 C T SNV DNMT3A 0.521 0.448179 p.Arg882His Y Y 
335141 chr13 28034113 T TTTGAGATCATATTCATATTCTCTGAAATCAACGTAG INDEL FLT3 0.216 0.188447 
p.Leu601_Lys602insAsnTyrValAsp
PheArgGluTyrGluTyrAspLeu Y Y 
335141 chr2 197402110 T C SNV SF3B1 0.394 0.443825 p.Lys700Glu Y Y 
155912 chr5 171410539 C CTCTG INDEL NPM1 0.371 0.384372 p.Trp288CysfsTer12 Y Y 
155912 chr2 25244337 A G SNV DNMT3A 0.369 0.421749 p.Cys557Arg Y Y 
155912 chr13 28034103 G GAAACTCCCATTTGAGATCATATTCATGTCT INDEL FLT3 0.179 0.128768 
p.Phe605_Pro606insArgHisGluTyr
AspLeuLysTrpGluPhe Y Y 
155912 chr11 32396401 G GCC INDEL WT1 0.421 0.432269 p.Arg369GlyfsTer7 Y Y 
155912 chr12 112502202 C T SNV PTPN11 0.476 0.457831 p.Thr553Met Y Y 
103744 chr17 7675212 A C SNV TP53 0.5 0.295972 p.Phe134Val Y Y 
956161 chr2 197402636 T G SNV SF3B1 0.491 0.449367 p.Lys666Thr Y Y 









673325 chr1 114716126 C T SNV NRAS 0.075 0.100521 p.Gly12Asp Y Y 
673325 chr21 43104346 G A SNV U2AF1 0.406 0.4625 p.Ser34Phe Y Y 
673325 chrX 124076340 CA C INDEL STAG2 0.611 0.949219 p.Glu849ArgfsTer23 Y Y 
673325 chr1 114716123 C T SNV NRAS 0.087 0.112836 p.Gly13Asp Y Y 
673325 chrX 40072420 G A SNV BCOR 0.95 0.961319 p.Arg976Ter Y Y 
451688 chr9 5073770 G T SNV JAK2 0.048   Y N 
451688 chr20 32434638 A AG INDEL ASXL1 0.302 0.306122 p.Gly646TrpfsTer12 Y Y 
451688 chr7 148818035 CCTCTT C INDEL EZH2 0.167 0.207852 p.Arg360ThrfsTer5 Y Y 
451688 chrX 15818643 G A SNV ZRSR2 0.68 0.594937  Y Y 




T INDEL ASXL1 0.082 0.188329 p.Glu635ArgfsTer15 Y Y 
891309 chr20 32435095 TC T INDEL ASXL1 0.048 0.0591982 p.Trp796GlyfsTer22 Y Y 
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891309 chr17 7673704 G A SNV TP53 0.195 0.224138 p.Arg306Ter Y Y 
572410 chr17 7674894 G A SNV TP53  0.127092 p.Arg213Ter N Y 
395906 chr17 31261733 C T SNV NF1 0.545 0.525622 p.Arg1534Ter Y Y 
395906 chr20 32435474 C T SNV ASXL1 0.586 0.482759 p.Ser921Phe Y Y 
395906 chr21 34886904 A G SNV RUNX1 0.352 0.431412 p.Phe97Ser Y Y 
395906 chr21 43104346 G A SNV U2AF1 0.568 0.434457 p.Ser34Phe Y Y 
395906 chr2 25234373 C T SNV DNMT3A 0.509 0.44625 p.Arg882His Y Y 
395906 chr17 60663185 T G SNV PPM1D 0.472 0.450064 p.Leu484Ter Y Y 
830563 chr17 7674872 T C SNV TP53 0.63 0.418228 p.Tyr220Cys Y Y 
830563 chr17 7675112 T TGTGA INDEL TP53 0.478 0.424208 p.Gln167LeufsTer15 Y Y 
467399 chr13 28018485 G T SNV FLT3 0.236 0.159091 p.Asn841Lys Y Y 
467399 chr4 105243605 G GTGTT INDEL TET2 0.434 0.402878 p.Val1213PhefsTer11 Y Y 
467399 chr4 105259626 T TG INDEL TET2 0.205 0.240192 p.Cys1271TrpfsTer29 Y Y 
467399 chr2 25234373 C T SNV DNMT3A 0.532 0.453649 p.Arg882His Y Y 
467399 chr5 171410539 C CTCTG INDEL NPM1 0.432 0.416667 p.Trp288CysfsTer12 Y Y 
764488 chr4 105269703 C T SNV TET2 0.462 0.489555 p.His1380Tyr Y Y 
764488 chr19 33302240 C CGG INDEL CEBPA 0.346 0.251295 p.Glu59ProfsTer102 Y Y 
764488 chr5 171410539 C CTCTG INDEL NPM1 0.333 0.304025 p.Trp288CysfsTer12 Y Y 
764488 chr2 25241710 G C SNV DNMT3A 0.524 0.468603  Y Y 
764488 chr13 28034192 A T SNV FLT3 0.173 0.139981 p.Leu576Gln Y Y 
764488 chr4 105276262 GA G INDEL TET2 0.361 0.453328 p.Ala1919ProfsTer31 Y Y 
809382 chr5 171410540 T TCTGC INDEL NPM1 0.446 0.365055 p.Trp288CysfsTer12 Y Y 
809382 chr17 76736877 G C SNV SRSF2 0.534 0.257143 p.Pro95Arg Y Y 
809382 chr4 105236826 C T SNV TET2 0.461 0.432432 p.Gln962Ter Y Y 
809382 chr4 105236412 A T SNV TET2 0.476 0.390805 p.Lys824Ter Y Y 
809382 chr2 25244163 G A SNV DNMT3A 0.49 0.42976 p.Gln615Ter Y Y 
211740 chr2 197402637 T C SNV SF3B1 0.391 0.555556 p.Lys666Glu Y Y 
211740 chr21 34859492 C T SNV RUNX1 0.353 0.285714 p.Gly199Arg Y Y 
211740 chr11 32392020 G A SNV WT1 0.172   Y N 
462268 chr10 110580903 G C SNV SMC3 0.373 0.439402  Y Y 
267935 chr4 54723599 TGAC T INDEL KIT  0.113437 p.Thr417del N Y 
267935 chr4 54723604 TACG T INDEL KIT  0.122227 p.Asp419del N Y 
491972 chr5 171410541 C CTGCT INDEL NPM1 0.491 0.272581 p.Trp288CysfsTer12 Y Y 
491972 chr2 25234362 G C SNV DNMT3A 0.481 0.341866 p.Gln886Glu Y Y 
491972 chr4 105236679 C T SNV TET2 0.465 0.289855 p.Gln913Ter Y Y 
872523 chr17 7674858 C T SNV TP53 0.429 0.443163  Y Y 
872523 chr21 34834517 C A SNV RUNX1 0.607 0.490385 p.Arg233Leu Y Y 
872523 chr17 7675237 C T SNV TP53 0.465 0.436013  Y Y 
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188798 chr17 7674221 G A SNV TP53 0.277 0.20453 p.Arg248Trp Y Y 
188798 chr17 7675178 A G SNV TP53 0.274 0.312127 p.Leu145Pro Y Y 
739025 chr17 7673796 C T SNV TP53 0.759 0.752982 p.Cys275Tyr Y Y 
506517 chrX 130013757 G C SNV BCORL1 0.485 0.495667 p.Val329Leu Y Y 
506517 chr5 171410539 C CTCTG INDEL NPM1 0.422 0.482097 p.Trp288CysfsTer12 Y Y 
506517 chr11 32396357 A AGATGCCGACCGTACAAGAGTCG INDEL WT1 0.514 0.388773 p.Glu384AspfsTer8 Y Y 
506517 chrX 40073314 G A SNV BCOR 0.526 0.459042 p.Pro678Ser Y Y 









INDEL FLT3 0.214 0.1 p.Phe594_Asp600dup Y Y 
985517 chr17 7674872 T C SNV TP53  0.0852149 p.Tyr220Cys N Y 
985517 chr10 110602879 G T SNV SMC3  0.0625 p.Gly1118Ter N Y 
537017 chr17 7675109 T C SNV TP53 0.432 0.331058 p.His168Arg Y Y 
666013 chr2 25247160 T G SNV DNMT3A 0.542 0.30184  Y Y 
666013 chrX 134415110 GA G INDEL PHF6 0.321 0.108225 p.Arg277GlufsTer2 Y Y 
666013 chrX 40074977 CT C INDEL BCOR 0.227 0.0941176 p.Gln123ArgfsTer38 Y Y 
666013 chr2 208248389 G A SNV IDH1 0.238 0.115979 p.Arg132Cys Y Y 
887041 chr21 34880580 C T SNV RUNX1 0.963 0.954333 p.Arg162Lys Y Y 
887041 chr2 208248388 C A SNV IDH1 0.553 0.444444 p.Arg132Leu Y Y 
887041 chr1 114716124 C G SNV NRAS  0.0694444 p.Gly13Arg N Y 
887041 chr13 28018503 A T SNV FLT3 0.174 0.216931 p.Asp835Glu Y Y 
887041 chr17 76736877 G T SNV SRSF2 0.431 0.464758 p.Pro95His Y Y 
887041 chr20 32434638 A AG INDEL ASXL1 0.508 0.387805 p.Gly646TrpfsTer12 Y Y 
887041 chr2 25244214 G A SNV DNMT3A 0.507 0.466172 p.Arg598Ter Y Y 
887041 chr2 25282695 G T SNV DNMT3A 0.516 0.494454 p.Thr65Lys Y Y 




T INDEL ASXL1 0.099 0.105932 p.Glu635ArgfsTer15 Y Y 
681540 chr21 34886941 G GGT INDEL RUNX1 0.505 0.443262 p.His85ThrfsTer38 Y Y 
681540 chr4 105276142 C T SNV TET2  0.0654326 p.Arg1878Cys N Y 
681540 chr4 105275394 T G SNV TET2  0.0576565 p.Tyr1628Ter N Y 
681540 chrX 15818643 G A SNV ZRSR2  0.247059  N Y 
748511 chrX 130025362 G A SNV BCORL1 1 1 p.Arg1354Gln Y Y 
748511 chr17 7673567 T A SNV TP53 0.239 0.284669 p.Lys321Ter Y Y 
748511 chr17 7670700 G A SNV TP53 0.271 0.354723 p.Arg337Cys Y Y 
416413 chr11 119278568 T A SNV CBL 0.409 0.43937 p.Ile429Asn Y Y 
416413 chr20 32434638 A AG INDEL ASXL1 0.359 0.414966 p.Gly646TrpfsTer12 Y Y 
416413 chr4 105236832 C T SNV TET2  0.452273 p.Gln964Ter N Y 
416413 chr1 114716126 C T SNV NRAS 0.273 0.273469 p.Gly12Asp Y Y 
416413 chr4 105235633 G A SNV TET2  0.50289 p.Trp564Ter N Y 
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416413 chrX 124081379 G A SNV STAG2  0.9375  N Y 
416413 chr17 7673773 G A SNV TP53 0.545 0.466263 p.Arg283Cys Y Y 
416413 chr19 33301429 T TC INDEL CEBPA  0.141844 p.Glu329GlyfsTer74 N Y 




G INDEL CEBPA 0.373   Y N 
853337 chr2 25244640 C A SNV DNMT3A 0.433 0.444315 p.Glu523Ter Y Y 
853337 chr10 110578707 G A SNV SMC3 0.48 0.372549  Y Y 
853337 chr12 112450362 A G SNV PTPN11 0.456 0.385787 p.Asp61Gly Y Y 
853337 chr2 208248388 C T SNV IDH1  0.0573248 p.Arg132His N Y 
853337 chr5 171410539 C CTCTG INDEL NPM1 0.383 0.426966 p.Trp288CysfsTer12 Y Y 
800962 chr21 43094667 T G SNV U2AF1 0.365 0.102083 p.Gln157Pro Y Y 
800962 chr20 32434638 A AG INDEL ASXL1 0.413 0.110988 p.Gly646TrpfsTer12 Y Y 
787399 chr21 43104346 G T SNV U2AF1 0.3 0.213693 p.Ser34Tyr Y Y 
293825 chr12 112450359 G C SNV PTPN11  0.137595 p.Gly60Ala N Y 
293825 chr5 171410540 T TCTGC INDEL NPM1 0.385 0.304487 p.Trp288CysfsTer12 Y Y 
293825 chr15 90088702 C A SNV IDH2 0.302 0.295045 p.Arg140Leu Y Y 
293825 chr2 25234374 G A SNV DNMT3A 0.333 0.292651 p.Arg882Cys Y Y 
541728 chr2 25240720 C T SNV DNMT3A 0.459 0.477824 p.Trp698Ter Y Y 
541728 chr1 114713909 G T SNV NRAS 0.433 0.428473 p.Gln61Lys Y Y 
541728 chr5 171410539 C CTCTG INDEL NPM1 0.407 0.444976 p.Trp288CysfsTer12 Y Y 




T INDEL ASXL1 0.433 0.453125 p.Glu635ArgfsTer15 Y Y 
632997 chr17 76736877 G T SNV SRSF2 0.722 0.59153 p.Pro95His Y Y 
632997 chr12 112489106 G T SNV PTPN11  0.283298 p.Gln510His N Y 
632997 chr12 11884558 G A SNV ETV6 0.615 0.445295 p.Gly375Arg Y Y 
187885 chr5 171410547 G GAGGA INDEL NPM1 0.509 0.461326 p.Trp290ArgfsTer10 Y Y 
187885 chr13 28018504 T G SNV FLT3  0.0743551 p.Asp835Ala N Y 
187885 chr13 28034144 A G SNV FLT3 0.196 0.131746 p.Val592Ala Y Y 
187885 chr2 25234374 G A SNV DNMT3A 0.5 0.485876 p.Arg882Cys Y Y 
187885 chr2 208248388 C T SNV IDH1 0.432 0.368295 p.Arg132His Y Y 
191374 chr20 32369060 T A SNV ASXL1 0.5 0.459397 p.Asn63Lys Y Y 
191374 chr4 105236370 C T SNV TET2 0.413 0.456621 p.Gln810Ter Y Y 
191374 chr7 102195540 G T SNV CUX1 0.528 0.505155 p.Glu398Ter Y Y 
191374 chr8 116851977 C T SNV RAD21 0.477 0.449458 p.Gly481Arg Y Y 
191374 chrX 134417275 T C SNV PHF6 0.96 0.924528 p.Ile314Thr Y Y 
191374 chr11 119278165 G T SNV CBL 0.562 0.415294  Y Y 
191374 chr4 105236672 AG A INDEL TET2 0.286 0.476404 p.Ala911LeufsTer10 Y Y 
314322 chr17 31227294 A T SNV NF1 0.686   Y N 
314322 chr17 31227278 CAGGAAACACT C INDEL NF1 0.758 0.6464 p.Gly772ArgfsTer16 Y Y 
314322 chr21 43104346 G A SNV U2AF1 0.469 0.433566 p.Ser34Phe Y Y 
 69 
480059 chr17 76736877 G A SNV SRSF2 0.491 0.532544 p.Pro95Leu Y Y 
480059 chr17 60663168 C A SNV PPM1D 0.4 0.278061 p.Cys478Ter Y Y 
480059 chr17 31236022 G A SNV NF1 0.349 0.285182  Y Y 
480059 chr5 171410539 C CTCTG INDEL NPM1 0.278 0.284821 p.Trp288CysfsTer12 Y Y 
480059 chr20 32434638 A AG INDEL ASXL1 0.464 0.416667 p.Gly646TrpfsTer12 Y Y 
905861 chr3 128481877 C T SNV GATA2 0.879 0.924138 p.Arg362Gln Y Y 
905861 chr17 7676051 G C SNV TP53 0.953 0.955598 p.Ser106Arg Y Y 
654925 chr2 208248389 G C SNV IDH1 0.421 0.408559 p.Arg132Gly Y Y 
654925 chr5 171410539 C CTCTG INDEL NPM1 0.351 0.406682 p.Trp288CysfsTer12 Y Y 
654925 chr2 25234377 TC T INDEL DNMT3A 0.441 0.340381 p.Met880IlefsTer26 Y Y 
654925 chr13 28034144 A G SNV FLT3  0.161203 p.Val592Ala N Y 
654925 chr13 28018483 T C SNV FLT3 0.186 0.0766269 p.Tyr842Cys Y Y 
653268 chr5 171410539 C CTCTG INDEL NPM1 0.393 0.421652 p.Trp288CysfsTer12 Y Y 
653268 chr13 28018504 T A SNV FLT3 0.147 0.118372 p.Asp835Val Y Y 
653268 chr1 114716123 C T SNV NRAS 0.079 0.065833 p.Gly13Asp Y Y 
653268 chr12 112489080 T C SNV PTPN11 0.159 0.124005 p.Ser502Pro Y Y 
653268 chr2 25240423 AACT A INDEL DNMT3A 0.364 0.464334 p.Glu733_Phe734delinsVal Y Y 
946179 chr5 171410542 T TGCCA INDEL NPM1 0.569 0.445455 p.Trp288CysfsTer12 Y Y 
946179 chr1 114716126 C T SNV NRAS 0.511 0.470024 p.Gly12Asp Y Y 











717042 chr5 171410539 C CTCTG INDEL NPM1 0.417 0.402138 p.Trp288CysfsTer12 Y Y 
717042 chr2 25234373 C T SNV DNMT3A 0.538 0.455 p.Arg882His Y Y 
262878 chr12 25245347 C T SNV KRAS  0.0517711 p.Gly13Asp N Y 
262878 chr12 25245350 C T SNV KRAS 0.117 0.0574866 p.Gly12Asp Y Y 
262878 chr13 28018505 C G SNV FLT3  0.131068 p.Asp835His N Y 
262878 chr8 116849009 GC G INDEL RAD21 0.339 0.362069 p.Gly547AlafsTer65 Y Y 
262878 chr5 171410539 C CTCTG INDEL NPM1 0.352 0.379061 p.Trp288CysfsTer12 Y Y 
262878 chr17 31221870 G T SNV NF1 0.511 0.420455 p.Gln554His Y Y 
516070 chr7 102197245 C T SNV CUX1 0.087 0.0434478 p.Gln623Ter Y Y 
869318 chr12 25245347 C T SNV KRAS 0.387 0.268056 p.Gly13Asp Y Y 
736399 chr4 105275734 C T SNV TET2 0.579 0.466248 p.Pro1742Ser Y Y 
736399 chr17 60663160 G T SNV PPM1D 0.657 0.459295 p.Glu476Ter Y Y 
736399 chr5 171410539 C CTCTG INDEL NPM1 0.392 0.465184 p.Trp288CysfsTer12 Y Y 
736399 chr4 105275730 ACC A INDEL TET2 0.419 0.479167 p.Pro1741ThrfsTer11 Y Y 
736399 chr4 105269665 C A SNV TET2 0.5 0.285057 p.Pro1367Gln Y Y 
183114 chr20 32434638 A AG INDEL ASXL1 0.524 0.40051 p.Gly646TrpfsTer12 Y Y 
924089 chr17 7675140 G C SNV TP53  0.178506 p.Arg158Gly N Y 
924089 chr12 112489081 C T SNV PTPN11 0.151 0.198807 p.Ser502Leu Y Y 
 70 
924089 chr11 119278299 T C SNV CBL 0.262 0.25594  Y Y 
924089 chr13 28034142 CAACGTAGAAGTA C INDEL FLT3 0.15 0.188322 p.Tyr589_Val592del Y Y 
924089 chr11 119278165 G T SNV CBL 0.26 0.16895  Y Y 
525644 chr12 112450352 A T SNV PTPN11  0.0551446 p.Asn58Tyr N Y 
 Downloadable version can be found here: https://wustl.box.com/v/rapidclinicalwgs-tables6   
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Favorable NA NK Y NA 
















NA Good N NA N 











APL NA N N NA 

















*23[46.3%] Intermediate NA 
t(7;21)(p22.1;q22.1
2)[23.1%] N NA 






NA Very good N NA N 










































0 TP53:p.R273H[80.0%] NA Very poor N NA N 






















Favorable NA N N NA 
120644 MDS BM unsuccessful None detected NA NA 0 0 0 NA Good NK NA Y 
281935 PNH BM 46,XY[20] PIGA:p.Tyr43ThrfsTer18[3.9%] NA NA 0 0 0 NA NA N NA Y 






Adverse NA N N NA 























0 TP53:p.R273H[84.4%] NA Very poor N NA N 






































































Adverse NA N N NA 









NA Adverse del(5)(q21.1q33.3)[36.8%] 0 0 Adverse NA N N NA 
















NA Good N NA N 

















NA Poor N NA N 















Adverse NA Not Complex Y NA 




















Adverse NA N N NA 


















Adverse NA N N NA 




























Adverse NA N N NA 



















NA Poor N NA N 











Intermediate NA N N NA 

















































Adverse NA N N NA 
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Favorable NA N N NA 











































Adverse NA N N NA 
150377 MDS BM 46,XX[20] None detected Good NA 0 0 0 NA Good N NA N 









NA Good N NA N 













NA Good NK NA Y 
606753 MDS BM 46,XY[20] ZRSR2:p.R442dup[100%] Good NA 0 0 
ZRSR2:p.R442d
up[68.0%] NA Good N NA N 





















Adverse NA N N NA 











NA Good N NA N 




























Favorable NA N N NA 



































0 APL NA Complex N NA 


















NA Good N NA N 
 74 
994807 None BM 46,XY[20] None detected NA NA 0 0 0 NA NA N NA Y 

























Favorable NA NK Y NA 
















































Adverse NA N N NA 















NA Poor del(13)(q14.2q14.3)[85.3%] NA N 










NA Good N NA N 















Favorable NA N N NA 





















Adverse NA N N NA 























Adverse NA N N NA 













Intermediate NA N N NA 
















Adverse NA N N NA 















Adverse NA N N NA 

























0 TP53:p.A86Cfs*63[27.5%] NA Very poor N NA N 















NA Good N NA N 
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Favorable NA N N NA 































Adverse NA Not Complex N NA 






































Adverse NA Complex Y NA 









23.3)[28.8%] 0 Adverse NA 
t(6;11)(q27;q23.3)[
28.8%] Y NA 






















0 TP53:p.F134V[50.0%] Adverse NA Complex N NA 



































Adverse NA N N NA 








































clones NA Y 































NA Good NK NA Y 
869692 MDS BM 46,XY[21] NA Good NA 0 0 SF3B1:p.E622D[37.0%] NA Good N NA N 






























0 0 NA Very poor N NA N 

























NA Poor Complex NA N 









































NA NA NA NA Y 


















Favorable NA N N NA 















593dup[17.2%] APL NA N N NA 


























Favorable NA Not Complex Y NA 
















Favorable NA N N NA 











609dup[50.5%] APL NA N N NA 
211740 AML BM 46,XX,t(3;3)(q21;q26.2)[20] 
SF3B1:p.Lys666Glu[55.6


























%] Favorable NA N N NA 

















0 Favorable NA N N NA 











Favorable NA N N NA 









NA Good N NA N 



























NA Very poor N NA N 






























Adverse NA N N NA 













0 TP53:p.C275Y[75.9%] NA Poor Complex NA N 






















Intermediate NA N N NA 




Intermediate NA +11[8.1%] 0 0 NA Intermediate N NA N 






















0 0 Adverse NA N N NA 










0 APL NA Not Complex N NA 





































0 TP53:p.H168R[43.2%] Adverse NA N N NA 


















967740 MDS BM 46,XX[18] TP53:p.Tyr126His[2.7%] NA NA 0 0 0 NA Good NK NA Y 
























Adverse NA N N NA 













NA Very good del(11q) NA Y 
















NA Poor Complex NA Y 




















NA Good N NA N 











NA Good N NA N 
228950 MDS BM 46,XY[20] None detected Good NA 0 0 0 NA Good N NA N 





















Favorable NA NK Y NA 









NA Intermediate N NA N 










NA Good NK NA Y 












Favorable NA N N NA 











NA Good N NA N 
















NA Intermediate N NA N 
207247 MDS BM unsuccessful DNMT3A:p.Val563Met[4.0%] NA NA 0 0 0 NA Good NK NA Y 















Favorable NA N N NA 





















NA Very good N NA N 














NA Good N NA N 
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Favorable NA N N NA 
































Adverse NA N N NA 

















Favorable NA N N NA 























Favorable NA N N NA 








































0 TP53:p.R175H[92.5%] NA Very poor N NA N 









Favorable NA N N NA 











































































Favorable NA N N NA 





















Wfs*12[11.0%] NA NA Complex NA Y 






















Adverse NA NK Y NA 












8.7%] Favorable NA N N NA 


















Favorable NA N N NA 
























0 TP53:p.R248W[31.2%] NA NA N NA Y 





Wfs*12[52.4%] Intermediate NA 
t(9;11)(p21.3;q23.3
)[50.0%] Y NA 

















Intermediate NA N N NA 































0 0 Adverse NA Complex N NA 























0 0 Adverse NA N N NA 
 81 

























0 NA NA NA NA Y 
Blank cells, ‘0’, or ‘NA’ indicate no data. 
Downloadable version with more information can be found here: https://wustl.box.com/v/rapidclinicalwgs-tables7  
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Favorable NA NK Y NA 

























120644 MDS BM unsuccessful None detected NA NA 0 0 0 NA Good NK NA Y 
















Adverse NA Not Complex Y NA 
















NA Good NK NA Y 



































0 APL NA Complex N NA 





























Favorable NA NK Y NA 
























































Adverse NA Not Complex N NA 
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Adverse NA Complex Y NA 









23.3)[28.8%] 0 Adverse NA 
t(6;11)(q27;q
23.3)[28.8%] Y NA 






















0 TP53:p.F134V[50.0%] Adverse NA Complex N NA 



















NA Intermediate Independent clones NA Y 












NA Good NK NA Y 





























NA Poor Complex NA N 































Favorable NA Not Complex Y NA 













0 TP53:p.C275Y[75.9%] NA Poor Complex NA N 










0 APL NA Not Complex N NA 
967740 MDS BM 46,XX[18] TP53:p.Tyr126His[2.7%] NA NA 0 0 0 NA Good NK NA Y 
















NA Very good del(11q) NA Y 


















NA Poor Complex NA Y 







































NA Good NK NA Y 
207247 MDS BM unsuccessful DNMT3A:p.Val563Met[4.0%] NA NA 0 0 0 NA Good NK NA Y 


























Adverse NA NK Y NA 












































0 0 Adverse NA Complex N NA 
Blank cells, ‘0’, or ‘NA’ indicate no data. 









































































































































































0 Adverse 16  16 0 0 1 
104895 60 F NH AA M2 32 2 24.3 7+3 46,XX,del(3)(q12)[16]/46,XX[4] Intermediate 
del(3)(q13.11q26.33)[
23.6%] 0 Intermediate 398 77 398 1 1 1 

















0 Adverse   18 0 0 1 










Favorable 733  733 0 0 0 





0 Adverse 40  102 1 0 1 












0 Adverse 34  34 1 0 0 
187885 66 M NH AA M1 78 39.4 66.7 7+3, midostaurin 46,XY[20] Favorable 0 0 Favorable 148  148 0 0 0 



















0 Adverse 182 90 182 0 1 0 




Favorable 342  591 1 0 1 
200915 53 M NH C M0 23 2.9 0 7+3 46,XY[20] Intermediate 0 0 Intermediate 1125  1125 0 0 0 
206801 60 F NH C M2 24 24 1.5 7+3 46,XX[20] Adverse 0 0 Adverse 989 87 989 0 1 0 
211740 73 F NH C 2ndary 28 3.8 0 Hypomethylating agents 
46,XX,t(3;3)(q21;






Adverse 209  209 0 0 0 










Adverse 112 230 112 0 1 0 
250911 59 M NH C M1 89 36.1 97.7 7+3 46,XY[20] Intermediate 0 0 Intermediate 1253  1253 0 0 0 









Favorable 2995  2995 0 0 1 
259112 75 M NH C N/A 73 4.8 34 Hypomethylating agent (decitabine), Venetoclax 46,XY[20] Intermediate 0 0 Intermediate 83 
 83 0 0 1 
262878 55 F NH C M5 46 26.9 12.7 7+3 46,XX[20] Favorable 0 0 Favorable 112  112 0 0 0 










Favorable 194  194 0 0 0 
275291 54 M NH C M4 87 119.7 0 
idarubicin, cytarabine, 






Favorable 273 344 526 1 1 1 
















Favorable   3081 0 0 0 
293825 71 F NH C M5 47 32.7 0 7+3, midostaurin 46,XX[21] Favorable 0 0 Favorable 158 115 158 0 1 0 





















0 Adverse 138  212 1 0 1 
312088 57 M NH C M2 68 28.4 30.2 7+3 47,XY,+21[17]/46,XY[3] Favorable 
gain(21)(q11.2qter)[88
.6%] 0 Favorable 98 
 98 1 0 1 































0 Adverse 476 145 476 1 1 0 






Favorable 1184 142 1184 0 1 0 











Intermediate 268 117 268 0 1 1 




0 Adverse 265  265 0 0 0 










Favorable 669  669 0 0 0 




Adverse del(1)(p35.1p36.32)[56.8%],-7[63.2%] 0 Adverse 333 
 333 0 0 0 




Adverse 346  359 1 0 1 
391518 52 M NH C M4 90 11.8 0 7+3 46,XY[21] Favorable 0 0 Favorable 575  575 0 0 0 










0 Adverse 107  107 0 0 1 















Adverse 4299 116 4299 0 1 0 
429293 35 F NH C M0 48 0.8 11.5 7+3 47,XX,+8[7]/46,XX[13] Adverse +8[50.3%] 0 Adverse 275 
 275 0 0 0 











Favorable 202  202 0 0 0 











Favorable 3777  3777 0 0 0 
465146 39 M NH C M5 60 35.4 44.3 7+3 47,XY,+8[19]/46,XY[1] Favorable +8[67.3%] 0 Favorable 21 
 58 1 0 1 
467399 34 M NH AA M5 65 88.7 49.6 7+3 46,XY[20] Favorable 0 0 Favorable 225  225 0 0 0 
467825 27 F NH C M2 43 9.8 0 7+3(Ida) 47,XX,del(7)(q22),+8[20] Adverse 
del(7)(q21.3q36.1)[92.
7%],+8[66.1%] 0 Adverse 966 170 966 0 1 0 
477377 50 M NH C M2 64 1.8 50.4 7+3 46,XY[20] Intermediate 0 0 Intermediate 278  278 0 0 0 






7%] 0 Favorable 4 
 4 0 0 1 
491972 50 M NH C M5 24 3.7 14.3 7+3 46,XY[20] Favorable 0 0 Favorable 214  214 0 0 0 




Adverse 0 0 Adverse 298 76 298 0 1 0 
499829 59 M NH C M5 49 91 5.2 7+3 47,XY,+8[2]/46,XY[18] Favorable 
gain(3)(q13.33qter)[8.
1%],+8[8.4%] 0 Adverse 7 
 819 1 0 0 
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504394 64 M NH C M2 22 96 18 7+3 47,XY,+8[8] Intermediate +8[85.8%] 0 Adverse 33  84 1 0 1 
506517 64 F NH C M1 88 84.4 84.3 7+3, midostaurin 46,XX[20] Intermediate 0 0 Intermediate 180  180 0 0 0 
509179 38 M NH C M5 79 154.5 14.2 7+3 46,XY[20] Favorable 0 0 Favorable 1023 
 1023 0 0 0 
















0 Adverse 55  55 0 0 0 





























0 Adverse 83  83 0 0 1 
























0 Adverse 173  173 0 0 0 
557196 54 M NH C M5 78 67.4 21.9 7+3 46,XY[20] Adverse 0 0 Adverse 332  332 0 0 0 
578200 38 M NH C M1 69 9.3 52.7 7+3 46,XY[20] Favorable del(9)(p13.3p21.3)[11.6%] 0 Favorable 275 374 275 1 1 0 




Intermediate 360 112 360 0 1 0 










Favorable 4244  4244 0 0 0 
607160 49 F NH C M2 61 7.6 42.7 7+3 46,XX[20] Intermediate 0 0 Intermediate 1074  1074 0 0 0 






Intermediate 178  274 1 0 1 
618671 56 F NH C M1 66 7.7 48.7 7+3(Ida) soc 46,XX[20] Favorable 0 0 Favorable 1383  1383 0 0 0 
623930 56 F NH C M2 68 23.6 43 7+3 46,XX[20] Favorable 0 0 Favorable 929  929 0 0 0 
653268 44 M NH C M5 66 76.3 8 7+3 46,XY[20] Favorable 0 0 Favorable 149  149 0 0 0 
654925 48 M NH C M1 80 22.9 89.7 7+3 46,XY[20] Favorable 0 0 Favorable 138  138 0 0 0 
662555 50 M NH C M1 67 80.9 54.203 7+3 46,XY[20] Intermediate 0 0 Intermediate 193 
 760 1 0 0 




1%] 0 Adverse 18 
 18 0 0 1 
668971 56 M NH C M5 81 2 2 7+3 45~47,XY,+8[cp10] Intermediate 0 0 Intermediate 
  4817 0 0 0 
672014 60 M NH C M5 77 28.3 0 7+3 46,XY[20] Favorable 0 0 Favorable 988 88 988 1 1 1 














0 Adverse 422  422 0 0 1 
677322 55 M NH C M2 50 3.6 32.8 7+3 46,XY[20] Favorable 0 0 Favorable 358 161 358 0 1 0 






23.3)[28.8%] Adverse 37 
 37 0 0 1 











Adverse 278  278 0 0 0 

















Adverse 5772 189 5772 0 1 0 
704854 55 M NH C M4 32 8.3 0 7+3 46,XY[20] Adverse 0 0 Adverse 58  281 1 0 0 
706350 41 F NH C M1 37 1.6 0 7+3 46,XX[20] Intermediate 0 0 Intermediate 964 94 964 0 1 0 
717042 48 M NH C M0 50 25.5 64.9 CLAG + midostaurin 46,XY[20] Intermediate 0 0 Intermediate 132  132 0 0 0 
 88 
726806 75 F NH C M1 88 49.6 87.4 Hypomethylating agent (decitabine), Venetoclax 46,XX[20] Adverse 0 0 Adverse 181 
 181 1 0 0 
736399 82 F NH C M1 93 87.9 85.5 Hypomethylating agent (azacitidine), Venetoclax 46,XX[20] Favorable 0 0 Favorable 79 
 79 0 0 0 











Favorable 1191  1191 0 0 0 
809382 63 F NH C M2 79 39.3 73.5 7+3, uproleselan on A041701 46,XX[20] Favorable 0 0 Favorable 214 222 214 0 1 0 




























0 Adverse 21  21 0 0 1 















Favorable 706 627 706 0 1 0 




21qter)[93.8%] 0 Intermediate 
 125 1676 0 1 0 








Favorable 79  79 0 0 0 
















Adverse 17  17 0 0 1 
879308 39 M NH C N/A 15 21 3.5 7+3 46,XY[20] Intermediate 0 0 Intermediate 460 165 460 0 1 0 
887041 64 M NH C M0 71 18.2 33.9 7+3 46,XY[20] Adverse 0 0 Adverse 168 159 168 0 1 0 
895870 63 F NH C M2 62 49 86.4 7+3, SOC on A0401701 46,XX[20] Favorable 0 0 Favorable 318  318 0 0 0 
902503 70 M NH C wMDS 22 5.8 51 Vyxeos 46,XY[20] Adverse 0 0 Adverse 353 158 353 0 1 0 




















0 Adverse 139 74 139 0 1 0 
907523 53 M NH C M1 94 212.5 78.2 7+3(Ida) 46,XY[20] Intermediate 0 0 Intermediate 82 167 82 1 1 0 






Intermediate 1151  1151 0 0 0 









Favorable 1134 194 1134 0 1 0 






Intermediate 105  105 0 0 0 





69.9 2.5 7+3 46,XX[20] Favorable 0 0 Favorable 279  279 0 0 0 
938927 53 F NH C M0 73 34.8 76.5 7+3 46,XX[20] Favorable 0 0 Favorable 923 85 923 0 1 0 




19 8.1 7+3 46,XX[20] Favorable 0 0 Favorable 133  133 0 0 0 
950919 51 M NH C M2 65 211.1 77.4 7+3 47,XY,+4[20] Intermediate +4[88.0%] 0 Intermediate 896 207 896 1 1 0 
956161 76 M NH C wMDS 40 49.3 20 
Hypomethylating agent 
(decitabine), Venetoclax 45,X,-Y[22] Adverse -Y[96.7%] 0 Adverse 250 
 250 0 0 0 






















0 Adverse 647  647 0 0 0 
 89 
978141 56 F H C N/A 32 18.8 0 7+3 46,XX[20] Favorable 0 0 Favorable 95  101 1 0 1 































0 Adverse 24 118 24 1 1 0 




Intermediate del(9)(q21.11q21.33)[23.2%],-X[95.9%] 0 Favorable 
  3532 0 0 0 
994357 77 F NH C 2ndary 22 11 0 
Hypomethylating agent 






Adverse 289  289 0 0 1 
 
Blank cells, ‘0’, or ‘NA’ indicate no data. 
Downloadable version can be found here: https://wustl.box.com/v/rapidclinicalwgs-tables9   
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%] Intermediate   5648 0 0 0 







288Cfs*12[27.9%] Intermediate 370  623 1 0 1 






_L610dup[21.8%] Intermediate 1147 84 1401 1 1 1 









0.7%] Favorable  175 719 0 1 0 
183114 28 F NH C M5 90 96.3 73.7 7+3 unsuccessful 0 
t(9;11)(p21.3;q2
3.3)[50.0%] ASXL1:p.G646Wfs*12[52.4%] Intermediate 64  64 0 0 0 




5.5%] Favorable   965 0 0 1 




*12[31.8%] Favorable 242  314 1 0 1 




Venetoclax 46,XY[5] 0 0 
IDH2:p.R140Q[37.7%],NPM1:
p.W288Cfs*12[15.5%],FLT3:p.
S585_L601dup[14.0%] Favorable 286  286 0 0 0 
277960 76 F NH C M1 79 25.5 91.9 
7+3 + 






612dup[16.4%] Intermediate   519 0 0 0 




37.3%] Favorable   37 0 0 1 







%] Adverse   576 0 0 1 





W288Cfs*12[46.4%] Intermediate   1179 0 0 1 




W288Cfs*12[25.5%] Favorable   341 0 0 1 








2[39.3%] Adverse 337 116 337 0 1 0 














12)[30.2%] 0 Favorable 341  678 1 0 1 
459785 24 F NH C M0 84 32 90 7+3 46,XX[11] 0 0 
FLT3:p.D835V[36.5%],STAG2:
NA[57.7%] Intermediate  114 3543 0 1 0 









p.E1370G[49.2%] Adverse 55 219 281 0 1 1 
516070 51 M NH C M0 25 2.7 0 7+3 46,XY[13] 0 0 
CUX1:p.Q623*[8.7%],ASXL1:p
.G646Wfs*12[4.8%] Adverse 87  87 0 0 0 







sGLIDFREYEYDL[17.3%] Intermediate   206 0 0 1 
544583 26 F NH C M5 dry tap 42.6 50 7+3 46,XX[11] 0 
t(11;19)(q23.3;p
ter)[18.0%] NF1:p.R1509H[54.0%] Adverse 265 295 300 1 1 1 
562600 60 M NH C wMDS 
dilute 20-






nsDYVDFR[15.5%] Intermediate 345  345 0 0 0 
 91 




2[42.4%] Favorable 59  157 1 0 1 




95L[37.5%] Intermediate   2648 0 0 0 
611521 64 M NH C M5 85 89.5 46 7+3 
49,XY,+3mar




Cfs*12[41.7%] Favorable  201 1123 0 1 0 




12[32.3%] Favorable  161 173 0 1 1 








P[43.6%] Adverse   58 0 0 1 






.W288Cfs*12[48.6%] Intermediate   170 0 0 1 




fs*30[8.8%] Adverse  137 199 0 1 1 
724606 72 F NH AA M2 45 3 0 7+3 unknown 0 0 0 Intermediate   57 0 0 1 





W288Cfs*12[52.4%] Intermediate 149  173 1 0 1 




2[51.9%] Favorable 372 163 372 0 1 0 





.F594_D600dup[9.8%] Intermediate   1305 0 0 0 
853337 70 F NH C M2 67 12.4 48.2 
7+3, 
uproleselan on 





[37.3%] Favorable 160  160 0 0 0 
875663 68 F NH C M4 59 57.7 0 
7+3 + 








.3%] Favorable 350 499 667 1 1 1 



















Q[8.9%] Adverse   100 0 0 1 













TP53:p.P152Rfs*18[70.1%] Adverse 62  154 1 0 1 






2%] Adverse   52 0 0 1 





FGK[11.8%] Intermediate 39  84 1 0 1 
Blank cells, ‘0’, or ‘NA’ indicate no data. 
Downloadable version can be found here: https://wustl.box.com/v/rapidclinicalwgs-tables10   
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